Stein Eye Institute

ANNUAL REPORT 2015-2016

Celebrating 50 Years of Vision

UCLA Stein Eye Institute
Vision-Science Campus

David Geffen School of Medicine at UCLA
University of California, Los Angeles
A Year in Review  1

UCLA Stein Eye Institute  2
Transitions  8
Alumni News  9
Honors and Awards  10
Research  15
Education  17
Community Outreach  21
JSEI Affiliates  23
Philanthropy  25
Thank You  27
Jules and Doris Stein  34
Board of Trustees and Executive Committee  36

Faculty  39

Programs  101

Patient Care Services  102
Research and Treatment Centers  105
Clinical Laboratories  110
Training Programs  112

Appendices  117

Volunteer and Consulting Faculty  118
Educational Offerings  122
Research Contracts and Grants  124
Clinical Research Studies  135
Publications of the Full-Time Faculty  142
Giving Opportunities  154
Dear Friends,

The UCLA Stein Eye Institute opened its doors in November 1966, and as we look forward to commemorating our 50th anniversary year, it is with pride that I reflect on the Institute’s dedication of purpose.

Over the course of five decades, every aspect of our work has been refined and redefined: constantly improving methods for patient care, extraordinary advances in research to increase understanding of the challenges of the eye, growing outreach programs to bring vision care to the underserved both locally and globally, and expanded training for the next generation of ophthalmologists.

Our physicians and vision-scientists are recognized for their exemplary work with the highest of accolades, and through the incredible efforts of the UCLA Department of Ophthalmology faculty, we are continuing to lead the charge to preserve and restore vision.

I thank our exceptional donors and friends for their dedication to the preservation of sight and whose contributions secure our current and future accomplishments. Their gifts to the Institute are key to our growth and achievement, ensuring that the Stein Eye Institute continues to build upon its legacy as one of the world’s finest eye research centers.

Please enjoy our highlights of the 2015–2016 academic year.

Sincerely,

Bartly J. Mondino, MD
Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology
Director, Stein Eye Institute
Chairman, Department of Ophthalmology
David Geffen School of Medicine at UCLA
This 2015–2016 academic year was highlighted by innovations to further build upon and expand the scope of our surgical care, welcoming of new UCLA Department of Ophthalmology faculty, and recognition of the upcoming

“Movements to advance science and medicine need the time, the effort, and the ability of those men and women who have learned to move the immovable mountain.”

– Dr. Jules Stein
The UCLA Stein Eye Institute is the fulfillment of a dream—an ambitious plan developed by Jules Stein, MD, in the late 1950s to prevent blindness by transforming the quality of vision research and patient care.

The Institute exists because of Dr. Stein, one of the most influential executives in entertainment, who returned to his roots as a medical doctor and became a national advocate for vision science, and Bradley R. Straatsma, MD, JD, who created a bold plan for building the scope of ophthalmology in the UCLA School of Medicine. Together Drs. Stein and Straatsma ensured that the Institute would take a central role in transforming vision science as a powerful platform for discovery and patient care to eradicate one of the great scourges of human existence: blindness.

Since opening its doors in 1966, the Stein Eye Institute has produced more than a half-century of progress in developing fundamental knowledge about the workings of the eye, and improving vision through its primary programs of patient care, research, education, and community outreach.

The Institute’s philosophy about patient care has been unaltered in 50 years: care is both the primary goal and the ultimate expression of the Institute’s research and education. Patient care has expanded and flourished since the Institute was founded; from 23,000 patient visits in the first full year, the Institute now treats more than 1,000 patients a day at the Westwood vision-science campus, and hundreds more at UCLA-affiliated hospitals and vision care centers across Southern California.
The Institute’s education programs train doctors as part of a challenging four-part mission: teaching the basics of vision science to all UCLA medical students, educating residents to become the next generation of ophthalmologists, training fellows in ophthalmic subspecialties, and fine-tuning the skills of practicing physicians in career-long experiences. The Institute’s involvement in resident training and patient care also includes fully integrated programs at the university’s affiliated hospitals—Harbor-UCLA Medical Center, the Veterans Affairs Greater Los Angeles Healthcare Center at West Los Angeles and Sepulveda, and Olive View-UCLA Medical Center—unique opportunities in medical education that train ophthalmologists in a scope of diseases.

Developing comprehensive community outreach programs for eye health has been a primary focus for the Institute from its earliest days by offering treatment where it is most needed—whether basic eye examinations for local preschool children or blindness-prevention surgery and care in low-resource countries around the world.

The UCLA Mobile Eye Clinic (UMEC), for example, supports patient care and screening programs in neighborhoods where poverty and disability intersect—visiting schools, senior centers, homeless shelters, and low-income clinics across Southern California. Since its establishment in 1975, almost 230,000 underserved children and adults have received free care from the UMEC.

Basic and clinical research flourish at the Institute, with studies to gain better understanding of the visual process and eye disease—leading to better detection and better prevention.

The harmony of clinical problems being investigated in collaboration with basic science research has driven work at the Institute since its inception, and for almost 50 years, the Institute has created a spectrum of discovery in specialties across ophthalmology.

The success of the Institute’s research, training, and patient care led to a 1989 milestone: the Stein Eye Institute was ranked the best ophthalmology center in the Western United States by U.S. News & World Reports, and thus among the best in the world—a position it has held ever since.

Under the leadership of Bartly J. Mondino, MD, director since 1994, the Institute has implemented a broad agenda of program-building and expansion in training, education, and patient care.

New enterprises were generated to broaden the Institute’s footprint. Affiliated with local hospitals and organizations for some 45 years, the Institute opened the Stein Eye Center–Santa Monica in 2012, bringing Institute faculty and services to a convenient neighborhood locale.

In 2013, Dr. Mondino took the broadest step yet to expand in Southern California by forming a partnership with the Doheny Eye Institute—a fixture in the Los Angeles medical community since 1946—creating the nation’s preeminent organization for ophthalmic patient care, vision research, and education. With the affiliation, three Doheny Eye Center UCLA locations opened, expanding patient access throughout greater Los Angeles and into Orange County.

But perhaps most ambitious of all, the original dream for ophthalmology at UCLA has evolved into the Institute’s bold transformation to a vision-science campus—an interconnected community of facilities and people in three buildings that merge research, training for new ophthalmologists, premier patient care, community outreach programs, and ongoing education for doctors worldwide. That plan was fulfilled in 2014, with the opening of the Edie & Lew Wasserman Building, a six-floor structure with laboratories for research and a patient-care center that unites and expands the Institute’s surgical facilities. The vision-science campus is currently being enhanced with a top-to-bottom overhaul of the original Jules Stein Building, with renovation to be completed in 2017.

As we look forward to its second half-century, the Stein Eye Institute continues to set a global standard for advances in vision science and patient care. Critically, the most important elements of the Institute’s original mandate are still paramount: the relentless drive for excellence and the constant search for new possibilities in the treatment of the eye.

The first half-century of the Institute’s achievements in vision research and patient care may have exceeded even the original soaring expectations of Jules Stein who, at the 1966 dedication ceremony, defined his own prophecy for the Institute and the medical field he loved:

“The men and women who will occupy this building and use its resources will share in future achievements that will outstrip any that have been seen; for science today is moving ahead with fantastic speed, and we must be sure that eye research moves with it. The history of this Institute begins with this dedication. I am confident that it will be a proud history.”
Expanding the Capacity and Quality of Surgical Care

This year, the UCLA Department of Ophthalmology brought increased innovation and expanded capacity to their surgical services at the Stein Eye Institute vision-science campus in Westwood and Harbor-UCLA Medical Center in Torrance.

Stein Eye Institute Outpatient Surgical Center: a new standard for patient care and medical progress

With the 2015 opening of the Stein Eye Institute’s outpatient surgical center, a new era for patient care began. The facilities bring greater patient comfort and new tools for surgical procedures while also serving as an incubator for advanced applications to come.

Located in the Edie & Lew Wasserman Building, the outpatient surgical center includes six new operating rooms, examination areas, and support facilities devoted to the full range of ophthalmic treatment.

“The facilities were created so every procedure, from the simplest to the most complex, is as easy as possible for our patients,” explains Susan Jones, RN, BSN, director of perioperative services for the Institute. To that end, patient space for preparation and recovery has more than doubled. “We used to have six beds—now we have 20 beds in private bays,” she adds.

Consideration has also been given to families and caregivers, who are no longer tied to a waiting room; individual pagers signal updates of a patient’s progress, and families can track the stages of a procedure from preparation through recovery.

“We now have the best facilities to complement the talents of our medical team,” says Bartly J. Mondino, MD, chairman of the UCLA Department of Ophthalmology and director of the Stein Eye Institute. “Everything about the center was planned with enlightened ideas about patient well-being and medical efficiency.”

The center also offers advanced surgical tools, such as the Alcon LenSx, a femtosecond laser that represents the world standard in precision for several types of surgical procedures, including cataracts—the most commonly conducted surgery in the United States.

“The femtosecond laser can be used for corneal incisions, lens softening during cataract surgery, and incisions to correct astigmatism,” reports Kevin M. Miller, MD, Kolokotrones Chair in Ophthalmology, who was instrumental in bringing the laser to Stein Eye. “With a femtosecond laser, we can operate more efficiently and more precisely. For our patients, it reduces the time the eye is open and eases the stress on the eye. And with such accuracy at our disposal, we believe that the laser will open whole new avenues of treatment that have never been possible before.”

To accommodate advances in teaching and training, the center includes a seating gallery for surgical observation. Monitors display the same view of the eye the surgeon is concurrently seeing through the microscope, and a related video system supports mass storage of surgical videos for distribution as educational tools or for review by colleagues at other institutions. The system also provides the opportunity for live streaming of surgical procedures at conferences, further enhancing the educational value.

“The outpatient surgical center was designed for today’s surgical needs and with foresight to anticipate new technology and procedures as they develop,” says Dr. Mondino. “The outpatient surgical center is everything that patients, caregivers, and medical staff could hope for: the finest facilities available.”

The new outpatient surgical center, located in the Edie & Lew Wasserman Building, is on pace to surpass 6,000 procedures annually.

The state-of-the-art facilities are also valued by community ophthalmologists, who bring their patients to the UCLA Stein Eye Institute for needed surgical procedures.
Increased access to operating rooms has allowed Harbor-UCLA to more than double the number of surgeries—now 1,200 procedures a year—producing a huge positive impact on the Medical Center’s ability to treat the underserved.

**Harbor-UCLA Medical Center:**
expanding the capacity of quality eye care for the underserved

With a new operating room and advanced medical technology at Harbor-UCLA Medical Center, the Stein Eye Institute is expanding both medical care for low-income, high-risk patients and training of the next generation of ophthalmic specialists.

When a 66-year-old resident of Wilmington recently needed treatment at Harbor-UCLA for retinal deterioration caused by diabetes, the outlook for scheduling his advanced care was brighter than it would have been a year prior.

Until recently, the strained medical facilities and high demand for services might have delayed this patient’s non-emergency procedure for weeks. But with the opening of new surgical space at Harbor-UCLA, the ability of Stein Eye Institute doctors, fellows, and residents to treat underserved, high-risk eye patients is being transformed.

“We have a superb team of eye specialists and residents here,” says **Pradeep S. Prasad, MD**, health sciences assistant clinical professor at the Stein Eye Institute and chief of the Division of Ophthalmology at Harbor-UCLA. “However, we lacked the facilities to meet the demand.”

That situation changed when Harbor-UCLA—the cornerstone of comprehensive health care for more than 700,000 patients annually from South Los Angeles—completed long-planned building and upgrades. Among the highlights of the construction was the addition of an operating room dedicated full-time to ophthalmology, as well as access to an additional operating room.
The result: more than double the capacity for surgery by the Stein Eye team and the end to long waits for scheduled procedures, and a formidable boost to the Institute’s ability to treat the more than 20,000 eye patients seen annually at Harbor-UCLA.

“Previously we had only 2.5 days per week of access to operating rooms—now we have six days each week,” explains Dr. Prasad. “This increased access has produced a huge positive effect on our ability to treat patients; for example, we once had 200 patients on the wait list for cataract surgery. Now that wait list is zero.”

The operating room at Harbor-UCLA supports vital care for a patient base that is chronically underserved. “Many of our patients come to us when their symptoms are seriously advanced—they look for medical care only as a last resort when they can no longer function in daily life—so the need for immediate treatment is great,” says Dr. Prasad.

Ophthalmologists at Harbor-UCLA provide comprehensive and subspecialty care, including corneal and retinal disease, pediatric issues, ocular trauma, and medical conditions particularly common in low-income populations, such as glaucoma and complications from diabetes.

“The Stein Eye Institute’s relationship with our affiliated hospitals such as Harbor-UCLA are creating tremendous improvements in eye care,” says Dr. Mondino. “Our team at Harbor-UCLA is comparable in quality to any premier teaching hospital, and now our doctors have the best facilities and equipment to do the job. Our patients are reaping the benefits.”

New Cataract and Refractive Surgery Division
Offers Patients Enhanced Eye Care Options

Beyond adding vital space to the UCLA Stein Eye Institute, the addition of the Edie & Lew Wasserman Building has created the opportunity for Stein Eye to expand existing programs and services to better treat patients with eye diseases.

Newly combined in 2015, the Cataract and Refractive Surgery Division provides expertise in the diagnosis and treatment of disorders of the anterior segment, especially cataract and refractive errors. Faculty members perform state-of-the-art refractive cataract surgery with multifocal, toric, and accommodating lens implants. They offer astigmatism management and femtosecond laser-assisted cataract surgery. In addition, Stein Eye ophthalmologists provide the full range of refractive surgical procedures, including laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), astigmatism correction, and corneal inlays, both as initial procedures and as enhancements to previous refractive or cataract surgery.

The Cataract and Refractive Surgery Division is supported by the diagnostic capabilities of the Anterior Segment Diagnostic Laboratory, a full-service diagnostic facility with the most advanced equipment. The laboratory is accessible to departmental faculty and trainees as well as community ophthalmologists. Imaging modalities include corneal topography and tomography, Scheimpflug imaging, endothelial cell analysis, anterior segment optical coherence tomography (OCT), optic nerve and macula OCT, partial coherence interferometry, lens power calculation, A and B scan ultrasound, color fundus and optic disc photography, slit lamp photography, ultrasound biomicroscopy, tear layer analysis, and wavefront analysis.
Jules Stein Renovation

Construction continues on the Jules Stein Building. Built in 1966, the five-story, 93,000 square foot building is being seismically strengthened and renovated. The project will replace aged building systems and provide accessibility upgrades.

Two floors are being renovated as modern wet labs for vision-science research. New windows in the west façade are being introduced to bring natural light into the renovated labs; and a three-story atrium lobby is being constructed to visually connect the B-Level lobby entrance with the ophthalmology check-in lobby and clinic on the first floor.

With the temporary closure of the Jules Stein Building, all patient services have relocated to the Doris Stein Building and the Edie & Lew Wasserman Building. University Ophthalmology Associates and the Institute’s Urgent Care Clinic have been relocated to the second floor of the Edie & Lew Wasserman Building. The Jules Stein Building will reopen in 2017.
IN MEMORIAM

Lee T. Nordan, MD, member of the UCLA Stein Eye Institute voluntary faculty, and acclaimed pioneer in corneal transplantation and refractive surgery, died on December 21, 2015, at the age of 69.

Dr. Nordan was a cornea fellow at Stein Eye during the 1977–1978 academic year. Well liked by colleagues, he had the reputation of being a hardworking and knowledgeable clinician, as well as outstanding surgeon, even at that early stage. He was also committed to teaching, and Gary N. Holland, MD, Jack H. Skirball Chair in Ocular Inflammatory Diseases, was a third-year medical student doing an elective in ophthalmology during Dr. Nordan’s fellowship year. “He was always available to us,” recalls Dr. Holland, “willing to explain concepts about eye disease, even if they were not in his area of subspecialty, and he would frequently seek us out to demonstrate interesting findings.”

Dr. Nordan’s loyal support of the Institute continued in the decades following his fellowship. According to Bartly J. Mondino, MD, chairman of the UCLA Department of Ophthalmology and director of the Stein Eye Institute, Dr. Nordan was a regular participant in teaching conferences conducted by the Cornea Service, and in particular, he made himself available to cornea fellows to discuss issues related to refractive surgery. “Dr. Nordan was also instrumental in establishing the Thomas H. Pettit Fund at UCLA to support activities of the Cornea-External Ocular Disease Division,” says Dr. Mondino. “The fund honors Dr. Pettit who, as then chief of the Division, was Dr. Nordan’s mentor. We are grateful for his generosity.”

IN REMEMBRANCE

Three dynamic women with strong ties to the Institute and its volunteer arm, the JSEI Affiliates, passed away this year.

Cherie Hubbell, BS, beloved wife of Wayne L. Hubbell, PhD, Jules Stein Chair in Ophthalmology, passed away on December 26, 2015, following a lengthy illness. Cherie was a research scientist with expertise in electron microscopy and served as manager of the Hubbell laboratory. She helped establish the Stein Eye Institute’s volunteer organization, the JSEI Affiliates, and served as its president from 1995 to 2015. Under Cherie’s leadership, the Affiliates developed successful community outreach programs, including Vision IN-School, which promotes vision education to elementary school students.

Gloria Jurisic, BA, MA, died on December 4, 2015, following a brief illness. She served as the Institute’s marketing and contracting director, overseeing promotional, communications, and contracting programs from 1981–2011. Gloria assisted in the development and management of the Institute’s website and helped conceive EYE newsletter, serving as the publication’s managing editor until her retirement from Stein Eye in 2011. A member of the JSEI Affiliates Advisory Board, Gloria helped spearhead the Institute’s pediatric ophthalmology book, Making Eye Surgery Bearable.

Ruth Straatsma, BM, MM, co-founder of the JSEI Affiliates, passed away at her home on January 21, 2016, following an extended illness. Wife of Bradley R. Straatsma, MD, JD, founding director of the Stein Eye Institute, Ruth was a gracious hostess and enthusiastic supporter of Stein Eye. Co-founder of the Institute’s volunteer arm, the JSEI Affiliates, Ruth served as its president from 1990 to 1995, and was an active member of the Advisory Board from 1995 to 2016. During Ruth’s tenure, vital community outreach programs were established, providing education and vision-screening services to children.

New Faculty

Michael S. Ip, MD, health sciences clinical instructor, was welcomed as a new full-time faculty member of the UCLA Department of Ophthalmology.

Dr. Ip received his medical degree from New York University School of Medicine in 1993. He completed his ophthalmology residency at the University of Pittsburgh School of Medicine in 1997, and completed a fellowship in vitreoretinal surgery at Tufts University New England Eye Center in 1999.

An expert in the field of vitreoretinal surgery and diseases, Dr. Ip’s research focuses on retinal vein occlusion and diabetic retinopathy. He sees patients at the Doheny Eye Center UCLA location in Pasadena.
Stein and Doheny Host Joint Alumni Reception at AAO Annual Meeting

Over 300 UCLA Stein Eye and Doheny Eye Institute faculty members and resident and fellow alumni from around the world gathered in Las Vegas, Nevada, on Sunday, November 15, 2015, for the UCLA Stein Eye Institute Alumni Association and Doheny Eye Institute Professional Alumni Association’s annual reception. Hosted by both associations, the reception provided an opportunity for alumni from various graduating classes to reconnect with colleagues and classmates.

At the event, Bartly J. Mondino, MD, chairman of the UCLA Department of Ophthalmology and director of the Stein Eye Institute, congratulated Anne L. Coleman, MD, PhD, on her presentation of the highly respected Jackson Memorial Lecture, and welcomed SriniVas R. Sadda, MD, as president and chief scientific officer of the Doheny Eye Institute.
**Doheny Eye Institute Names New President and Chief Scientific Officer**

**SriniVas R. Sadda, MD**, UCLA Department of Ophthalmology faculty member, has been named as president and chief scientific officer of the Doheny Eye Institute.

In this role, Dr. Sadda will help lead the Doheny Eye Institute in its 99-year affiliation agreement with the UCLA Stein Eye Institute, forging a preeminent capability to advance vision research, education, and patient care across Southern California.

Dr. Sadda was recognized for his tremendous credibility both within the Doheny-UCLA-Stein affiliation, and among the ophthalmology community at large. During his tenure at Doheny, Dr. Sadda has played an integral role in its growth and success, including establishment of the Doheny Image Reading Center, recognized as one of the top ophthalmology reading centers in the world.

Specializing in retinal and macular diseases, Dr. Sadda sees patients at the Doheny Eye Center UCLA locations in Arcadia and Pasadena.

**Faculty Honored at 2015 AAO Annual Meeting**

Stein Eye Institute faculty members held leadership positions at the American Academy of Ophthalmology (AAO) Annual Meeting November 14–17, 2015, in Las Vegas, Nevada, contributing to scientific and educational programs, serving on committees, moderating symposia, and teaching instructional courses. In addition, specific faculty members were honored for their contributions to the Academy.

**2015 Jackson Memorial Lecture**

**Anne L. Coleman, MD, PhD**, The Fran and Ray Stark Foundation Chair in Ophthalmology, presented the Jackson Memorial Lecture at the opening session of the AAO. Dr. Coleman is only the third woman to deliver the lecture, which was established in 1944 and is considered one of the most prestigious honors in ophthalmology.

Dr. Coleman’s lecture, How Big Data Informs Us About Cataract Surgery, explored the use of big data to uncover new findings about cataract surgery and the dramatic improvements in visual outcomes following surgery. She also presented an advance look at her upcoming paper in the *American Journal of Ophthalmology* about the nation’s first electronic registry of eye diseases and conditions, which can be referenced for benchmarks to validate quality of care.

**2015 Life Achievement Honor Award**

▶ **Anthony C. Arnold, MD**, Jerome and Joan Snyder Chair in Ophthalmology

▶ **Robert Alan Goldberg, MD**, Karen and Frank Dabby Endowed Chair in Ophthalmology

**2015 Secretariat Award**

▶ **Kevin M. Miller, MD**, Kolokotrones Chair in Ophthalmology
UCLA Department of Ophthalmology Awards and Honors

- **Anthony C. Arnold, MD**, Jerome and Joan Snyder Chair in Ophthalmology, presented the W. Thomas Shults Lecture, September 26, 2015, in Portland, Oregon; the Taylor Asbury Lecture, October 14, 2015, in Cincinnati, Ohio; and the William F. Hoyt Lecture, November 16, 2015, in Las Vegas, Nevada.

- **Richard S. Baker, MD**, associate professor of ophthalmology, received the California Medical Association Foundation Ethnic Physician Leadership Award at the Building Healthy Communities Summit on September 1, 2015, in Riverside, California.

- **Dean Bok, PhD**, Dolly Green Chair of Ophthalmology, Stein Eye Institute Emeritus Faculty Member, Distinguished Professor, Departments of Neurobiology and Ophthalmology, received the Helen Keller Prize for Vision Research at the May 1–6, 2016, Association for Research in Vision and Ophthalmology meeting in Seattle, Washington.

- **Anne L. Coleman, MD, PhD**, The Fran and Ray Stark Foundation Chair in Ophthalmology, was honored with the Los Angeles County Medical Association’s 2015 Innovation Award–Community Service at the L.A. Healthcare Awards ceremony on November 19, 2015, in Los Angeles, California.

- **Sophie X. Deng, MD, PhD**, associate professor of ophthalmology, received the IEEE Transactions on THz Science and Technology Best Paper Award for a significant contribution to the field of endeavor in May 2016.

- **Lynn K. Gordon, MD, PhD**, Vernon O. Underwood Family Chair in Ophthalmology, received the Suzanne Véronneau-Troutman Award from Women in Ophthalmology at the 2015 American Academy of Ophthalmology annual meeting in Las Vegas, Nevada.

Dr. Gordon was also formally nominated for the position of vice chair of the AAO Council, where she will be a member of the AAO Board of Trustees and occupy a major role in encouraging, facilitating, and coordinating communications and strategies among the Academy, state societies, and ophthalmic organizations.

- **Alex A. Huang, MD, PhD**, assistant professor, was presented with the Heidelberg Engineering Xtreme Research award at the May 2016 Association for Research in Vision and Ophthalmology meeting in Seattle, Washington.

- **John A. Irvine, MD**, health sciences clinical professor of ophthalmology, presented the 14th Thomas H. Pettit Lecture at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California.

At the same event, Dr. Irvine was awarded the S. Rodman Irvine Prize for his demonstrated excellence in professional actions and exemplary dedication to teaching future generations of ophthalmologists.

- **Sherwin J. Isenberg, MD**, Laraine and David Gerber Chair in Ophthalmology, received the Marshall M. Parks M.D. Bronze Medal for Distinguished Service from the Children’s Eye Foundation of the American Association for Pediatric Ophthalmology and Strabismus on April 7, 2016, in Vancouver, BC, Canada.
Bartly J. Mondino, MD, Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology, delivered the 24th Walter J. Stark Memorial Lecture on September 28, 2015, at Dean McGee Eye Institute in Oklahoma City, Oklahoma.

Peter A. Quiros, MD, health sciences associate clinical professor, received the International Council of Ophthalmology’s Mark Tso Golden Apple Award for excellence in medical education and teaching at the August 2015 Pan-American Association of Ophthalmology Congress in Bogotá, Colombia.

SriniVas R. Sadda, MD, professor, presented the 47th Jules Stein Lecture at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California.

Alfredo A. Sadun, MD, PhD, Flora Thornton Chair of Vision Research, presented the 14th Bradley R. Straatsma Lecture at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California. In addition, he gave the Carol Zimmerman Lecture on September 26, 2015, at UT Southwestern Medical Center in Dallas, Texas; the keynote lecture at the International Congress of Neuro-Degeneration on March 19, 2016, in Milan, Italy; the Knapp Symposium keynote lecture for the American Ophthalmological Society on May 20, 2016, in Colorado Springs, Colorado; and the keynote lecture at the Canadian Ophthalmological Society meeting on June 20, 2016, in Ottawa, Canada.

Dr. Sadun was also the recipient of the Purpura Award for Contributions to Science and Medicine given by the Albert Einstein College of Medicine on May 25, 2016, at Lincoln Center, New York, New York.

Steven D. Schwartz, MD, The Ahmanson Chair in Ophthalmology, presented the keynote lecture at the Moorfields Eye Hospital alumni meeting held at the Royal Society of Medicine on March 11, 2016, in London, England.

Bradley R. Straatsma, MD, JD, founding chairman of the UCLA Department of Ophthalmology and founding director of the Stein Eye Institute, was recognized for his leadership in the field of ophthalmology at the opening ceremony of the World Ophthalmology Congress of the International Council of Ophthalmology on February 5, 2016, in Guadalajara, Mexico.

Federico G. Velez, MD, health sciences clinical professor of ophthalmology, was introduced as a member of the Association for Research in Strabismus, also known as the North American Squint Club, in 2015.

Dr. Velez was also presented with an Honor Award for distinguished service by the American Association for Pediatric Ophthalmology and Strabismus on April 6, 2016, in Vancouver, BC, Canada.
Institute Honors

Stein and Doheny Eye Institutes Best in the West for Eye Care

The Stein and Doheny Eye Institutes were honored as being among the top five eye care centers in the United States and the best in the Western United States, according to a ranking in U.S. News & World Report’s “Best Hospitals 2015–2016.”

UCLA’s hospitals in Westwood and Santa Monica have again earned a place on the magazine’s Honor Roll. UCLA Health is ranked No. 5 in the country and No. 1 in California. UCLA is among only 17 hospitals out of nearly 5,000 nationwide to be named to the Honor Roll.
Custom-Molded Lens Brings Hope to Patients with Irregular Eye Surfaces

Patients who cannot benefit from standard visual correction due to eye surface irregularities can now achieve better vision, thanks to a technology that allows for custom lens fabrication, according to Vivian Shibayama, OD, the specialty contact lens expert at the UCLA Stein Eye Institute.

Scleral contact lenses have long been the go-to solution for patients with hard-to-fit eyes in need of correction. Designed to vault over the corneal surface and land on the sclera, scleral lenses are similar to regular contact lenses but are commonly used in patients with irregular corneas, as well as to treat high refractive errors and presbyopia. Scleral lenses are also prescribed to provide relief for patients with severe dry eyes by holding fluid against the cornea.

Basic scleral lenses use a standard fitting set, which includes about 20 prefabricated lenses of different shapes, and doctors adjust the standardized curvatures on the lenses to estimate the fit that each patient needs. But the curvature design of scleral lenses makes fitting challenging for patients with an irregular eye surface, according to Dr. Shibayama, because the lens needs to land on a smooth surface to fit properly.

For these patients, the EyePrintPRO™ lens may provide the needed solution. Unlike prefabricated lenses, each EyePrint lens is individually created from an impression of the patient’s ocular surface, allowing it to match the contour of any eye. The resulting lens is made from a high-oxygen permeable material and improves vision much like standard correction, by creating a smooth refractive surface for the affected eye.

“The customized lens is a perfect fit for every patient, since it is created from a scan of that individual’s eye,” explains Dr. Shibayama. EyePrint works well for most patients who cannot wear prefabricated lenses due to irregular eye surfaces resulting from multiple surgeries, scarring, chemical burns, or ocular trauma. “The lens provides therapeutic relief in eye pain and discomfort associated with ocular surface disease, and masks a corneal irregularity to give the patient better vision,” says Dr. Shibayama.

Obtaining the custom mold takes approximately five minutes and no anesthetic is required. “Like a dentist takes a mold of your teeth, I take an impression of the eye that is sent to the lab,” says Dr. Shibayama. “The impression material may feel a little cold and bulky, but it’s painless.” The lenses, worn daily and removed every night, last about a year with proper care.

The Stein Eye Institute’s Contact Lens Center is one of only 26 centers in the United States working with the EyePrintPRO™ lens, and it is the only center that offers this technology within a 100-mile radius of Los Angeles.

Dr. Shibayama takes a custom mold of the patient’s eye. The procedure, which lasts about five minutes, is painless and requires no anesthetic.
Macular Imaging with Spectral Domain OCT Proving Beneficial for Glaucoma Patients

A growing body of evidence points to the benefits of macular imaging with spectral domain optical coherence tomography (SD-OCT) in glaucoma patients—both for early detection and for monitoring disease progression, according to Kouros Nouri-Mahdavi, MD, MSc, associate professor of ophthalmology and director of the Glaucoma Imaging Research Laboratory at the UCLA Stein Eye Institute.

“For a long time we believed that the central part of the retina, where the macula is located, sustains damage very late in glaucoma. But new evidence has shown that the damage to the retinal ganglion cells in the central part of the retina actually occurs early in the disease,” says Dr. Nouri-Mahdavi. “By using SD-OCT to measure the mass of ganglion cells in the macula, we can gauge the damage to these cells at various stages of the disease, making it useful both potentially for detection of early glaucoma and for identifying deterioration of the disease in later stages.” While early detection is important for treating and preventing visual loss from glaucoma, he notes, the ability to detect worsening of the disease is critical for monitoring the impact of treatment.

Dr. Nouri-Mahdavi notes that approximately half of the retinal ganglion cells—the cells damaged in glaucoma—are located in the macula within 4–5 millimeters of the foveal center, and these tend to be the last ganglion cells to die. That means that in advanced disease, when other structural parameters such as those involving the optic nerve head and retinal nerve fiber layer (RNFL) are no longer useful, measurements of the macula can still be used to detect deterioration, he says.

One of the major advantages to SD-OCT as a tool for detecting glaucoma progression is that the reproducibility of the images is high—whether in the same session or over time. “There’s little ‘noise,’ which means that if you see changes over time, they’re very likely to be real,” Dr. Nouri-Mahdavi explains.

Dr. Nouri-Mahdavi believes as many as half of glaucoma specialists in the United States are not conducting macular imaging with SD-OCT, continuing to rely on RNFL imaging only. But the newer approach continues to become more widely used in clinical settings—a trend Dr. Nouri-Mahdavi expects to continue. “In glaucoma diagnostics, we always require confirmation of change, and with macular imaging we can confirm the RNFL findings with a different modality on the same visit,” he says. “Macular OCT imaging is useful for the entire spectrum of glaucoma, from early detection to progression. It is focused on the most visually important part of the retina. It has an excellent reproducibility profile, and is complementary to optic nerve head and RNFL imaging. Given all of these factors, it is expected to play an important role in the near future for glaucoma detection and treatment.”
2016 Clinical and Research Seminar

Ophthalmologists gathered at the Stein Eye Institute on June 10, 2016, for the Institute’s most prestigious annual academic event, the Clinical and Research Seminar. Sponsored by the UCLA Department of Ophthalmology Association, the Seminar provides an opportunity for discussion of emerging vision research and celebrates teaching and faculty volunteerism.

47th JULES STEIN LECTURER
SriniVas R. Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute
Stephen J. Ryan–Arnold and Mabel Beckman Endowed Chair
Professor of Ophthalmology
David Geffen School of Medicine at UCLA
Los Angeles, CA

14th BRADLEY R. STRAATSMA LECTURER
Alfredo A. Sadun, MD, PhD
Vice Chairman, Doheny Eye Center UCLA
Flora Thornton Chair of Vision Research
David Geffen School of Medicine at UCLA
Los Angeles, CA

14th THOMAS H. PETTIT LECTURER
John A. Irvine, MD
Medical Director, Doheny Eye Center UCLA
Health Sciences Clinical Professor
David Geffen School of Medicine at UCLA
Los Angeles, CA Clinical and Research Seminar Awards

Clinical and Research Seminar Awards

In acknowledgment of their service, selected volunteer and clinical faculty received awards of distinction at the Clinical and Research Seminar. The S. Rodman Irvine Prize recognizing excellence in the UCLA Department of Ophthalmology faculty was given to John A. Irvine, MD. Senior Honor Awards were presented to Andrew M. Chang, MD, and Troy R. Elander, MD, distinguished volunteer faculty who have been members of the UCLA Department of Ophthalmology for at least 25 years.

The Faculty Teaching Award, honoring contributions to residency education, was presented to Michael Kapamajian, MD.
Aesthetic Eyelid and Facial Rejuvenation Course

The annual Aesthetic Eyelid and Facial Rejuvenation Course, under the direction of Program Chair Catherine Hwang MD, was hosted at the UCLA Stein Eye Institute July 31–August 1, 2015. The conference drew over 100 attendees from Central America, Europe, India, Taiwan, Korea, and North America. This popular course sold out months in advance and featured both lectures and laboratory demonstrations of state-of-the-art techniques in aesthetic surgery, focusing on minimally invasive techniques that have been pioneered by the Institute’s Orbital and Ophthalmic Plastic Surgery Division.

International fellowship graduate Yoon Duck Kim, MD, from Korea, delivered the Axelrod Memorial Lecture, and Stein Eye fellow alumni and community-based faculty participated as instructors. Steven Leibowitz, MD, moderated a new breakout audio-visual satellite session. The course showcases UCLA faculty, improves patient safety by teaching safe, conservative techniques, and serves as a platform to bring together the Stein Eye Institute’s family of alumni, staff, and faculty.

21st Annual Vision Science Conference

The annual Stein Eye Institute Vision Science Conference celebrated its twenty-first year October 9–11, 2015, at the UCLA Lake Arrowhead Conference Center. Sponsored by a National Institutes of Health training grant, the retreat highlights research by graduate students, postdoctoral fellows, and faculty. Attending were 83 basic scientists, clinical researchers, postdoctoral fellows, graduate students, and invited guests who participated in scientific discussions, learning activities, and social events.

Awards were presented at the Conference for top Oral Presentations and Posters. Recipients were: Kaushali Thakore-Shah, PhD (1st place, Oral Presentation), Anna Matynia, PhD (2nd place, Oral Presentation), Sachin Parikh (1st place, Poster), and Iris Kong (2nd place, Poster).
Ophthalmology Residents and Fellows Gain Training in Cataract Surgery

Trainees from across the southland attended the Alcon Laboratories Basic Cataract Surgery Course in Costa Mesa, California, on October 24, 2015, and the Abbott Medical Optics Advanced Cataract Surgery Course, in Santa Ana, California, on April 23, 2016.

The basic training course covers general topics in cataract surgery and provides a supervised “hands-on” learning experience, and the advanced course encompasses a variety of complementary topics. The courses are recognized for their value by residency and fellowship programs throughout Southern California and are directed by Kevin M. Miller, MD, chief of the Stein Eye Institute’s Cataract and Refractive Surgery Division.

Optometric Symposium on Advances in Eye Care

The Southern California College of Optometry (SCCO) at Marshall B. Ketchum University in Fullerton, California, was host of the January 24, 2016, symposium “Advances in Eye Care.” The joint one-day event is an annual collaboration with SCCO, UCLA Stein Eye Institute, and Doheny Eye Institute. The program included lectures by: Susan A. Cotter, OD, MS, Brian A. Francis, MD, MS, Hugu Y. Hsu, MD, Peter A. Quiros, MD, William H. Ridder, OD, PhD, Vivian P. Shibayama, OD, and Barry A. Weissman, OD, PhD.

Comprehensive Ophthalmology Review Course

The Stein Eye Institute and the Doheny Eye Institute teamed up to sponsor the 11th annual Comprehensive Ophthalmology Review course February 18–21, 2016. The course co-directors, Sherwin J. Isenberg, MD, Laraine and David Gerber Chair in Ophthalmology at the Stein Eye Institute, and John A. Irvine, MD, medical director Doheny Eye Center UCLA, organized a program concentrating on the epidemiology, clinical presentation, diagnosis, and management of ophthalmological disease.
International Retinal Imaging Symposium

The UCLA Stein Eye Institute hosted the fourth International Retinal Imaging Symposium (IRIS) on March 19, 2016, which featured a series of lectures focusing on the latest developments in retinal imaging.

David Sarraf, MD, and K. Bailey Freund, MD, were directors of the symposium, and SriniVas R. Sadda, MD. Richard F. Spaide, MD, and Lawrence A. Yannuzzi, MD, were the event’s co-directors.

Master’s Orbital Surgery Symposium

The Orbital and Ophthalmic Plastic Surgery Division hosted a Master’s Symposium on Orbital Surgery at the Stein Eye Institute March 4–5, 2016. The course, which included both laboratory and didactic components, was highlighted by the inaugural Jack Rootman Lecture, “Reimagining Orbital Surgery,” which was given by Jack Rootman, MD.

Robert Alan Goldberg, MD, and Jack B. Rootman, MD, MS, were the program chairs and Catherine J. Hwang, MD, was the dissection laboratory chair.

Dr. Robert Goldberg demonstrates transcaruncular medial orbital decompression.

Dr. Giulio Bonavolonta lectures in the dissection laboratory.

At the inaugural Jack Rootman Lecture, Dr. Jack Rootman presented an illustrative discussion regarding the future of orbital surgery.
Much of the Stein Eye Institute’s reputation springs from its first-class patient care, which includes care of those in underserved communities. The Institute is dedicated to the preservation and restoration of vision through its global programs and innovative research, quality patient care, and multidisciplinary and integrative education, all with community outreach.

UCLA Department of Ophthalmology
Serving the Most Vulnerable Members of Our Community

Care Harbor/LA Free Clinic

By the numbers, the Care Harbor/LA Free Clinic brings together more than 3,000 volunteers annually to provide 15,000 free medical, dental, and vision evaluations to the uninsured, underinsured, and underserved at-risk members of our community.

Dedicated to the principle that all individuals deserve the best vision attainable, the Stein Eye Institute has a long tradition of community service and leadership at the interface of ophthalmology and public health.

At Care Harbor’s October 15–18, 2015, event at the Los Angeles Convention Center, the UCLA Department of Ophthalmology’s team of committed volunteers conducted vision care services with the UCLA Mobile Eye Clinic (UMEC) as their base—making the difference in someone’s ability to drive, work, or see the board at school.

“We are fortunate to have such a strong and committed team who strive to help individuals see better and fully realize their potential,” says Anne L. Coleman, MD, PhD, The Fran and Ray Stark Foundation Chair in Ophthalmology and director of the UCLA Mobile Eye Clinic.

Attendees at Care Harbor received vision exams and needed prescription glasses. Comprehensive dilated exams were given to patients at risk for eye disease, which would include a history of diabetes or hypertension, a family history of glaucoma, or decreased vision not corrected with eyeglasses. Patients requiring further treatment were referred to community eye specialists who provide additional care at no charge.
Like his fellow volunteers, UCLA ophthalmology resident Shawn Lin, MD, understands the critical importance of community outreach. Working with hospice patients at UCLA-Olive View Internal Medicine during the week, Dr. Lin spent his weekend administering care and expertise to the patients attending Care Harbor.

**West Hollywood Homeless Project**

Through the West Hollywood Homeless Project, UCLA medical students provide free weekly medical services and examinations to homeless individuals. The clinic, which has been steadily growing through word of mouth, has been providing beneficial health services for over 10 years.

In 2015, the UMEC joined forces with the clinic, enabling patients to obtain detailed on-site vision screening and referral, if necessary, to community eye specialists.

Illustrating the importance of outreach events, ophthalmic technician Rene Galvan recalls one patient who was seen at the clinic and required immediate urgent care. “The UCLA medical students were so compassionate; they personally transported the patient to a nearby hospital for emergency medical attention.”
JSEI Affiliates Celebrate 25 Years of Community Service

The JSEI Affiliates annual holiday luncheon on Tuesday, December 8, 2015, marked the Affiliates 25th anniversary of providing outreach to the greater Los Angeles community through vision-science education and services. “Since our 1990 inception, we have accomplished impressive results of community outreach—results that would not have been possible without the commitment of our advisory board and dedication of our volunteers,” remarked Marcia Lloyd, chair of the JSEI Affiliates.

Make Surgery Bearable Program
Two successful sponsorship drives were held this year for the JSEI Affiliates’ Make Surgery Bearable program, an initiative that provides Dr. Teddy bears to each pediatric patient undergoing eye surgery at the Stein Eye Institute. The cuddly bears dressed in green scrubs and tagged with the name of the donor, help children feel comforted and secure during what could otherwise be a frightening time.

The Affiliates, at the suggestion of the Pediatric Ophthalmology and Strabismus Division, introduced a Spanish version of their children’s book Making Eye Surgery Bearable, which helps pediatric patients feel more comfortable with the surgical experience by providing age-appropriate information about what they can expect when they come to the Stein Eye Institute.

MagniVision Program
The Affiliates MagniVision program provides financial and volunteer support for the UCLA Vision Rehabilitation Center (VRC). Volunteers train low-vision patients on the use of magnifiers and various vision aids, and financial assistance from the Affiliates enables purchase of low-vision tools for the VRC lending library.

Preschool Vision Screening
The Affiliates Preschool Vision Screening program began 16 years ago with the inspiration and support of Mrs. Glorya Kaufman and under the supervision of the late Dr. Leonard Apt, founding chief of the Division of Pediatric Ophthalmology and Strabismus. During the 2015–2016 school year, 52 Affiliates volunteers, under the supervision of four retired optometrists, visited 39 preschools to screen 978 children between three and five years of age.
Shared Vision Program
The Affiliates Shared Vision program collected and recycled approximately 2,200 donated eyeglasses for those in need this year. Recycled eyeglasses were cleaned, tagged with the vision correction, and distributed to clinic missions conducted by nonprofit groups in Africa, Central America, and other developing nations.

Vision Education
Vision IN-School (VIS) is a vision education program offered free of charge to fourth- through seventh-grade public school students in Los Angeles. The curriculum is fun and interactive, covering the anatomy of the eye, the developing eye and possible eye problems, eye care and eye safety tips, and optical illusions. One of the presentation highlights is the dissection of a cow eye. Forty VIS volunteers visited 29 classrooms this past year, presenting the curriculum to over 994 elementary students. The program’s goal is to create a greater awareness of vision and the eyes, thus inspiring the children to protect their precious gift of sight for a lifetime of good vision.

Vision Walk
On November 7, 2015, Team Stein Eye participated in the ninth annual Los Angeles Foundation Fighting Blindness Vision Walk, which was held at Woodley Park in the San Fernando Valley. The event, supported by both Stein Eye Institute employees and volunteers from the JSEI Affiliates, raises funds for retinal eye disease research.
The Karl Kirchgessner Foundation, established in 1979, has generously supported critical research and outreach activities of UCLA’s Stein Eye Institute. This tradition of giving dates back to 1963, when a long-time business associate and friend of Dr. Jules Stein, known only as “Mr. K,” began making anonymous donations to support the Stein Eye Institute. Mr. K maintained this anonymous status throughout his life and was inspired by Dr. Stein’s philanthropy and dedication to vision science.

Mr. K began seeking treatment at Stein Eye under the care of Robert E. Christensen, MD, the late founding chief of the Glaucoma Division. As their relationship grew, Mr. K asked Dr. Christensen’s assistance in building a program that would bring eye care to underserved communities. After years of planning, development, and assembly, UCLA’s Mobile Eye Clinic (UMEC) was launched on May 2, 1975. Mr. K also created the Uncle Claude Fund, an endowment that was invested and monitored by Mr. K’s son Mr. Karl F. Kramer and the Foundation.

In 1979, along with Mr. Martin Webster (Mr. K’s attorney and friend) and Mr. Kramer, Mr. K began the process of establishing a new charitable entity, The Karl Kirchgessner Foundation, to provide vision care to disadvantaged persons. Because of Mr. K’s desire for anonymity, the Foundation was named after a great-uncle, whose German last name, Kirchgessner, roughly translates as “churchgoer.”

As treasurer and director of the Foundation for the next 30-plus years, Mr. Kramer worked tirelessly to ensure that the assets consistently grew and resulted in a steady increase of its annual giving. From inception through its fiscal year ending June 30, 2014, the Foundation made approximately $18 million in grants, with UMEC receiving $3.7 million in operating support.

In 2005, Mr. Webster and Mr. Kramer transferred the Uncle Claude endowment for the benefit of UMEC to UCLA. Over the life of The Karl Kirchgessner Foundation, UCLA and the Stein Eye Institute have received more than $8.2 million from these two intertwined entities.

In 1998, the Foundation launched a program to underwrite the vision research of promising young scientists affiliated with universities throughout the United States. Mr. Kramer led this effort, coordinating with the Foundation’s Scientific Advisory Board (SAB), initially comprised of professors from UCLA, including Stein Eye faculty Dean Bok, PhD, and Gabriel Travis, MD. From inception through its fiscal year ending June 30, 2014, SAB awarded research grants totaling $2,275,000 to 43 investigators.

Under Mr. Kramer’s steadfast guidance, the Foundation created The Karl Kirchgessner Foundation Ophthalmology Endowment Fund in 1984 to support pioneering vision research at Stein Eye. The Foundation established a Chair in 2001 to further basic-science investigations, and Debora B. Farber, PhD, DPhhc, Kirchgessner Foundation Chair in Vision Science, is making great strides in the isolation and characterization of genes involved in inherited retinal degenerations.

The Stein Eye Institute is indebted to the long-time support of Karl F. Kramer and the tremendous legacy left by the Kramer family. It is because of Mr. Karl F. Kramer’s lifelong efforts that The Karl Kirchgessner Foundation will continue to make a significant difference in the lives of thousands of individuals.
We are grateful for the generous and steadfast support the Stein Eye Institute receives for research, education, patient care, and community outreach. This investment has a positive impact on ophthalmology and related disciplines at UCLA and throughout the state, nation, and world. Thank you for your commitment to preserve and restore the vision of countless children and adults.

**Major Gifts $25,000 and above:**

Albert Sarnoff
Andrea Bocelli Foundation
Aramont Foundation
Arnold and Mabel Beckman Foundation
Bernice (Morris) Belfer Trust
Bert O. Levy
Bradley R. Straatsma, MD, JD
BrightFocus Foundation
Bruce Ford and Anne Smith Bundy Foundation
Carol and Timothy W. Hannemann
Charles B. Ortner
David R. Fett, MD
Donna Cloninger Trust
Elaine Sarkaria, EdD
Fairchild-Martindale Foundation
Glaucoma Research Foundation
Helen Keller Foundation for Research and Education, Inc.
Jerome and Joan Snyder
John and Susan Hess
John Wickham and Joan L. Wickham Family Trust
Jonathan D. Christenbury, MD
Judith and George Andrews
Jules and Doris Stein UCLA Support Group
Knights Templar Eye Foundation, Inc.
Lavery Foundation
Leonard Apt Trust
Macula Vision Research Foundation
Nancy and Allen Kramer
Patricia and Joseph Yzurdiaga
Ralph and Shirley Shapiro
Randi Levine
Research to Prevent Blindness, Inc.
Richard B. Shapiro Vision Fund (Dr. Gary Holland)
Ruth and George E. Moss
The Carl and Roberta Deutsch Foundation
The Karl Kirchgessner Foundation
The Louis and Harold Price Foundation, Inc.
The Mary Oakley Foundation
The Nicholas Endowment
The Simms/Mann Family Foundation
Vision of Children Foundation, Sam and Vivian Hardage, Co-Founders
Wendy and Theo Kolokotrones
Wilbur May Foundation
William & Margaret Fern Holmes Family Foundation
William R. Payden Philanthropic Fund
Ziemer USA, Inc.
The following individuals were honored with a tribute gift this past year:

In Honor of:
Dr. Anthony J. Aldave
Dr. Joseph Caprioli
Dr. Richard Casey
Anthony Chinn
Dr. Melissa Chun
Dr. Peter J. Cornell
Dr. Joseph L. Demer
Dr. Scott Feiler
Dr. Robert A. Goldberg
Dr. Lynn K. Gordon
Dr. Michael B. Gorin
Dr. Allan E. Kreiger
Theresa and Antoinette Kruger
Marsha G. Lefton
Erin B. Lessner
Randi Levine
Dr. Tara A. McCannel
Dr. Kevin M. Miller
Dr. Bartly J. Mondino
Shirley Philips
Dr. Jack Rootman
Dr. Norman Shorr
Alan B. Skuba
Rania Stone
Dr. Bradley R. Straatsma

In Memory of:
Dr. Leonard Apt
William and Helen Braddock
Reba Byrne
Robert West Carpenter
Gordon B. Crary, Jr.
Elena Diane Curris
Lucio Estrada
Peggy Giambrocco
Dr. Herbert J. Grossman
Athena Kostas Kalpaxis
Reverend George E. Kalpaxis
Ione J. Kanne
Kenneth Klein
Allen Mann
Sue Moesser
Paul H. Orlopp
Virginia Ann Pavlina
Dr. Arthur Rosenbaum
Stanley K. Rothstein
Maurine Reedy Ruzek
Harold Shapiro
Lucia I. Spada
Ruth R. Straatsma
Nickie Voget
Wendell Williams
Joseph Yzurdiaga

Endowed Chairs and Fellowships

ENDOWED CHAIRS

The Ahmanson Chair in Ophthalmology
Established in 2006 by The Ahmanson Foundation as an administrative chair for the Retina Division Chief to further research, education, and clinical care programs.
Steven D. Schwartz, MD
2007–Present

Leonard Apt Endowed Chair in Pediatric Ophthalmology
Established in 2004 by Professor Emeritus of Ophthalmology and Founding Director of the Division of Pediatric Ophthalmology and Strabismus, Dr. Leonard Apt, with a gift from the trust of Frederic G. Rappaport, Dr. Apt’s nephew.
Joseph L. Demer, MD, PhD
2005–2015

Karen and Frank Dabby Endowed Chair in Ophthalmology
Established in 2007 by Dr. and Mrs. Dabby as a term chair to support the activities of a distinguished faculty member in the area of orbital disease.
Robert Alan Goldberg, MD
2008–Present

Charles Kenneth Feldman Chair in Ophthalmology
Established in 1982 by various donors in memory of Charles Kenneth Feldman, an entertainment industry executive.
Robert D. Yee, MD
Professor 1984–1987
Hillel Lewis, MD
Scholar 1989–1993
Gabriel H. Travis, MD
2001–Present
Laraine and David Gerber Chair in Ophthalmology
Established in 1998 as a term chair by Mr. and Mrs. Gerber and, with an additional pledge, converted to a permanent-appointment chair in 2009.

Joseph L. Demer, MD, PhD
2000–2004
Sherwin J. Isenberg, MD
2004–Present

Dolly Green Chair of Ophthalmology
Established in 1980 by Ms. Dorothy (Dolly) Green.
Dean Bok, PhD
1984–Present

Ernest G. Herman Chair in Ophthalmology
Established in 2008 by Mr. Ernest G. Herman to support a vision scientist or a clinician-investigator.
Xian-Jie Yang, PhD
2012–Present

Karl Kirchgessner Foundation Chair in Vision Science
Established in 2001 as a term chair by a colleague of Dr. Jules Stein to promote basic-science research initiatives.
Debora B. Farber, PhD, DPhhc
2001–Present

Kolokotrones Chair in Ophthalmology
Established in 2004 by Wendy and Theo Kolokotrones to support the teaching and research of a cataract surgeon and scientist.
Kevin M. Miller, MD
2005–Present

Grace and Walter Lantz Endowed Chair in Ophthalmology
Established in 1991 as a term chair by Mr. and Mrs. Lantz and, with an additional pledge, it was converted to a permanent-appointment chair in 2010.

J. Bronwyn Bateman, MD
Grace and Walter Lantz Scholar 1993–1995
Sherwin J. Isenberg, MD
Grace and Walter Lantz Scholar 1993–1995
Professor 1996–2004
Joseph L. Demer, MD, PhD
Professor 2004–2005

Walton Li Chair in Cornea and Uveitis
Established in 2013 by Walton W. Li, MD, as an administrative chair for the Cornea and Uveitis Division to further research and teaching activities.
Anthony J. Aldave, MD
2014–Present

David May II Endowed Chair in Ophthalmology
Established in 1998 as a term chair by the family of Mr. David May II, a founding member of the Institute’s Board of Trustees, to perpetuate, in memoriam, Mr. May’s association with the Stein Eye Institute; after an additional pledge from the Wilbur May Foundation, it was converted to a permanent-appointment chair in 2009.
Gary N. Holland, MD
1999–2004
Joseph Caprioli, MD
2004–Present

Mary Oakley Foundation Chair in Neurodegenerative Diseases
Established in 2012 by The Mary Oakley Foundation to support neurodegenerative diseases.

Oppenheimer Brothers Chair
Established in 2002 as a term chair by the Oppenheimer Brothers Foundation.
Joseph Horwitz, PhD
2003–Present

Harold and Pauline Price Chair in Ophthalmology
Established in 2000 by the Louis and Harold Price Foundation and, with an additional pledge, it was converted to a permanent-appointment chair in 2006.
Michael B. Gorin, MD, PhD
2006–Present

Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology
Established in 2007 by Mr. and Mrs. Gottlieb as an administrative chair for the Division of Pediatric Ophthalmology and Strabismus in honor of the late Dr. Arthur L. Rosenbaum. The chair was originally named the Brindell and Milton Gottlieb Chair in Pediatric Ophthalmology.
Arthur L. Rosenbaum, MD
2008–June 2010
Joseph L. Demer, MD, PhD
2015–Present

Jack H. Skirball Chair in Ocular Inflammatory Diseases
Initiated in 2008 by The Skirball Foundation in honor of Jack H. Skirball’s long-standing friendship with Dr. Jules Stein and Lew Wasserman.
Gary N. Holland, MD
2009–Present

Smotrich Family Optometric Clinician-Scientist Chair
Established in 2016 to support an optometric clinician-scientist at the UCLA Stein Eye Institute and will fund the appointee’s education and research programs.
Jerome and Joan Snyder Chair in Ophthalmology
Established in 2008 by Mr. and Mrs. Snyder to support the activities of a distinguished faculty member who directs the ophthalmology residency program, ensuring that UCLA’s accredited program continues to offer rigorous and comprehensive instruction for individuals of the highest caliber.

Anthony C. Arnold, MD
2008–Present

Joan and Jerome Snyder Chair in Cornea Diseases
Established in 2013 by Mr. and Mrs. Snyder to support the activities of a distinguished faculty member in the area of corneal diseases and research.

The Fran and Ray Stark Foundation Chair in Ophthalmology
Established in 1992 as a term chair by the Fran and Ray Stark Foundation, and with an additional commitment, it was converted to a permanent-appointment chair in 2007.

Joseph Caprioli, MD
1997–2004

Anne L. Coleman, MD, PhD
2004–Present

Jules Stein Chair in Ophthalmology
Established in 1982 as a memorial tribute to Dr. Jules Stein by his many friends, with the leadership of Mr. Samuel Goldwyn, Jr.

Wayne L. Hubbell, PhD
1983–Present

Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology
Established in 1994 to honor founding director of the Stein Eye Institute, Bradley R. Straatsma, MD, JD.

Bartly J. Mondino, MD
2000–Present

Vernon O. Underwood Family Chair in Ophthalmology
Established in 1995 as a term chair by Mrs. Adrienne Underwood Pingree in memory of her late husband, Mr. Vernon O. Underwood.

John R. Heckenlively, MD
1997–2004

Gary N. Holland, MD
2004–2009

Lynn K. Gordon, MD, PhD
2012–Present

Edith and Lew Wasserman Professor of Ophthalmology
Established in 1977 by Edie and Lew Wasserman to honor Dr. Jules Stein.

Manfred Spitznas, MD
1979–1981

Bartly J. Mondino, MD
Scholar 1984–1988
Professor 1988–2000

Ben J. Glasgow, MD
2003–Present

FELLOWSHIP FUNDS AND ENDOWMENTS

Rosalind W. Alcott Fellowship
Established in 1978 by the Rosalind W. Alcott Charitable Remainder Trust for the training of outstanding postdoctoral fellows.

Negin Agange, MD
2015–2016

Leonard L. Apt, MD, Pediatric Fellowship Fund
Established in 2015 by the trust of Leonard Apt, MD, founding chief of the Pediatric Ophthalmology and Strabismus Division, to support pediatric ophthalmology fellowships.

Thelma and William Brand Director’s Fund
Established in 2004 with a trust from Mr. William F. Brand to benefit worthy students at the Stein Eye Institute.

Aaron Nagiel, MD, PhD
2015–2016

Cooperman Fellowship Fund
Established in 1988 by the Coopermans to support eye research and education, with emphasis on clinical ophthalmology.

Wenjing Liu, MD
2015–2016

David and Randi Fett Orbital and Ophthalmic Plastic Surgery Fellowship Endowment
Established in 2013 by Dr. David R. Fett and Ms. Randi Levine to support fellows in the Orbital and Ophthalmic Plastic Surgery Division.

Erin Lessner, MD
2015–2016

Klara Spinks Fleming Fellowship Fund
Established in 1985 by Klara Spinks Fleming to support cataract research.

Elizabeth R. Richter, MD, PhD
2015–2016

Frances Howard Goldwyn Fellowship
Established in 1977 by Mr. Samuel Goldwyn, Jr., with gifts from Mrs. Goldwyn’s estate and Dr. and Mrs. Jules Stein.

Salwa Abdel-Aziz, MD
2015–2016
Elsa and Louis Kelton Fellowship
Endowed by the Keltons in 1982 to support postdoctoral research and training.
Aaron Nagiel, MD, PhD
2015–2016

Jerome Comet Klein, MD, Fellowship Fund
Established in 2007 by the Irving & Estelle Levy Foundation to provide fellowship and lecture support in the areas of orbital and ophthalmic plastic surgery.
Erin Lessner, MD
2015–2016

Bert Levy Research Fellowship Fund
Established in 1995 by Mr. Bert Levy to enhance the educational opportunities of vision science scholars and advance research in neuro-ophthalmology.
Daniel Choi, MD
2015–2016
Lilit Minasyan, MD
2015–2016

Wilbur D. May Fellowship
Established in 2013 by the May family as a tribute to Mr. Wilbur D. May, the beloved uncle of Mr. David May II.
Andrew Salem, MD
2015–2016

John and Theiline McCones Fellowship
Established in 1989 by the McCones to support and enhance education programs and fellowship training in macular disease.
Michael A. Klufas, MD
2015–2016
Robert Lalane, MD
2015–2016

Abe Meyer Memorial Fellowship Fund
Established in 1969 by various donors to support clinical fellows at the Institute.
Tina Damarjian, MD
2015–2016

Audrey and Jack Skirball Ocular Inflammatory Disease Fellowship
Established in 2011 by The Skirball Foundation to support the training of fellows specializing in ocular inflammatory disease.
Megan Berkenstock, MD
2015–2016

The Harold and Pauline Price Fellowship
Established in 1987 by the Louis and Harold Price Foundation to support research and education in ophthalmology and vision care.
Sohrab Tofigh, MD
2015–2016

Frederic G. Rappaport Endowed Fellowship in Retina/Oncology
Established in 2004 by Mrs. Jeanne A. Rappaport as a memorial to her son Frederic.
Elizabeth R. Richter, MD, PhD
2015–2016

Dr. Jack Rubin Memorial Fellowship
Established in 1987 by the family of Dr. Jack Rubin to support postdoctoral fellows.
Andrew Salem, MD
2015–2016
Anushree Sharma, MD
2015–2016
Sohrab Tofigh, MD
2015–2016

The Mae and Lee Sherman Fellowship Fund
Established in 1981 by the Sherman family to support postdoctoral fellows.
Andrew Salem, MD
2015–2016

Sanford and Erna Schulhofer Fellowship Fund
Established in 1986 by Mr. Sanford Schulhofer to support postdoctoral research and training in vision science.
Laura Vickers, MD
2015–2016
Endowments for Research, Education, and Patient Care

Albert Sarnoff Endowed Cataract Fund
Amalia Simon Roth Endowment
Anne H. West Estate Fund
Anthony Eannelli Fund
Arna Saphier Macular Degeneration Fund
Arthur Spitzer Fund
Audrey Hayden-Gradle Trust
Barbara P. Taylor Fund
Bradley R. Straatsma Research Fund
Card Family Research Fund
Chesley Jack Mills Trust
Daniel B. Whipple Fund
Dr. William F. Stein and Esther Elizabeth Stein Memorial Fund
Edward and Hannah Carter Fund
Elsie B. Ballantyne Regents Fund
Elsie B. Ballantyne UCLA Foundation Fund
Emily G. Plumb Estate and Trust
Emma B. Gillespie Fund
Endowment for Children with Uveitis
Esther Shandler Research Fund
Gerald Oppenheimer Family Foundation Center for the Prevention of Eye Disease Endowment Fund
Herb Ritts, Jr., Memorial Vision Fund
Herman King Fund
Hintz Glaucoma Research Fund
J. Richard Armstrong and Ardis Armstrong Fund
Jerome T. Pearlman, MD, Fund
John and Theiline McConce Macular Disease Research Fund
JSEI Maintenance Fund
Katherine L. Gardner Research Fund

Maggi Kelly Vision Fund
Marie and Jerry Hornstein Family Endowed Macular Degeneration Research Fund
Michael Huffington Ophthalmology Scholarship Fund
Pat and Joe Yzurdiaga Endowed Cataract Fund
Patricia and Joseph Yzurdiaga Endowed Vision Science Research Fund
Patricia Pearl Morrison Research Fund
Paul J. Vicari Endowed Cataract Research Fund
Raymond and Ruth Stotter Vision Science Research Fund
Richard B. Shapiro Vision Fund
Sara Kolb Memorial Fund
Stella F. Joseph Fund
The Annenberg Foundation Fund
The Karl Kirchgessner Foundation Ophthalmology Endowment Fund
The Leonard L. Apt, MD, Pediatric EyeSTAR Residency Training Fund
The Skirball Foundation Fund
UCLA Center for Eye Epidemiology
Uncle Claude Fund
Virginia Burns Oppenheimer Endowment Fund
William R. Payden Fund for Glaucoma Research
William, Richard, & Roger Meyer Fund
The legacy of Dr. and Mrs. Jules Stein arises from their role in the 20th century as visionaries. Through brilliance and beneficence, they created a multitude of programs aimed specifically at one goal: preserving and restoring eyesight. They approached this task dauntlessly, integrating the worlds of business, medicine, and philanthropy in such a way as to enhance each and leave in trust the promise of limitless accomplishment in the advancement of eye research and treatment. The Stein Eye Institute was established as a result of their philanthropy.
Jules Stein

Jules Stein is the foremost benefactor in the world history of vision science and blindness prevention. He combined his love for music and medicine with a unique talent for analysis and organization to produce a lifetime of celebrated achievements as musician, physician, business leader, and humanitarian.

Born in South Bend, Indiana, in 1896, Jules Stein received a bachelor of philosophy degree from the University of Chicago at age 18 followed by a medical degree from Rush Medical College. After completing postgraduate studies at the University of Vienna and Chicago’s Cook County Hospital, he began medical practice and was certified by the American Board of Ophthalmology.

A musician from an early age, he financed his education by playing in and leading his own band. As his reputation increased, he began booking other musicians for professional engagements, and in 1924, founded Music Corporation of America (MCA). Shortly thereafter, he gave up the practice of medicine to concentrate on this enterprise. Within 10 years, MCA represented most of the great name bands and corporate activities began to extend to representation of film stars, directors, writers, and musical artists. MCA entered the promising new field of television at its inception, eventually acquiring the Universal City property, Universal Pictures, and other enterprises to become pre-eminent in the entertainment industry.

Throughout his phenomenally successful career, Jules Stein maintained a strong interest and emotional investment in medicine, particularly his own field of ophthalmology. In the late 1950s, urged by his wife, Doris, he chose to direct his considerable talents to blindness prevention. The result was a concert of ideas and achievements that encompassed philanthropy, government, and academic medicine.

By his efforts, Research to Prevent Blindness was created, now recognized as the world’s leading voluntary organization in support of studies of the eye and its diseases. Jules Stein was largely responsible for the passage of legislation to establish the National Eye Institute as a separate entity in the National Institutes of Health. Under his leadership, the Stein Eye Institute was founded as a multidisciplinary center for vision science. Since its establishment, the Institute has become internationally identified as the focus for coordinated programs of research in the sciences related to vision, ophthalmic education, and the care of patients with eye disease. Jules Stein died in 1981, leaving a legacy of hope to the world. Through his accomplishments and philanthropy, he created ever-replenishing resources for eye research and the means to preserve and restore sight for future generations.

Doris Stein

Doris Stein’s purposeful, yet richly varied life, earned the respect and affection of the many people who benefited from her humanitarianism. Inspiring partner of her husband for more than half a century, Doris Stein shared with him the accomplishments of his philanthropic endeavors and guided his interests in ophthalmology, beginning with a visit to the New York Lighthouse for the Blind in the late 1950s. Deeply moved, Doris Stein urged her husband to “do something!” From that passionate beginning came a broad base of programs that catalyzed eye research.

Doris Stein was a major force in this vision renaissance. She served as an officer and director of Research to Prevent Blindness, personally leading the appeal to establish more resources for investigations into eye diseases. She suggested that Jules Stein assume the principal role in the creation of an eye institute at UCLA, and her unflagging enthusiasm nurtured the Institute’s development as a unique provider of every facet of vision research and patient care. Serving as Trustee, she focused special attention on Institute initiatives to combat blindness throughout the world. She devoted her last days, until her death in 1984, to the development of an expansion and companion building for eye research. In 1989, dedication ceremonies were held for the Doris Stein Eye Research Center.

With grace, vision, and meaningful action, Doris Stein enhanced the lives of all privileged to know her, stimulated a cascade of progress in eye research, co-founded the Institute with its boundless scientific potential, and extended the miracle of sight to untold numbers of people.
Board of Trustees

The Stein Eye Institute Board of Trustees was established in 1977 to ensure the Institute’s orderly growth and development. The Board meets regularly during the year, with each Trustee providing his/her unique counsel. Collectively, their invaluable contributions have included fiscal planning for the Institute, adoption of measures to facilitate recruitment of the world’s finest vision scientists, allocation of funds for the purchase of vision research equipment, and recommendations for facilities expansion programs.

Current Members

Bartly J. Mondino, MD
Director
Stein Eye Institute
1994–present

Nelson C. Rising, Esq.
Chairman and
Chief Executive Officer
Rising Realty Partners
2011–present

Ronald L. Olson, Esq.
Partner
Munger, Tolles & Olson
1995–present

Katrina vanden Heuvel
Publisher and Editor
The Nation
1984–present

Gerald H. Oppenheimer
President
Gerald Oppenheimer Family Foundation
1994–present

Casey Wasserman
President and
Chief Executive Officer
The Wasserman Foundation
1998–present

Observer
Marissa Goldberg
Executive Director and
Chief Financial Officer
Doheny Eye Institute
2015–present
The Executive Committee

The Executive Committee of the Stein Eye Institute and UCLA Department of Ophthalmology meets regularly during the year, with each member providing their unique expertise. The Executive Committee ensures the orderly growth and development of the Institute and Department. It is involved in fiscal planning for the Institute, space, recruitments, program development, and resolution of interdivisional issues.

Bartly J. Mondino, MD
Director, Stein Eye Institute
Chairman, UCLA Department of Ophthalmology

Wayne L. Hubbell, PhD
Gabriel H. Travis, MD
Associate Directors, Stein Eye Institute

Anne L. Coleman, MD, PhD
Vice-Chair, UCLA Department of Ophthalmology

Jonathan D. Smith
Chief Administrative Officer, Stein Eye Institute

SriniVas Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute

Alfredo A. Sadun, MD, PhD
Vice Chairman
Doheny Eye Center UCLA
The Stein Eye Institute at UCLA is a vision-science campus dedicated to the preservation and restoration of vision through its global programs and innovative research, quality patient care, and multidisciplinary, integrative education, all with community outreach.
Faculty
Anthony J. Aldave, MD

Walton Li Chair in Cornea and Uveitis
Professor of Ophthalmology
Chief of the Cornea and Uveitis Division
Member of the Stein Eye Institute

RESEARCH SUMMARY

Discovering the Genetic Basis of the Corneal Dystrophies

The Cornea Genetics Laboratory, under Dr. Aldave’s direction, is involved in identifying and elucidating the genetic basis of inherited corneal disorders, such as posterior polymorphous and Lisch corneal dystrophies.

Public Service
Associate Examiner, American Board of Ophthalmology
Chair, American Academy of Ophthalmology Practicing Ophthalmologists Curriculum, Cornea and External Disease Panel
Chair, Cornea Society Scientific Program Committee
Member, Cornea Society Board of Directors
Member, Eye Bank Association of America Medical Advisory Board
Member, Editorial Board, Cornea
Reviewer for many scientific journals

Research Grants
National Eye Institute: Identification and Characterization of the Genetic Basis of PPCD, 12/1/12–11/30/17
JAEB Center for Health Research: Effect of the Corneal Preservation Time on Long-Term Graft Success (CPTS), 3/6/12–8/31/17
National Eye Institute (subaward from Cedars-Sinai Medical Center): Genetic Factors in Keratoconus, 12/1/14–2/28/17
Anthony C. Arnold, MD

Jerome and Joan Snyder Chair in Ophthalmology
Professor of Clinical Ophthalmology
Chief of the Neuro-Ophthalmology Division
Director of the UCLA Optic Neuropathy Center
Member of the Stein Eye Institute

RESEARCH SUMMARY

Ischemic and Inflammatory Diseases of the Optic Nerve

Dr. Arnold directs a neuro-ophthalmology research program concerned with diseases of the optic nerve. The overall goals of the program are the development of new techniques for imaging the optic nerve and its blood supply; an improved understanding and classification of ischemic and inflammatory optic nerve diseases; and the development and evaluation of new therapeutic modalities for these diseases.

Dr. Arnold was a principal investigator in the National Eye Institute-sponsored clinical study of optic nerve sheath decompression surgery for nonarteritic anterior ischemic optic neuropathy, and he was on the study’s Visual Field Data Analysis Committee. He is a primary advisor for an international multicenter study of risk factors for nonarteritic anterior ischemic optic neuropathy.

Ongoing additional research studies include clinical characteristics of ischemic optic neuropathy in young patients; improved differentiation of arteritic from nonarteritic anterior ischemic optic neuropathy; identification of ischemic aspects of other rare optic neuropathies, such as diabetic papillopathy, uremic optic neuropathy, and chemotherapy-induced optic neuropathy after bone marrow transplantation; and classification of unusual optic neuropathies, such as ethambutol-induced optic neuropathy and focal congenital optic nerve hypoplasia. A study of differentiation of optic disc drusen from papilledema has recently been completed. A major thesis entitled, The Spectrum of Optic Disc Ischemia, has been submitted to the American Ophthalmological Society.

Honors
Presented the W. Thomas Shults Lecture, September 26, 2015, in Portland, Oregon.
Gave the Taylor Asbury Lecture, October 14, 2015, in Cincinnati, Ohio.
Received the Life Achievement Honor Award at the November 2015 American Academy of Ophthalmology annual meeting in Las Vegas, Nevada.
Delivered the William F. Hoyt Lecture, November 16, 2015, in Las Vegas, Nevada.

Public Service
Faculty, Stanford/Bay Area Basic Science Course in Neuro-Ophthalmology
Faculty, Lancaster Course in Ophthalmology, Colby College
Board Director, American Board of Ophthalmology
Chair, ACGME Residency Review Committee for Ophthalmology
Chair, ACGME Milestones Committee for Ophthalmology
Reviewer for many scientific journals
Richard S. Baker, MD

Associate Professor of Ophthalmology
Associate Director, Stein Eye Institute Center for Community Outreach and Policy, UCLA Center for Eye Epidemiology
Executive Director, Center for Health Services Research
Charles R. Drew University of Medicine and Science
Chairman, Department of Ophthalmology
Charles R. Drew University of Medicine and Science
Member of the Stein Eye Institute
Vice Dean for Medical Education, Wayne State University School of Medicine

RESEARCH SUMMARY

Ophthalmic Epidemiology and Health Services Research

Dr. Baker’s primary areas of research interest are in the fields of ophthalmic epidemiology, health services research, and health information technology, including telemedicine. Current projects in ophthalmic epidemiology include statistical analysis of national and statewide databases to produce definitive population-based estimates of the distribution and the determinants of major ophthalmic diseases and their treatments.

As executive director of the Charles R. Drew Center for Health Services Research, Dr. Baker works closely with collaborators at the Stein Eye Institute and across UCLA on multiple projects related to improving access to care, optimizing the quality of care, and eliminating health disparities in diverse and underserved populations.

Public Service
Trustee, California Medical Association
Chairman, Council for Scientific and Clinical Affairs, California Medical Association
Secretary, Board of Trustees, Los Angeles County Medical Association
Chairman, African American Physician Advisory Committee, Los Angeles County Medical Association
Secretary, Board of Trustees, Latino Physicians of California
Reviewer for multiple National Institutes of Health and Agency for Healthcare Research and Quality Special Emphasis Panels
Reviewer for many scientific journals

Honors
Received the California Medical Association Foundation Ethnic Physician Leadership Award at the Building Healthy Communities Summit on September 1, 2015, in Riverside, California.

Research Grants
National Institutes of Health: NIH Diversity Program Consortium Coordination and Evaluation Center at UCLA, 7/1/15–6/30/16
John D. Bartlett, MD

Health Sciences Assistant Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Cataract and Refractive Surgery

Dr. Bartlett has an ongoing clinical interest in cataract surgery, particularly refractive cataract surgery where the goal is to improve the focusing of the eyes and reduce dependence on glasses, while restoring vision potential. He is involved with teaching these surgical techniques to the Stein Eye residents, training the next generation of eye surgeons to deal with challenging cases.

Clinical Informatics

As one of UCLA’s physician informaticists, Dr. Bartlett is involved in the ongoing implementation and optimization of electronic health records (EHRs). UCLA physician informaticists engage in all aspects of understanding and promoting effective organization, analysis, management, and use of clinical information. Dr. Bartlett is interested in using EHRs to reach the “Triple Aim” of improved patient care and satisfaction, improved population health, and decreased cost of health care.
Dr. Bhat’s laboratory studies the regulation of gene activity during differentiation and development of the vertebrate eye. This involves isolation and characterization of genes and gene products, identification of the regulatory elements and factors, and elucidation of their mechanisms employing both in vivo and in vitro paradigms with manipulated gene sequences.

Two areas of research currently under investigation are focused on gaining deeper insight into molecular mechanisms that developmentally predispose the eye to visual impairment through ocular lens pathologies such as cataracts, and through retinal diseases including age-related macular degeneration (AMD).

One area of attention is the study of the developmental and tissue-specific control of the αB-crystallin gene and its involvement in cataractogenesis. Another is the elucidation of the physiological function of the αB-crystallin protein in the ocular lens, in the neuroretina and retinal pigment epithelium (RPE), and in the brain. Technically this work involves gene manipulations and the study of their consequences on the phenotype, both in vitro (cultured cells) as well as in vivo (transgenic animals).

Studies on the regulation of the expression of the small heat-shock protein gene, αB-crystallin, are focused on heat-shock transcription factor 4 (HSF4), which Dr. Bhat’s laboratory has reported to be the predominant heat-shock transcription factor of the developing lens, and its post-natal expression correlating with the most prevalent form of early childhood lamellar cataracts. Dr. Bhat’s group has generated mouse models of this cataract, thus enabling first-time investigation of this childhood pathology.

Studies on the function of the αB-crystallin protein in the lens and the RPE (in particular its relation to AMD) are focused on elucidating its “non-crystallin” function, which is relevant both in the transparent and nontransparent physiology. These investigations have led Dr. Bhat’s laboratory to the discovery of the secretion of αB-crystallin from the RPE in lipoprotein vesicles known as exosomes, and to initiate studies on elucidation of intercellular communication (via exosomes) in the RPE, in health, and in disease.
**RESEARCH SUMMARY**

**Functional and Structural Organization of the Mammalian Retina**

Dr. Brecha’s research focuses on the elucidation of the structural and functional organization of the outer and inner retina for understanding visual information processing by the retina. Morphological studies are focused on defining the different cell types and their microcircuitry organization in the outer and inner retina. Neurochemical studies have investigated the action of the excitatory and inhibitory neurotransmitters and neuroactive peptides in these retinal microcircuits. Experimental work has clarified the functional role of neuropeptides in the inner retina and supports the current hypothesis that certain dopamine and neuropeptides are modulators of retinal neurons and circuitry that influence light and dark adaptation; they also influence retinal circuitry that mediate pupillary reflexes and eye movements.

Other experimental work has investigated the photoreceptor synaptic triad, a specialized synaptic complex that is the site of initial transfer of visual information from photoreceptors and is critically important for visual processing. Experimental studies are testing the idea that a GABA mediated vesicular release underlies horizontal cell feedback and feed forward signaling, to cones and bipolar cells, respectively. The horizontal cell microcircuitry is critically important for the formation of visual receptive fields, blue-yellow color opponency, and ganglion cell gain. These investigations are fundamental steps in establishing the retina’s functional organization and provide the basis for understanding the pathophysiology of retinal dysfunction concomitant with retinal disease and injury.
Dr. Caprioli’s long-term objective in his clinical and basic research is to identify those individuals at greatest risk for visual loss and to implement new treatment strategies to prevent blindness. Currently, the only tool that physicians have to treat glaucoma is reduction of intraocular pressure. This treatment does not prevent visual loss in a substantial proportion of patients whose damage progresses quickly. The development of effective neuroprotective avenues of treatment will be a hallmark advance to eliminate blindness from this disease.

Evaluation of Methods to Measure Rates of Glaucomatous Optic Nerve Damage

Accurate assessment of optic nerve and nerve fiber layer is important to the early detection and timely treatment of glaucoma. Studies are underway to develop novel structural measures of the optic nerve and nerve fiber layer, which are sensitive and specific for early and progressive glaucomatous optic nerve damage. The goals of this work include identifying clinically implementable techniques to measure the rate of progressive damage. It is unlikely that a single structural or functional technique will be best throughout the course of the disease, and different methods will need to be applied at different stages to best measure disease progression.

Molecular Mechanisms of Retinal Ganglion Cell Damage and Neuroprotective Approaches to Treatment

Basic science research under Dr. Caprioli’s direction involves the mechanisms of glaucomatous optic nerve damage. The stress protein response in a glaucoma model is being intensively studied. An important goal in this research is to identify neuroprotective drugs that prevent the death of retinal ganglion cells in mammalian models of glaucoma, and to apply these findings to clinical trials of human glaucoma.
Richard Casey, MD

Health Sciences Clinical Professor of Ophthalmology
Associate Member of the Stein Eye Institute

RESEARCH SUMMARY

Cornea External Disease

Dr. Casey’s research is focused on understanding the causes of a variety of ocular surface and corneal disorders, and his goal is to develop or improve treatments for patients with these disorders. He is currently collaborating with both the Retina and Ophthalmic Pathology Divisions in separate clinical research projects. Dr. Casey is engaged in a study to evaluate the ocular surface of patients undergoing corneal transplantation surgery to establish previously undescribed clinical-pathologic correlation with tear insufficiency and corneal epithelial abnormalities. The goal of these investigations is to improve the success of corneal transplantation in high-risk patients with the comorbid conditions of tear insufficiency and other anterior segment disorders. He is also working with the Retina Division to determine which variables improve corneal transplant survival when corneal transplantation is combined with vitreoretinal surgery.

Public Health Services/Health Access

Dr. Casey has elected to dedicate a significant portion of his professional career to improving access to health care in specific underserved communities of Los Angeles. He has focused on assessing unmet needs in vision health and developing innovative strategies to meet these deficits. He established the Los Angeles Ophthalmology Medical Group in 2001, which provides comprehensive eye care services in South Los Angeles.
Anne L. Coleman, MD, PhD

The Fran and Ray Stark Foundation Chair in Ophthalmology
Professor of Ophthalmology
Professor of Epidemiology
Director of the Stein Eye Institute Centers for Community Outreach and Policy, Eye Epidemiology, and the UCLA Mobile Eye Clinic
Vice Chairman of Academic Affairs, UCLA Department of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Glaucoma, Cataract, and Age-Related Macular Degeneration

Dr. Coleman’s research is directed toward the diagnosis, treatment, and societal impact of glaucoma, cataracts, and age-related macular degeneration, including the study of lifestyle limitations imposed on patients with these kinds of eye diseases. Clinical projects include studies that analyze the genetic markers in the trabecular meshwork of patients undergoing glaucoma surgery, the prevention of visual impairment and blindness in school-age children, comparative effectiveness research, and glaucomatous visual field and optic nerve progression.
Joseph L. Demer, MD, PhD

Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology
Professor of Ophthalmology
Professor of Neurology
Chief of the Pediatric Ophthalmology and Strabismus Division
Member of the Stein Eye Institute

**Research Summary**

**Motility and Vision**

Dr. Demer studies the role of the brain and extraocular muscles in the control of eye movements and visual perception. He is directing a National Eye Institute research project aimed at developing an understanding of the role of orbital connective tissues and nerves in the development of binocular coordination disorders, such as strabismus, and is developing new technologies for magnetic resonance imaging of extraocular muscles and nerves. This research has contributed to the knowledge of the functional anatomy of extraocular muscles and connective tissues, allowing development of new types of surgeries. An emerging research topic is the possible role of extraocular muscle forces in the development of optic neuropathies, such as glaucoma and anterior ischemic optic neuropathy.

Dr. Demer’s research also employs novel micro- and nano-technological techniques to study the biomechanical properties of the extraocular muscles and associated tissues, as well as optical and x-ray imaging of the effects of physiological forces in the tissues.

**Public Service**

- Editorial Board Member, *Investigative Ophthalmology and Visual Science*
- Editorial Board Member, *Journal of the American Association for Pediatric Ophthalmology and Strabismus*
- Associate Editor, *Strabismus*
- Grant Reviewer, United States Public Health Service
- Scientific Advisory Committee Member, Knights Templar Eye Foundation
- Council Member, International Strabismological Association
- Reviewer for many medical and scientific journals

**Research Grants**

- National Eye Institute: Biomechanical Analysis in Strabismus Surgery, 5/1/16–4/30/20
- Knights Templar Eye Foundation Inc.: Ghada Sein El-Abedin Rajab, Training Mentors in Developing Countries (TMDC) Pediatric Ophthalmology Fellowship, 9/1/15–8/31/16
Sophie X. Deng, MD, PhD

Associate Professor of Ophthalmology
Member of the UCLA Jonsson Comprehensive Cancer Center
Member of the UCLA Broad Stem Cell Research Center
Member of the Stein Eye Institute

RESEARCH SUMMARY

Limbal Stem Cell Deficiency

Dr. Deng’s research is focused on improving the current diagnosis and treatments for patients with limbal stem cell deficiency. One of her ongoing clinical studies using laser scanning in vivo confocal microscopy in patients with limbal stem cell deficiency shows correlated cellular changes in the cornea and limbus. Damages to the limbal stem cells could be detected and correlated with clinical presentation. This new technique could allow for a better understanding of the pathophysiology of limbal stem cell deficiency. Another study focuses on finding a better diagnostic marker for limbal stem cell deficiency. By using the new diagnostic marker and in vivo confocal imaging, a timely diagnosis and staging of disease progression could be achieved.

Dr. Deng’s laboratory studies the microenvironment/niche of the limbal stem cells to elucidate those factors that govern the fate of limbal stem cells. The role of the Wnt signal transduction pathway in human limbal stem/progenitor cells is under investigation. Recent study in her laboratory reveals that activation of the Wnt/β-catenin promotes self-renewal of limbal stem cells and that Frizzled 7 might be the receptor that mediates the Wnt activation. Use of small molecules to modulate Wnt signaling is being investigated to increase the efficiency of ex vivo expansion of limbal stem cells for transplantation.

Dr. Deng’s laboratory is also trying to achieve patient-specific therapy by regenerating autologous limbal stem cells in a xenobiotic-free culturing system for transplantation. They have developed xenobiotic-free and feeder-free culture methods to expand autologous limbal stem cells in culture. Preclinical studies are ongoing to bring this stem cell therapy to restore vision in patients who suffer from limbal stem cell deficiency.

Cornea Endothelial Dysfunction

Another area of Dr. Deng’s research is the development of cell therapy to treat endothelial dysfunction by regeneration of human corneal endothelial cells. Currently, her laboratory focuses on investigating the signature genes of cornea endothelial cells and the regulation of these quiescent cells. Another project aims to increase the efficiency of expansion of corneal endothelial cells in culture and derivation of these cells from pluripotent stem cells.

Research Grants

California Institute for Regenerative Medicine (CIRM): Regeneration of Functional Human Corneal Epithelial Progenitor Cells, 3/1/11–4/30/15

Dompe Pharmaceutical: An 8-week Phase II, Multicenter, Randomized, Double-Masked, Vehicle Controlled Parallel Group Study with a 24 or 32 Week Follow-Up Period to Evaluate the Efficacy of a Formulation Containing Antioxidant of Recombinant Human Nerve Growth Factor, 3/17/15–3/16/17

National Eye Institute: Ex Vivo Expansion of Human Limbal Stem Cells for Transplantation, 9/1/12–8/31/17

Honors

Received the IEEE Transactions on THz Science and Technology Best Paper Award for significant contribution to the field of endeavor in May 2016.

Public Service

Member, American Academy of Ophthalmology Ophthalmic Technology Assessment Committee, Cornea and Anterior Segment Disorders Panel

Member, Annual Meeting Program Committee (Cornea Section), Association for Research in Vision and Ophthalmology

Reviewer for many scientific journals

Sophie X. Deng, MD, PhD

Associate Professor of Ophthalmology
Member of the UCLA Jonsson Comprehensive Cancer Center
Member of the UCLA Broad Stem Cell Research Center
Member of the Stein Eye Institute
Gordon L. Fain, PhD

Distinguished Professor of the Departments of Integrative Biology/Physiology and of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Physiology of Photoreceptors in the Vertebrate Eye

Dr. Fain’s primary research interest is in the physiology of photoreceptors in the vertebrate eye. A vertebrate photoreceptor uses a photopigment called rhodopsin and a G-protein cascade to produce the electrical response that signals a change in light intensity. Powerful new techniques have made it possible to understand the working of this cascade in extraordinary detail. Practically all the protein molecules involved in the cascade in a photoreceptor—from the pigment molecule to the G-protein and channels, but also including a large number of control proteins—are expressed only in the photoreceptors and nowhere else in the body. This has enabled scientists to use genetic techniques to create mice in which these proteins have been knocked out, over- or under-expressed, or replaced with proteins of modified structure.

Dr. Fain’s laboratory uses electrical recording to study the effects of such genetic alterations on the light responses of mouse rods, in order to understand the role of these proteins in the visual cascade. His research team is especially interested in modulatory enzymes and their function in light and dark adaptation. Dr. Fain also has a long-standing interest in mechanisms of photoreceptor degeneration in genetically inherited disease. His laboratory is presently the only laboratory measuring changes in calcium from mouse rods with fluorescent dyes. Findings have implicated both increases and decreases in calcium concentration as contributing factors in the triggering of apoptosis. Such information may provide insight into the mechanisms of retinal degeneration.

Research Grants
National Eye Institute: Physiology of Photoreceptors, 8/1/12–7/31/17
Great Lakes Fishery Commission: Detection of Light by the Sea Lamprey Petromyzon Marinus, 1/14–12/16
Dr. Farber’s research focuses on the isolation and characterization of genes involved in inherited retinal diseases. Her team has cloned several genes encoding proteins that play a key role in vision, and that when mutated cause blinding diseases. These include the β-PDE gene (mutations cause blindness in rd mice and Irish setter dogs), and in one type of human autosomal recessive retinitis pigmentosa (arRP); the RP1 gene (responsible for a type of autosomal dominant RP); the gene causing disease in rd7 mouse—a model for Enhanced S-Cone Syndrome; the α-transducin gene, disrupted in the Rd4 mouse, another model of retinal disease; and the mouse homologue of the gene causing X-linked juvenile retinochoroidopathy (Xlrs1).

Utilizing gene therapy methods, Dr. Farber and collaborators delivered the normal β-PDE gene to rd mouse retinas and rescued their photoreceptors.

Dr. Farber’s group also worked on the mechanisms that regulate transcription and expression of retinal genes. They found that the transcription factor SP4 controls the activity of the β-PDE promoter and mutations in both SP4 and α-transducin cause digenic arRP and cone-rod dystrophy (arCRD). Other projects included the identification of the novel cone genes, ZBED4 and RHBD2, and of mutations in them causing arCRD and arRP, respectively; and the characterization of animal models of ocular albinism, which lack the OA1 gene and are affected with permanent visual impairment. An important discovery related to this work is that specific activation by OA1 of Gαi3 is the first step in the cascade of events involved in RPE melanogenesis, which is abnormal in ocular albinism.

Lately, Dr. Farber’s team pioneered the characterization of microvesicles released by embryonic stem cells (ESMVs), determined how they transfer their cargo to other stem cells or cells of other origin, and studied the effects that they have on cultured retinal progenitor Müller cells in vitro. These studies led them to investigate a totally unexplored possibility: the use of ESMVs in the rescue of damaged retinas. This work is currently the main focus of Dr. Farber’s group.
JoAnn A. Giaconi, MD

Health Sciences Associate Clinical Professor of Ophthalmology
Chief of the Ophthalmology Section at the Greater Los Angeles VA Healthcare System
Co-Director of Medical Student Education at the David Geffen School of Medicine, UCLA
Member of the Stein Eye Institute

RESEARCH SUMMARY

Glaucoma

Dr. Giaconi’s research focuses on the treatment of glaucoma. She is interested in glaucoma surgery outcomes and side effects. She is currently working on various projects in the Veteran population, including examination of the overtreatment or undertreatment of glaucoma. She is enrolling patients in two clinical studies at the Stein Eye Institute. One study is examining the effect of various glaucoma surgeries on the corneal endothelium, which is the layer of cells that keeps the cornea clear, and the other study is investigating a new surgical device.
Dr. Glasgow’s research interests are primarily in the field of ophthalmic pathology. His major focus is the role of human lacrimal gland proteins in the protection and maintenance of the eye. His laboratory is investigating the structure-function relationship of tear lipocalin, the principal lipid carrier protein of tears. Currently, the laboratory has developed a technique called site-directed tryptophan fluorescence to probe and report information regarding molecular motion and solution structure. By studying the molecular mechanisms of tear proteins, Dr. Glasgow is seeking to learn the normal functions of tear lipocalin and its role in maintaining the health of the ocular surface and in the prevention of dry eye diseases. It is hoped that this research will lead to new treatments for dry eye and have broad application to numerous other members of this protein family that transport small, insoluble molecules through the body.
RESEARCH SUMMARY

Diseases and Therapy of the Eyelid and Orbit

Outcomes of medical and surgical treatment of orbital and eyelid disorders are being studied in an organized, prospective fashion in order to better understand which treatments are most effective.

Research into the various surgical approaches to Graves orbitopathy (thyroid eye disease) has resulted in new techniques that include less invasive small incision surgical approaches. In addition, detailed clinical information gathered from patients with Graves orbitopathy is being recorded in a shared database as a way to understand the natural history and response to treatment of this multifaceted disease, which is a cause of significant visual loss and discomfort. Multicenter studies are underway. Dr. Goldberg is also investigating the underlying causes of thyroid-related orbitopathy. The goal of this research is to develop better tests to monitor disease activity, as well as new treatments to address the basic cause of the disease.

Research into orbital and eyelid anatomy, currently in progress, is resulting in improved techniques and approaches to deep orbital disease. Included is the use of high-resolution magnetic resonance imaging and high-resolution dynamic ultrasonography to evaluate motility problems following trauma and orbital surgery, and three-dimensional analysis of orbital anatomy. Improved understanding of eyelid and orbital physiology and anatomy is the basis for developing improved surgical techniques. Instrumentation and devices that allow less invasive surgical approaches, such as hyaluronic acid gels, are being developed and studied. In collaboration with the Department of Engineering, custom materials for orbital reconstruction are investigated.
Dr. Gordon’s laboratory is involved in two primary areas of research. One project investigates the role for epithelial membrane protein 2 (EMP2) in controlling ocular pathologic responses. Dr. Gordon and her colleagues identified that EMP2 plays an important role in an in vitro model of proliferative vitreoretinopathy (PVR) and have evidence that EMP2 is highly expressed in human retinal diseases. In addition, they recently identified that EMP2 controls VEGF production in epithelial cells and in specific tumors. The laboratory, in collaboration with others at UCLA, has recently developed a designer antibody fragment that has demonstrated efficacy in in vitro studies in the PVR model and in other animal models in vivo. This antibody has now been successfully used to control pathologic neovascularization in a corneal burn model, achieving proof of principle for using this antibody to control disease.

The second area of interest of Dr. Gordon’s group is the role of programmed death 1 (PD-1), a molecule that is known to play an important role in immune regulation in the eye. PD-1 has a major function as a negative regulator in the immune system. Although previous studies identified PD-1 expression in the lymphoid system, Dr. Gordon and her colleagues identified its expression in neuronal cells of the retina. Additionally her laboratory has identified that blockade of the PD-1 pathway may be protective in uveitis. Studies are ongoing to identify the mechanisms of that protection.
Michael B. Gorin, MD, PhD

Harold and Pauline Price Chair in Ophthalmology
Professor of Ophthalmology
Professor of Human Genetics
Chief of the Division of Retinal Disorders and Ophthalmic Genetics
Member of the Stein Eye Institute

RESEARCH SUMMARY

Heritable Eye Disorders and Molecular Genetics of Age-Related Maculopathy

Dr. Gorin’s primary research focus is molecular genetics of heritable eye disorders, specifically age-related macular degeneration (AMD). His research group was the first to identify specific regions of the genome that contributed to ARM development in families, leading to discovery of gene variations that contribute to the risk of developing ARM. He continues to work on studies of the genetics of AMD, in particular the use of genetic risk profiles to test for clinical markers, including sensitive methods for detecting changes in retinal structure and function that precede the onset of clinical disease.

Dr. Gorin investigates the molecular genetics of complex disorders such as cystoid macular edema, age-related cataracts, and glaucoma, as well as monogenic disorders such as hereditary retinal degenerations, glaucoma, cataracts, and ocular syndromes. He is pursuing studies to identify genetic variations that contribute to the severity, complications, and therapeutic responses of these conditions. Dr. Gorin and his clinical team work with the clinical and research human genetics group at UCLA to explore use of new technologies, including next-generation sequencing for clinical utility in ophthalmic genetics.

Research also focuses on the neurobiology of ocular pain and photophobia (sensitivity to light) to understand the basic biology and neural pathways that contribute to photophobia so that new therapeutic strategies can be developed. Based upon preliminary work, opportunities have emerged to investigate the pathogenesis of light sensitivity for individuals who suffer from migraines and/or mild traumatic brain injury.

Clinical research efforts are directed towards developing methods to monitor and quantify retinal function in progressive retinal disorders (such as diabetic retinopathy, Stargardt disease, and retinitis pigmentosa) and in patients with potential ocular toxicities from systemic medications. Applied research interests include bioinformatics in clinical ophthalmic practice and public health issues pertaining to ocular disease.

Public Service

Member, Medical Education Committee, David Geffen School of Medicine at UCLA
Editorial Board Member, Current Eye Research and Experimental Eye Research
Advisory Board Member, American Health Assistance Foundation
Member, Ad Hoc Committee for Faculty Advancement and Promotions for the Department of Human Genetics, UCLA
Member, Special National Institutes of Health Study Sections for the National Eye Institute, National Institute on Aging (Claude Pepper Grants), National Human Genome Research, Center for Inherited Disease Research
Scientific Advisory Committee Member, BrightFocus Foundation and the Knights Templar Eye Research Foundation
Founding Member, von Hippel-Lindau Center of Excellence at UCLA Medical Center
Member, Clinical Research Governance Committee for UCLA
Member, Data Safety Monitoring Board for jCyte RP Trial JC-01
Reviewer for many scientific journals

Research Grants

Arnold and Mabel Beckman Foundation: Genetics-based Testing of Functional and Structural Endophenotypes for Pre- and Early-Age-Related Macular Degeneration (AMD), 7/1/14–6/30/17
Nightstarx: Natural History of the Progression of Choroideremia Study, 6/18/15–5/31/17
Alkeus Pharmaceuticals Inc.: A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease, 5/23/16–5/23/18
David Rex Hamilton, MD, FACS

Health Sciences Clinical Professor of Ophthalmology
Director of the UCLA Laser Refractive Center
Member of the Stein Eye Institute

RESEARCH SUMMARY

Advanced Intraocular Lenses

Dr. Hamilton’s research interests are in the areas of corneal biomechanics and tomography (3D imaging of the cornea), screening for corneal ectatic disorders, and the clinical study of intraocular lenses (IOLs) for the treatment of high myopia (phakic IOLs), astigmatism (toric IOLs), and presbyopia (multifocal and accommodating IOLs). Dr. Hamilton is actively involved in training residents and fellows in the surgical treatment of refractive errors and cataracts.

Public Service

Editorial Board Member, Ophthalmology, Journal of Refractive Surgery, and Journal of Cataract and Refractive Surgery
Member, Refractive Leadership Council, Alcon Laboratories
Member, ASCRS Refractive Surgery Clinical Committee
Member, ASCRS Refractive Surgery/Cataract Clinical Subcommittee
Member, American Academy of Ophthalmology, Preferred Practice Pattern Committee for Refractive Surgery
Member, American Academy of Ophthalmology, ONE Network, Refractive Surgery
Gary N. Holland, MD

Jack H. Skirball Chair in Ocular Inflammatory Diseases
Professor of Ophthalmology
Director of the Ocular Inflammatory Disease Center
Director of the UCLA Department of Ophthalmology Clinical Research Center
Co-Director of Medical Student Education
Member of the Stein Eye Institute

RESEARCH SUMMARY

Uveitis and Cornea-External Ocular Diseases

Dr. Holland’s research deals with infectious and inflammatory diseases of the eye, including ocular toxoplasmosis; HIV-related eye disease; chronic anterior uveitis in children; and birdshot chorioretinopathy. Clinical studies are being performed to identify populations at greatest risk for these ocular diseases and factors that influence disease severity. Studies also investigate the course of these diseases and response to new treatments. Better understanding of these conditions may lead to improved disease management.

Ocular toxoplasmosis, caused by a parasite, is the most common retinal infection in the general population. With investigators in North America, Brazil, and Europe, Dr. Holland is studying human and parasitic genetic factors that influence risk for ocular involvement among people infected with the parasite.

Dr. Holland continues to study cytomegalovirus (CMV) retinitis, the most serious eye problem among HIV-infected individuals, and still a major public-health problem in many areas of the world because of the AIDS pandemic. He is also investigating HIV-related “neuroretinal disorder” (NRD), a degenerative condition that causes deterioration of vision and reduced quality of life, even among individuals whose immune function has improved because of antiretroviral drugs. NRD is also a marker of non-ocular, life-threatening diseases among HIV-infected people.

Chronic anterior uveitis is a common complication of juvenile idiopathic arthritis (JIA). Dr. Holland is studying risk factors for, and treatment of, vision-threatening complications of JIA-associated uveitis, including glaucoma, and he is interested in the psychosocial impact of uveitis on children and their families.

Birdshot chorioretinopathy is a chronic autoimmune disease of the eye. Dr. Holland is participating in several multicenter studies involving retinal imaging and electrophysiologic techniques to understand the basis for vision loss among people with the disease. He also helped to organize and is analyzing data from a 10-year longitudinal clinical study of the disease that involves a large cohort of patients.

Public Service
Associate Editor, American Journal of Ophthalmology
Editorial Board, EyeNet Magazine (American Academy of Ophthalmology), Section Editor, Uveitis
Executive Committee Member, American Uveitis Society

Research Grants
Ocata Therapeutics (formerly Advanced Cell Technology, Inc.): ARO Agreement A Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation…Patients with Stargardt Macular Dystrophy SMD, 4/25/11–12/12/16
Ocata Therapeutics (formerly Advanced Cell Technology, Inc.): ARO Agreement A Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation…Patients with Advanced Dry AMD, 5/31/11–12/12/16
Ocata Therapeutics (formerly Advanced Cell Technology, Inc.): Monitoring of a Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation…Patients with Geographic Atrophy Secondary to Myopic Macular Degeneration, 3/31/14–3/31/16
National Eye Institute (subaward from Johns Hopkins University): Multicenter Uveitis Steroid Treatment (MUST) Trial, 6/1/12–4/30/17
National Eye Institute (subaward from Johns Hopkins University): Macular Edema Treatment Trial Associated with MUST (META-MUST), 9/30/14–1/31/17
University of Pittsburgh, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (SITE), 3/2/16–3/2/21
University of Pittsburgh, Systemic Immunosuppressive Therapy for Eye Disease (Cancer Surveillance and Research Branch/CCR), 3/2/16–3/2/21
Dr. Horwitz is conducting research on the biochemical and biophysical properties of normal and cataractous lens proteins. In addition, he is investigating the molecular chaperone properties of the lens’ alpha-crystallin, a protein that plays an important role in keeping the eye lens clear during normal aging. Alpha-crystallin is also involved in age-related macular degeneration, as well as in many other neurodegenerative diseases. New spectroscopical techniques are currently being developed for studying protein function and structure utilizing extremely high hydrostatic pressure.
Wayne L. Hubbell, PhD

Jules Stein Chair in Ophthalmology  
Distinguished Professor of Ophthalmology  
Distinguished Professor of Chemistry and Biochemistry  
Co-Chief of the Vision Science Division  
Associate Director of the Stein Eye Institute

RESEARCH SUMMARY

**Molecular Basis of Phototransduction in the Vertebrate Retina**

Dr. Hubbell’s research is focused on understanding the complex relationship between molecular structure, plasticity, and conformational changes that control protein function in the visual system. Of particular interest are proteins that behave as “molecular switches,” that is proteins whose structures are switched to an active state by a physical or chemical signal. Examples include rhodopsin, the membrane-bound photoreceptor protein of the retina, and transducin and arrestin, proteins that associate with rhodopsin during function. The overall goal is to determine the structure of these proteins in their native environment, monitor the changes in structure that accompany the transition to an active state, and to understand the role of protein flexibility in function.

To investigate these and other proteins, Dr. Hubbell’s laboratory has developed the technique of site-directed spin labeling, a novel and powerful approach to the exploration of protein structure and dynamics. By changing the genetic code, a specific attachment point in the protein is created for a nitroxide spin label probe. Analysis of the electron paramagnetic resonance (EPR) spectrum of the spin label provides information about the local environment in the protein. With a sufficiently large set of labeled proteins, global information on structure is obtained and changes in the structure during function can be followed in real time. While determination of static protein structure is important to understanding function, current research has highlighted a crucial role for protein flexibility (dynamics), which has not been previously appreciated. To explore molecular flexibility in proteins of the visual system, Dr. Hubbell’s group is developing novel methods using time-domain and high-pressure EPR.
Jean-Pierre Hubschman, MD

Associate Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Advanced Vitreoretinal Surgical Interventions and Robotics

Dr. Hubschman’s clinical research focuses on the development and evaluation of new vitreoretinal surgical techniques and robotics for ophthalmic surgery. Automated surgery utilizing robotics promises to increase surgical precision and accuracy, as well as improve access to medical care. Dr. Hubschman’s publications include research papers on the development of a new retinal patch for the treatment of retinal detachment, on the feasibility of robotic surgery in ophthalmology, and results of various clinical trials. Currently, he is also investigating the use of the terahertz laser for the evaluation of ocular tissue hydration.

Public Service
Reviewer for many scientific journals

Research Grants
National Eye Institute: Intraocular Robotic Interventional Surgical System for Cataract Surgery Project, 9/30/14–9/29/16
Lowy Medical Research Institute: A Ph 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (Mac Tel), 8/6/14–6/30/18
Lowy Medical Research Institute: A Natural History of Macular (Parafoveal) Telangiectasia, 9/1/05–12/31/18
Ophthotech Corporation: A Phase 3, RDM, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Apramer) Administered… ARMD, 12/4/13–12/3/16
Thrombogenics, Inc.: Ocriplasmin Research to Better Inform Treatment, 7/16/14–7/15/16
RESEARCH SUMMARY

Pediatric Ophthalmology, Amblyopia, and Ophthalmic Pharmacology

Dr. Isenberg’s research activities have concentrated on various aspects of surgical and medical diseases of children’s eyes. The goal is to decrease the frequency of blindness in children worldwide. In a series of studies of newborns, Dr. Isenberg has characterized a number of elements, including: the type and source of bacteria of the external eye at birth; the evolution of iris structural changes; the development of the macula, which is the source of central vision; and pupillary responses after birth. Recent publications have characterized the production and nature of tears of infants and the development of the cornea in the first year of life. He has also reported the ocular signs in newborns whose mothers abuse cocaine, facilitating the diagnosis of newborn cocaine intoxication.

In another avenue of research, povidone-iodine eyedrops have been found to treat bacterial conjunctivitis successfully in a three-year, international study with the University of the Philippines. The eyedrops were also found to be safer and more effective in preventing eye infections than the currently used agents. Dr. Isenberg and other investigators have now proven that the povidone-iodine eyedrops can treat the number one cause of preventable pediatric blindness in the world—corneal infections due to bacteria. These studies, conducted in children and adults in India and the Philippines, should reduce the number of 400,000 children now blind from corneal infections. A new study investigating fungal infections of the eye, which blind approximately 10,000 children annually, has been completed at three sites in India.

Lastly, a new device that reports blood gases from the conjunctiva, such as oxygen and carbon dioxide, is being developed. Preliminary trials have been completed in animals and in adults undergoing cardiac bypass surgery. The hope is to apply the device to the eyes of premature newborns. The continuous readout of tissue blood gas levels should enable the pediatrician to prevent damage to the baby’s brain and keep the oxygen at an appropriate level, minimizing the possibility of blindness from retinopathy of prematurity.
Dr. Law’s principal research interest focuses on the structural appearance of the optic disc in different ocular diseases, including patients with high myopia. Assessment of optic disc size is an important component of the diagnostic evaluation for glaucoma. Patients with high myopia are at greater risk of developing glaucoma, and they also have an atypical optic disc that makes diagnosis difficult. The purpose of Dr. Law’s research is to characterize the appearance of the optic disc in eyes with high myopia and to identify the related risk factors for development of glaucoma.

**Glaucoma Tube Shunt Procedure**

To prevent intraocular pressure spikes after an Ahmed valve or tube shunt procedure for glaucoma, Dr. Law is evaluating the effect of using antiglaucoma medications at different times following surgery. Patients are randomized to receive antiglaucoma medications either at an early phase or at the standard time following the surgical procedure.

**Acupuncture and Glaucoma**

Dr. Law is conducting a prospective study to evaluate the effect of acupuncture in glaucoma.Acupuncture is a popular alternative medicine based on traditional Eastern medical theory. Its effect on glaucoma has not been objectively and scientifically studied.
Ralph D. Levinson, MD

Health Sciences Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Ocular Inflammatory Diseases

Dr. Levinson’s research interest is ocular inflammatory diseases. He is the primary investigator on international research projects in both the clinical aspects of uveitis and the basic mechanisms and immunogenetics of ocular inflammation. Current projects include a collaborative longitudinal study of a chronic inflammatory disease, birdshot chorioretinopathy, with investigators in France. The study focuses on the interrelationship of disease factors, as well as the course of disease and response to treatment.

Dr. Levinson is also conducting laboratory research on cell-based therapies for uveitis.
Colin A. McCannel, MD

Professor of Clinical Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Vitreoretinal Surgery

Dr. McCannel has a longstanding interest in the management of vitreoretinal conditions, particularly complex retinal detachments, complications of diabetic retinopathy, macular holes and epimacular membranes, and age-related macular degeneration. His clinical research efforts are directed at the improvement of vitreoretinal surgical techniques and outcomes, including the prevention of endophthalmitis following intravitreal injections.

Dr. McCannel devotes time to educational research as well. Currently, he is investigating the utility of virtual reality surgery simulation in teaching ophthalmic surgery. He has several ongoing protocols that assess ophthalmic surgical simulation in surgical teaching.

Public Service
Moderator, “Retina Talk” online discussion forum, American Association of Retina Specialists
Chair, Editorial Committee, Retina and Vitreous Basic and Clinical Science Course, Section 12, American Academy of Ophthalmology
Medical Information Technology Committee Member, American Academy of Ophthalmology
Reviewer for many scientific journals

Research Grants
Genentech, Inc.: A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration, 9/22/15–1/31/17
Tara A. McCannel, MD, PhD
Health Sciences Associate Clinical Professor of Ophthalmology
Director of the Ophthalmic Oncology Center
Member of the Stein Eye Institute

RESEARCH SUMMARY

Metastatic Ocular Melanoma

Dr. McCannel’s primary research interest is metastatic ocular melanoma. Under her direction, the Ophthalmic Oncology Laboratory is studying molecular markers in ocular melanoma to provide prognostic information to patients and advance understanding of metastatic disease. Discovery of candidate genes from tissue of patients undergoing surgical treatment for ocular melanoma is being explored. This information will be important to establish a better understanding of the biology of metastatic ocular melanoma and help develop better treatments for this cancer. New modalities are being investigated to predict, detect, and ultimately treat choroidal melanoma metastasis.

Surgical Approaches to Vitreoretinal Disease and Cancer

Dr. McCannel is both a vitreoretinal surgeon and an ophthalmic oncologist. She manages the spectrum of vitreoretinal disease in addition to the surgical management of ocular melanoma, allowing patients to benefit maximally from her wide range of surgical prognostic and therapeutic expertise.

Vitrectomy with silicone oil placement is a novel therapeutic strategy, which was discovered at UCLA to reduce radiation exposure to the healthy structures of the eye during plaque surgery for melanoma treatment. Dr. McCannel offers this potentially sight-saving technique to patients who need radiation treatment.

Health Psychology and Ocular Melanoma

Central to incorporating an integrative approach to health care, the concerns and wishes of the patient as a whole are important aspects of cancer management. In collaboration with the UCLA Department of Health Psychology and the Jonsson Comprehensive Cancer Center, Dr. McCannel works closely with health psychologists who are interested in providing clinical care while researching factors, which predict psychological adjustment to cancer.
Kevin M. Miller, MD
Kolokotrones Chair in Ophthalmology
Professor of Clinical Ophthalmology
Chief of the Cataract and Refractive Surgery Division
Director of the Anterior Segment Diagnostic Laboratory
Member of the Stein Eye Institute

RESEARCH SUMMARY

Cataract and Refractive Surgery

Dr. Miller’s research interests are in cataract and refractive surgery, intraocular lenses, artificial iris implants, ophthalmic optics, surgical devices, and surgical outcomes.

Dr. Miller’s clinical practice focuses primarily on refractive cataract surgery and the surgical correction of presbyopia and astigmatism with premium technology intraocular lenses. He developed an astigmatism management service for treating corneal astigmatism at the time of cataract surgery that optimizes postoperative uncorrected visual acuity. He developed a nomogram for peripheral corneal relaxing incisions and participated in the clinical trial of the world’s most popular toric intraocular lens. He was instrumental in bringing femtosecond laser technology to UCLA for use in cataract surgery. He described a non-parametric multivariate technique for comparing astigmatism outcomes between treatment groups. In addition to refractive cataract surgery and ICL implantation, he also performs DSEK, LASIK, PRK, and other cornea-based laser refractive procedures.

Dr. Miller runs several clinical trials of artificial iris implants to treat congenital and acquired aniridia. He completed the multicenter Ophtec 311 clinical trial. He has an individual device exemption from the FDA to study Morcher GmbH artificial iris implants. He is the only surgeon in the United States who is permitted by the FDA to implant Morcher devices at this time. He is also studying a custom artificial iris implant from Dr. Schmidt Intraocularlinsen, a subsidiary of HumanOptics AG. All of these devices are showing promising results in patients who suffer from congenital and acquired iris defects.

Finally, he is an investigator in the Calhoun Vision light adjustable lens study and the Alcon high-power toric lens post-market approval study.

Honors
Received the Secretariat Award at the November 2015 American Academy of Ophthalmology annual meeting in Las Vegas, Nevada.
First listing in Ocular Surgery News’ Premier Surgeon 300, Innovators in Refractive Cataract Surgery.

Public Service
Course Director, Southern California Basic and Advanced Cataract Surgery Courses for Residents and Fellows
Co-Organizer, Biannual Curso Universitario Internacional de Oftalmologia, Santiago, Chile
American Academy of Ophthalmology, Skills Transfer Course Advisory Committee
American Academy of Ophthalmology, Annual Meeting Program Committee, Cataract Subcommittee
American Academy of Ophthalmology, Preferred Practice Patterns Committee, Anterior Segment Panel
American Society of Cataract and Refractive Surgery, Cataract Clinical Committee, Retina Clinical Committee, and Skills Transfer Subcommittee
Executive Editor, American Journal of Ophthalmology
Faculty of 1000, Post-Publication Peer Review, Lens Disorders Section
International Editorial Board, Oftalmologia Em Foco and Revisita Brasileira de Oftalmologia
Editorial Board, Cataract Section, American Society of Cataract and Refractive Surgery, EyeWorld Magazine
Editorial Board, Cataract and Refractive Surgery Today
Editorial Board, American Academy of Ophthalmology, EyeNet Magazine
Reviewer for many scientific journals

Research Grants
Alcon Laboratories, Inc.: Post Approval Study of the Acrysof IQ Toric High Cylinder Power Intraocular Lens (IOL), 4/17/12–11/18/16
Calhoun Vision, Inc.: A Prospective Randomized Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens, 7/26/12–7/28/16
Clinical Research Consultants, Inc.: Safety and Effectiveness of the Customflex Artificial Iris Prosthesis for the Treatment of Iris Defects (AI-001), 6/12/14–4/26/17
Bartly J. Mondino, MD

Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology
Distinguished Professor of Ophthalmology
Chairman, UCLA Department of Ophthalmology
Director, Stein Eye Institute
Member, UCLA Brain Research Institute
Board of Directors (Observer), Doheny Eye Institute
Affiliation Chairman, Doheny Eye Institute

RESEARCH SUMMARY

Cornea and External Ocular Diseases and Immunological Disorders

Dr. Mondino’s research activity is focused on cornea-external ocular diseases, with particular emphasis on immunological disorders. He has studied the role of lymphocytes and the complement system in the immunopathogenesis of anterior segment diseases. In addition, a model of staphylococcal hypersensitivity lesions of the cornea was explored as well as the immune response to staphylococcal endophthalmitis. Other research interests included corneal dystrophies, peripheral corneal ulcers, bullous diseases of the skin and mucous membranes, collagen shields, and contact lens-related corneal ulcers.

Honors
Delivered the 24th Walter J. Stark Memorial Lecture on September 28, 2015, at Dean McGee Eye Institute in Oklahoma City, Oklahoma.

Public Service
Medical Advisory Board Member, Braille Institute
Editorial Board Member, *Ophthalmic Surgery, Lasers and Imaging*
Vice President and Board of Directors Member, National Alliance for Eye and Vision Research
Affiliation Chairman, Doheny Eye Institute

Research Grants
Research to Prevent Blindness: Departmental Unrestricted Grant Award (Annual), 1/1/12–12/31/16
Dr. Nouri-Mahdavi’s research is focused on improving methods to detect early glaucoma and glaucoma deterioration with spectral-domain optical coherence tomography (SD-OCT) and various perimetry techniques. More specifically, he is interested in detection of glaucoma progression in patients with advanced disease. Dr. Nouri-Mahdavi is currently exploring the role of macular imaging for detection of glaucoma progression in a cohort of advanced glaucoma patients.

Glaucoma Treatment Outcomes and Role of Ethnicity

Dr. Nouri-Mahdavi is also interested in studying glaucoma treatment outcomes and their variations as a function of ethnicity. An ongoing study is comparing the long-term outcomes of trabeculectomy with adjunctive mitomycin C in patients of African descent to those of European descent.
Steven Nusinowitz, PhD

Professor of Ophthalmology
Co-Director of the Visual Physiology Laboratory
Director of the Live Imaging and Functional Evaluation (LIFE) Core
Member of the Stein Eye Institute

RESEARCH SUMMARY

Mechanisms of Retinal Degeneration

Dr. Nusinowitz’s primary research interest is focused on understanding the cellular contributions to noninvasive measures of visual function and defining the sites and mechanisms of disease action in inherited retinal and visual pathway disorders. In his research laboratory, Dr. Nusinowitz’s main approach to gaining an understanding of the site and mechanism of vision loss in humans is to study the patterns of electrophysiological responses obtained from mice in which the disruption of different cells or pathways in the visual system are specifically targeted by genetic manipulation. By comparing the patterns of responses in human disease with the patterns of responses from rodents with targeted cellular disruption, Dr. Nusinowitz is able to test hypotheses about the underlying pathophysiology in human disease and to provide a mechanism for the development of specific diagnostic tools that are sufficiently sensitive for early detection and better diagnosis of clinical disease. In addition, on a more applied level, Dr. Nusinowitz’s research studies in both humans and mice have involved investigations testing the efficacy of multiple therapeutic interventions for retinal disease, including pharmacological, viral, and stem cell therapies.

Public Service
Editorial Board Service, Current Eye Research
Grant Reviewer: National Eye Institute (ad hoc)
Intramural Program Review Committee: National Eye Institute
Scientific Advisor: The Mouse Mutant Resource, The Jackson Laboratory; and Ionis (formerly ISIS) Pharmaceuticals, Inc.
Data Safety Monitoring (Clinical Trials): New Drug Investigations, Ionis (formerly ISIS) Pharmaceuticals, Inc. Allergan Pharmaceuticals

Research Grants
BrightFocus Foundation: Scotopic Critical Flicker Fusion in Preclinical AMD, 7/1/15–6/30/17
Dr. Pineles’ research interests include evaluating the surgical outcomes of strabismus surgery and studying pediatric optic nerve diseases. With her dual training in pediatric ophthalmology and neuro-ophthalmology, she has a special interest in pediatric neuro-ophthalmic diseases, as well as adult patients with amblyopia and neurologic causes of strabismus.
Natik Piri, PhD

Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Retinal Ganglion Cell Biology, Glaucomatous Neurodegeneration, and Neuroprotection

The main directions in Dr. Piri’s research are defining the mechanisms leading to retinal ganglion cell (RGC) degeneration in glaucomatous neuropathy; developing strategies for preserving RGCs against neurodegeneration; and identifying and characterizing the genes critical for RGC function and integrity. Different types of RGCs have been identified based on their morphological and physiological characteristics, yet current knowledge of RGC molecular biology is very limited. Characterization of RGC-expressed genes is fundamental to a better understanding of normal RGC physiology and pathophysiology.

Another area of investigation focuses on understanding the degeneration of RGCs and their axons, which is a hallmark of glaucoma. Dr. Piri’s laboratory is analyzing retinal gene expression profiles from the glaucoma model with the aim of identifying factors involved in the initiation and execution of RGC apoptosis. Study results have implicated several members of the crystallin superfamily in this process, including alpha crystallins. Dr. Piri is also studying the involvement of oxidative stress and proteins of the thioredoxin system, particularly in RGC degeneration in the glaucoma model, and the neuroprotective effects of these proteins against glaucomatous RGC death.

Public Service

Reviewer for many scientific journals
Dr. Prasad specializes in the medical and surgical management of diseases of the retina and vitreous. His research is focused on teleretinal screening for diabetic retinopathy, applications of wide-field fundus photography for retinal vascular disease, and health care delivery for low-income populations. Dr. Prasad also serves as the chief of the Division of Ophthalmology at Harbor-UCLA Medical Center where he provides clinical supervision and instruction to UCLA medical students as well as to Stein Eye residents and vitreoretinal fellows.
Alapakkam P. Sampath, PhD

Associate Professor of Ophthalmology and Neurobiology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Molecular Mechanisms Underlying Early Visual Processing

The Sampath laboratory is interested in understanding the molecular mechanisms underlying early visual processing. In particular, the focus of laboratory researchers has been on elucidating mechanisms that set the sensitivity of night vision. Night blindness, or nyctalopia, is a condition that results from abnormal signaling by the rod photoreceptors, or the retinal circuits that process rod-driven signals. Using physiological and genetic methods, the laboratory studies signal transmission in these retinal rod pathways to identify how these processes are optimized to allow our exquisite visual sensitivity.

Public Service
Member, Association for Research in Vision and Ophthalmology Publications Committee
Member, Neurotransmitters, Transporters, Receptors and Calcium Study Section, NIH

Research Grants
National Eye Institute: Functional Characteristics of Rod Pathways in the Retina, 2/1/14–7/31/17
National Eye Institute (subaward from University of Southern California): Experimental and Clinical Investigations of Retinal Stimulation, 10/1/13–2/28/17
David Sarraf, MD

Health Sciences Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Age-Related Macular Degeneration and Retinal Imaging

Dr. Sarraf is a member of the Retinal Disorders and Ophthalmic Genetics Division of the Stein Eye Institute. He has published approximately 150 research papers, case reports, reviews, and book chapters and is co-author of *The Retinal Atlas*, 2nd edition.

Dr. Sarraf’s focus of research interest is the dry and wet forms of age-related macular degeneration (AMD) and specifically the evaluation of pigment epithelial detachment (PED) and retinal pigment epithelial tears. He was nominated to the American Ophthalmological Society because of his research work on the subjects of PED and AMD.

Dr. Sarraf has been awarded achievement and secretariat awards by the American Academy of Ophthalmology, and he is a leader in advanced retinal imaging. He has published extensively in the area of spectral domain optical coherence tomography (SD-OCT) analysis of AMD and other novel and established macular disorders. He was one of the first researchers to describe ischemia of the deep retinal capillary plexus using advanced SD-OCT imaging, and he is a world expert on the clinical application of OCT angiography.

Public Service
Assistant Editor, *Retina*
Associate Editor, *Retinal Cases and Brief Reports*
Associate Editor, *Ophthalmic Surgery, Lasers and Imaging Retina* (OSLI Retina)
Advisory Board Member, Diabetic Retinopathy Clinical Research Network
Advisory Board Member, Optovue
Committee Member, BCSC Retina Committee, American Academy of Ophthalmology
Executive Committee and Chair, Young Members Committee, Macula Society
Member, American Society of Retinal Specialists, Retina Society, Macula Society, and Gass Club
Co-Director, Pacific Retina Club and International Retinal Imaging Symposium
Reviewer for many scientific journals

Research Grants
Genentech Inc.: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, 11/21/14–9/27/18

Southern California Desert Retina Consultants: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment (EVEN Study), 2/7/13–7/21/16

Allergan Pharmaceutical: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neurovascular Age-Related Macular Degeneration Sequoia Study, 4/14/16–5/31/20
Steven D. Schwartz, MD

The Ahmanson Chair in Ophthalmology
Professor of Ophthalmology
Chief of the Retina Division
Director of the UCLA Diabetic Eye Disease and Retinal Vascular Center
Director of the Macula Center
Member of the Stein Eye Institute

RESEARCH SUMMARY

Stem Cell Research

Dr. Schwartz is leading two new clinical trials testing the use of stem cell-derived retinal pigment epithelial cells to address vision loss in people suffering from Stargardt macular dystrophy and dry age-related macular degeneration.

Retinal Diseases

Dr. Schwartz’s primary areas of research include early diagnosis and treatment of diseases such as retinopathy of prematurity (ROP), diabetic eye disease, and macular degeneration. Additionally, his focus includes development and evaluation of novel medical device technologies, imaging technologies, surgical equipment (including surgical robots), and drug-delivery systems, with particular emphasis on diagnostic and treatment applications. Dr. Schwartz’s clinical research focuses on trials of novel pharmacotherapeutic agents to discover treatments for both wet and dry age-related macular degeneration, ROP, and diabetic retinopathy.

Through innovative teleophthalmological approaches to screen for eye diseases, such as diabetic retinopathy and ROP, Dr. Schwartz is dedicated to improving both the quality of and access to specialized ophthalmology care. Currently, a collaborative program with UCLA’s Gonda Diabetes Center and Venice Family Clinic is underway, in which screening for diabetic retinopathy is conducted with a nonmydriatic camera (a camera that does not require dilation of the eyes) as part of each patient’s regular diabetes treatment. Results are telecommunicated to specialists at the Stein Eye Institute for interpretation and further action.

Honors

Presented the keynote lecture at the Moorfields Eye Hospital alumni meeting held at the Royal Society of Medicine on March 11, 2016, in London, England.

Public Service

Program Committee Member, Association for Research in Vision and Ophthalmology
Diabetic Eye Disease Screening, Venice Family Clinic

Research Grants

Ocata Therapeutics (formerly Advanced Cell Technology): A Phase II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation...in Patients with Stargardt Macular Dystrophy (SMD), 3/23/11–1/12/17

Ocata Therapeutics (formerly Advanced Cell Technology): A Phase II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation...in Patients with Advanced Dry (AMD) 4/5/11–1/28/17

Ocata Therapeutics (formerly Advanced Cell Technology): A Phase II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation...in Patients with Geographic Atrophy Secondary to Myopic Macular Degeneration, 4/10/14–9/1/16

Neurotech Pharmaceuticals, Inc.: Phase I Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasis Type 2, 7/19/11–7/18/17

Genentech, Inc./Hoffman La Roche Inc.: A Phase III, Multicenter, Randomized Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to ARMD, 11/18/14–9/27/18

Ocata Therapeutics (formerly Advanced Cell Technology): A Phase 2, Double-Masked, Randomized, Parallel Group, Sham Surgery Placebo Cohort Multi-Center Study to Evaluate Systemic Immunosuppression Regimens as Graft Rejection Prophylaxis Following Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to ARMD, 10/7/15–10/7/17
Hui Sun, PhD
Professor of Physiology and Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Molecular Mechanism of Vitamin A Transport for Vision; Identification of New Therapeutic Targets for Blinding Diseases

Dr. Sun’s laboratory studies the molecular mechanism of vitamin A transport for vision and new therapeutic targets for blinding diseases. Vitamin A is essential for vision because it is the precursor for the chromophore of photoreceptor proteins and also plays critical roles in eye development. Plasma retinol binding protein (RBP) is the principal carrier of vitamin A in the blood. Dr. Sun’s laboratory identified the long-sought RBP receptor, which functions simultaneously as a membrane receptor and a membrane transporter that mediates cellular uptake of vitamin A. His laboratory is using a variety of techniques to study this membrane transport system.

Dr. Sun’s lab is also identifying new therapeutic targets. Specifically, his lab identified new factors that protect cone photoreceptor cells and is testing these factors in vivo in collaboration with Dr. Xian-Jie Yang’s lab. A second project is studying the newly identified membrane receptors for a factor that has broad therapeutic value in treating diverse cancer types and blinding diseases, such as diabetic retinopathy, ischemia-induced retinopathy, and age-related macular degeneration. In addition to studying the signaling mechanism, Dr. Sun’s lab has developed an innovative high-throughput screen technique that allows the identification of chemical compounds that specifically target the receptors of this therapeutic factor and mimic its function. These compounds are a potential first-in-class medicine to treat some current incurable human diseases.
Gabriel H. Travis, MD

Charles Kenneth Feldman Chair in Ophthalmology
Professor of Ophthalmology
Co-Chief of the Vision Science Division
Associate Director of the Stein Eye Institute

RESEARCH SUMMARY

Biochemistry of Vertebrate Photoreceptors and Mechanisms of Retinal Degeneration

Dr. Travis’ laboratory uses biochemical and genetic approaches to study the visual cycle and its role in retinal and macular degenerations. Vision in vertebrates is mediated by two types of light-sensitive cells: rods and cones. These cells contain light-detecting molecules called opsin pigments. Detection of a single light particle bleaches the opsin pigment. Restoring light sensitivity to a bleached opsin involves an enzymatic pathway called the visual cycle. Mutations in the genes for many proteins of the visual cycle cause inherited blinding diseases.

One project in Dr. Travis’ laboratory studies the function of a transporter protein in rods and cones called ABCA4. Mutations in the human ABCA4 gene cause recessive Stargardt macular degeneration and cone-rod dystrophy. Dr. Travis’ group generated mice with a null mutation in this gene. Biochemical analysis of the phenotype in these ABCA4 “knock-out” mice led them to the function of ABCA4 in photoreceptors, and the biochemical etiology of Stargardt disease. This understanding suggested a pharmacological strategy to reverse the biochemical defect in patients with Stargardt disease and age-related macular degeneration. A phase II clinical trial is currently underway to test a drug based on this strategy as a treatment for age-related macular degeneration.

Another ongoing project in Dr. Travis’ laboratory characterizes Rpe65, which catalyzes the critical isomerization step in the visual cycle. Previously, Dr. Travis and co-workers identified Rpe65 as the retinoid isomerase. Still another project in Dr. Travis’ laboratory concerns the mechanism of visual-pigment regeneration in cone photoreceptors. Despite the importance of cones, little is known about how visual pigments are replenished to permit sustained vision under daylight conditions. Recent results from Dr. Travis’ group point to the existence of a new enzymatic pathway for regenerating visual pigments in cones. His group is currently working to purify and clone the enzymes that define this new biochemical pathway.
Irena Tsui, MD
Assistant Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Clinical Vitreoretinal Research

Dr. Tsui’s research focuses on improving clinical outcomes in patients with retinal diseases. Her areas of interest include retinopathy of prematurity, diabetic retinopathy, ultra-wide field imaging, surgical techniques, and studying patient-centered outcomes in veterans.

In addition to providing patient care at the Stein Eye Institute in Westwood, Dr. Tsui also sees patients at the Doheny Eye Center UCLA–Arcadia.
Federico G. Velez, MD

Health Sciences Associate Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Strabismus and Childhood Eye Disorders

Dr. Velez’s primary research interest is studying the mechanisms of congenital and acquired forms of strabismus. He has participated in the development of guidelines for preoperative assessment and surgical approaches to patients with convergent (esotropia), divergent (exotropia), and vertical forms of strabismus, and has developed new techniques to treat pediatric patients with eyelid abnormalities and cataracts.

Dr. Velez has recently completed studies that apply bioengineering technology to the correction of ocular motility disorders. He has also identified a new ocular motility disorder in patients with the human immunodeficiency virus. He provides patient care at the Stein Eye Institute in Westwood and the Doheny Eye Center UCLA–Orange County.

Honors
Introduced as a member of the Association for Research in Strabismus, also known as the North American Squint Club.

Presented with an Honor Award for distinguished service by the American Association for Pediatric Ophthalmology and Strabismus on April 6, 2016, in Vancouver, BC, Canada.

Public Service
Editorial Board Advisory Panel Member, Treatment Strategies—Pediatrics, The Cambridge Research Centre


Member, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, Latin American Council of Strabismus, Latin American Pediatric Ophthalmology Society, Colombian Society of Ophthalmology, and Colombian Society of Pediatric Ophthalmology and Strabismus

Reviewer for many scientific journals

Research Grants
Omeros Inc., A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction with or Without Lens Replacement, 8/6/15–8/6/17

Bausch and Lomb, A Randomized, Multicenter, Double Masked, Parallel-Group Study Assessing the Safety and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5% Versus Prednisolone Acetate Ophthalmic Suspension, 1% for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract, 9/17/15–9/17/17

Retrophin, Inc., An Observational, Multicenter Study of the Prevalence of Cerebrotendinous (CTX) in Patient Population Diagnosed with Early-Onset Idiopathic Bilateral Cataracts, 1/6/16–1/5/18
David S. Williams, PhD
Jules and Doris Stein Research to Prevent Blindness Professor of Ophthalmology
Professor of Neurobiology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Cell Biology of the Retina and Inherited Retinal Disease

Dr. Williams’ laboratory focuses on the cell biology of photoreceptor and retinal pigment epithelium cells. His group is especially interested in proteins that function in transport and compartmentalization within these cells. These proteins include those that underlie Usher syndrome and macular degeneration. A translational area of his research involves gene therapy experiments aimed at preventing the blindness that ensues from Usher syndrome type 1B.
Xian-Jie Yang, PhD

Ernest G. Herman Chair in Ophthalmology
Professor of Ophthalmology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Development and Disease Therapy of the Retina

Dr. Yang’s laboratory studies the molecular and cellular mechanisms underlying retinal development and repair. Blinding diseases such as retinitis pigmentosa, geographic atrophy, and glaucoma involve the permanent loss of photoreceptors or retinal ganglion cells. A potential treatment strategy is to supply diseased retinas with a protective agent that can prolong neuronal survival. One area of current research focus in the Yang laboratory is to understand how certain growth factors enhance neuronal viability under retinal degeneration conditions. These investigations use genetic and biochemical approaches to dissect cellular events triggered by growth factor treatments in disease models, thus providing insight into clinical application of neuroprotective therapies for patients afflicted with retinal degenerative diseases. Another major research direction of the Yang laboratory is to enable stem cell-based derivation of human retinal organoids in culture and to induce differentiation of retinal neurons, especially retinal ganglion cells. These studies utilize cutting-edge stem cell technologies and apply known developmental regulatory principles to establish in vitro models of human retinogenesis. Outcomes of the research will provide stem cell-based tools to study human retinal differentiation and diseases, and opportunities to develop new therapeutic treatments.
RESEARCH SUMMARY

Therapeutic Development in Ophthalmology

Dr. Zheng's research is at the interface of biochemistry, computational biology, systems pharmacology, and drug discovery with an emphasis on therapeutic development in ophthalmology. Taking advantage of increasing computer capability, Dr. Zheng's research group finds that the combination of experimental and computational studies gives them a unique strength, and on the basis of this strength, Dr. Zheng's laboratory has achieved great successes.

The current focus of the laboratory is to develop proteins and small molecules that can modulate signal transduction pathways, such as Wnt, Hedgehog, BMP, and Hippo pathways, in an effort to better understand the biological functions of these signaling pathways and to explore the therapeutic potential of these compounds and proteins. Aiming to establish new translational research within the vision research community at UCLA, the goal of Dr. Zheng's research is to develop novel therapies for retinal degenerative diseases, glaucoma, and corneal disorders.
Through the historic alliance between the UCLA Stein Eye Institute and the Doheny Eye Institute, Doheny physician-scientists are UCLA Department of Ophthalmology faculty members.

The affiliation introduced the Doheny Eye Center UCLA, which provides comprehensive eye care covering the full disease spectrum. The Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena offer neighborhood convenience for patients and community ophthalmologists, as well as being a resource for local physicians who need to refer patients for ophthalmic care.

Vikas Chopra, MD
Health Sciences
Associate Clinical Professor
Medical Director,
Doheny Eye Center UCLA–Pasadena

RESEARCH SUMMARY
Glaucoma
Dr. Chopra specializes in glaucoma, and his research activities include advanced optic nerve and retinal nerve fiber layer imaging for early glaucoma detection, as well as development and validation of novel parameters for use in anterior segment optical coherence tomography devices as principal investigator at the Doheny Image Reading Center. Dr. Chopra also evaluates laser and surgical techniques for the management of glaucoma.

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Pasadena

Brian A. Francis, MD, MS
Health Sciences Clinical Professor
Medical Director, Doheny Eye Center UCLA–Orange County

RESEARCH SUMMARY
Glaucoma
Dr. Francis’ clinical specialties are glaucoma and cataract. His research activities include: innovative glaucoma surgeries, minimally invasive glaucoma surgery, novel visual field techniques, glaucoma diagnostic and functional imaging, anterior segment imaging (ultrasound biomicroscopy and Fourier domain optical coherence tomography), and glaucoma laser surgery.

Research Grants
Quark Pharmaceuticals Inc.: Phase IIA Double-Masked Randomized Sham Controlled Trial of Qpi-1007 Delivered by a Single Intravitreal Injection to Subjects with Acute Primary Angle-Closure Glaucoma (APACG), 9/25/14–9/24/16
Diopsys Inc., Study for Benchmarking the Management of Ophthalmic Diseases Using the Diopsys Visual Evoked Potential/Pattern ERG/ERG Protocol, 2/21/16–1/31/18

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Orange County
Doheny Eye Center UCLA–Pasadena
Gad Heilweil, MD
Health Sciences
Assistant Clinical Professor

RESEARCH SUMMARY
Degenerative Retinal Disease
Dr. Heilweil’s research activities include stem-cell therapy for degenerative retinal disease; retinal and uveal drug toxicity; and pharmacokinetics of intravitreal drugs. In addition to providing patient care at the Doheny Eye Center UCLA, Dr. Heilweil sees patients at the Stein Eye Institute in Westwood.

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Orange County
Doheny Eye Center UCLA–Pasadena

Hugo Y. Hsu, MD
Health Sciences
Associate Clinical Professor

RESEARCH SUMMARY
Cornea and External Diseases
Dr. Hsu specializes in corneal infection and inflammation, corneal transplantation, anterior segment reconstruction, and cataract surgery. His research interests include corneal and ocular infections and ophthalmic antibiotics.

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Orange County
Doheny Eye Center UCLA–Pasadena

Alex A. Huang, MD, PhD
Assistant Professor

RESEARCH SUMMARY
Glaucoma
Dr. Huang’s clinical specialties include glaucoma, minimally invasive glaucoma surgery, trabeculectomy, glaucoma drainage devices, cyclodestruction, and complex cataracts. His research activities involve characterizing post trabecular meshwork and scleral changes in glaucoma, optical coherence tomography visualization of aqueous humor outflow pathways in the eye, and angiographic visualization of aqueous humor outflow in the eye. His goal is to provide the most individual centric care, and through the use of research, develop means to customize glaucoma management and surgery for each patient.

Awards/Honors
Presented with the Heidelberg Engineering Xtreme Research Award at the May 2016 Association for Research in Vision and Ophthalmology meeting in Seattle, Washington.

Research Grants
American Glaucoma Society: Real-time Imaging of Aqueous Humor Outflow, 1/1/15–12/31/15
National Eye Institute: Discovery and Characterization of Anterior Sclera Pathology in Glaucoma, 9/30/14–9/29/19
National Space Biomedical Research Institute (subaward from Baylor College of Medicine): Validation of a Cephalad Fluid Shift Countermeasure, 6/1/15–5/31/17
Research to Prevent Blindness: RPB Career Development Award, 1/1/16–12/31/19

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Pasadena
Michael S. Ip, MD
Health Sciences Clinical Instructor (Interim)

RESEARCH SUMMARY
Vitreoretinal Disease
Dr. Ip’s research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, age-related macular degeneration, and retinal venous occlusive disease. He has served as the national director for numerous National Eye Institute funded ophthalmic clinical trials. Additionally, as director of the Doheny Image Reading Center, Dr. Ip assists with the collection, analysis, and dissemination of important secondary outcomes in many important clinical trials in the field of ophthalmology.

Research Grants
National Eye Institute (subaward from Penn State University College of Medicine): Studies of Comparative Treatments in Retinal Vein Occlusion 2 (SCORE 2), 6/16/16–3/31/19

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Pasadena

John A. Irvine, MD
Health Sciences Clinical Professor
Medical Director, Doheny Eye Center UCLA

RESEARCH SUMMARY
Cornea and External Diseases
Dr. Irvine’s clinical specialties are cornea and external diseases (e.g., tumors, infections), anterior segment surgical consultation, and prosthetic replacement of the ocular surface ecosystem (PROSE). His research activities focus on ocular infections.

Honors
Presented the 14th Thomas H. Pettit Lecture at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California.
Received the S. Rodman Irvine Prize for demonstrated excellence in professional actions and exemplary dedication to teaching future generations of ophthalmologists at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California.

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Orange County
Doheny Eye Center UCLA–Pasadena

Olivia L. Lee, MD
Health Sciences Assistant Clinical Professor

RESEARCH SUMMARY
Cornea/External Diseases and Uveitis; Corneal Imaging
Focusing on cornea/external diseases and uveitis, Dr. Lee’s particular interest is in inflammatory ocular surface disease, corneal melts, pterygia, and anterior segment complications of uveitis. Dr. Lee performs all types of corneal transplants, as well as complex cataract surgery in uveitic eyes.

Dr. Lee’s research interests are anterior segment imaging applied to the tear film, cornea, and conjunctiva. With her expertise in corneal imaging, a specular microscopy reading center was developed at the Doheny Image Reading Center, where she serves as an investigator.

Research Grants
Xoma (US) LLC: A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Noninfectious Intermediate Posterior or Pan-Uveitis Currently Controlled with Systemic Treatment, 1/8/13–3/31/16
Xoma (US) LLC: A Randomized Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Noninfectious Intermediate Posterior, or Pan-Uveitis, 1/8/13–12/10/15

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Orange County
Doheny Eye Center UCLA–Pasadena
Kenneth L. Lu, MD  
Health Sciences  
Assistant Clinical Professor  
Medical Director, Doheny Eye Center  
UCLA–Arcadia

**RESEARCH SUMMARY**  
**Cataract and Refractive Surgery**

Dr. Lu specializes in cataract and refractive surgery, and his research activities are focused in the same areas.

**PRACTICE LOCATIONS**  
Doheny Eye Center UCLA–Arcadia

---

Peter A. Quiros, MD  
Health Sciences  
Associate Clinical Professor

**RESEARCH SUMMARY**  
**Neuro-Ophthalmology**

Specializing in neuro-ophthalmology, the clinical specialties of Dr. Quiros are: optic nerve disease, including optic neuritis and multiple sclerosis; double vision and adult strabismus; eye pain, headache, and idiopathic intracranial hypertension; Graves disease; orbital inflammatory syndromes; and stroke. Dr. Quiros’ research activities include idiopathic intracranial hypertension, headache, ocular myasthenia gravis, Graves disease, optic neuritis and multiple sclerosis, and visual rehabilitation after stroke. Dr. Quiros was the principal investigator for the recently completed idiopathic intracranial hypertension treatment trial and is currently the principal investigator for the longitudinal idiopathic intracranial hypertension treatment trial. Dr. Quiros is also a member of the Neuro-Ophthalmology Researcher and Disease Investigators Consortium (NORDIC) and is the local NORDIC director.

**Honors**

Received the International Council of Ophthalmology Mark Tso Golden Apple Award for excellence in medical education and teaching at the August 2015 Pan-American Association of Ophthalmology Congress in Bogotá, Colombia.

---

**Research Grants**

National Eye Institute: Long-Term Follow-up of the Cohort from a Multicenter, Double-Masked, Randomized, Placebo-Controlled Study of Weight-Reduction and/or Low-Sodium Diet Plus Acetazolamide vs. Diet Plus Placebo in Subjects with Idiopathic Intracranial Hypertension with Mild Visual Loss, 1/7/14–1/31/15

**PRACTICE LOCATIONS**  
Doheny Eye Center UCLA–Orange County  
Doheny Eye Center UCLA–Pasadena
Daniel B. Rootman, MD, MS
Assistant Professor

RESEARCH SUMMARY
Orbit and Ophthalmic Plastic Surgery

Dr. Rootman is an orbit and ophthalmic plastic surgery specialist. His clinical expertise includes Graves disease, orbital surgery, orbital tumors, ptosis, lacrimal disorders, blepharoplasty, blepharospasm, Botox®, cosmetic dermal fillers, endoscopic eyebrow lift, eyelid surgery, eyelid tumors, and trauma. Research activities are on developing and refining patient-centered outcome measures for surgical care; randomized clinical trials in surgery, including ptosis, Graves orbitopathy and lacrimal disease; health economics of eyelid and facial surgery; sociodemographics of facial trauma; physiology and pathobiology of ptosis; new approaches to surgery; and measurement and assessment in medical education. In addition to providing patient care at the Doheny Eye Center UCLA, Dr. Rootman sees patients at the Stein Eye Institute in Westwood.

Research Grants
Galderma Laboratories L.P.: Hyaluronic Acid Gels for Upper Lid Retraction in Thyroid Eye Disease, 6/8/16–10/8/17

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Orange County
Doheny Eye Center UCLA–Pasadena
UCLA Stein Eye Institute–Westwood

SriniVas R. Sadda, MD
Professor
President and Chief Scientific Officer, Doheny Eye Institute

RESEARCH SUMMARY
Retinal and Macular Diseases

Dr. Sadda specializes in age-related macular degeneration, hereditary retinal degenerations, diabetic retinopathy, venous occlusive disease, telemedicine screening and consultation programs, as well as retinal disease diagnosis and classification. His research activities include: quantitative, automated retinal image analysis; retinal substructure assessments; advanced retinal imaging technologies; genotype-phenotype correlative studies; and vision restoration technologies, such as stem cells and prosthetic vision.

Honors
Presented the 47th Jules Stein Lecture at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California.

Research Grants

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Pasadena
Alfredo A. Sadun, MD, PhD
Flora Thornton Chair of Vision Research
Vice Chairman, Doheny Eye Center UCLA
Professor of Ophthalmology

RESEARCH SUMMARY

Neuro-Ophthalmology
Clinical specialties of Dr. Sadun include neuro-ophthalmology, optic nerve, optic neuropathies (eg, posterior ischemic optic neuropathy, anterior ischemic optic neuropathy, and traumatic optic neuropathy), Leber hereditary optic neuropathy, toxic and nutritional optic neuropathies, vision in Alzheimer’s, AIDS, and other central nervous system disorders. Dr. Sadun’s research activities focus on human visual neuroanatomy; retinal ganglion cell degeneration and regeneration; axon populations in the human optic nerve in development, aging, and disease; and mitochondrial impairments as a cause of optic neuropathy and other forms of neurodegeneration.

Honors
Presented the Carol Zimmerman Lecture on September 26, 2015, at UT Southwestern Medical Center in Dallas, Texas.
Gave the Keynote Lecture at the International Congress of Neuro-Degeneration on March 19, 2016, in Milan, Italy.
Recipient of the Purpura Award for Contributions to Science and Medicine given by the Albert Einstein College of Medicine on May 25, 2016, at Lincoln Center, New York, New York.

Presented the 14th Bradley R. Straatsma Lecture at the UCLA Stein Eye Institute Clinical and Research Seminar on June 10, 2016, in Los Angeles, California.
Gave the Keynote Lecture at the Canadian Ophthalmological Society meeting on June 20, 2016, in Ottawa, Canada.

Research Grants
Edison Pharmaceuticals, Inc.: Emergency Administration of EPI-743 to a Single Patient with Leber’s Hereditary Optic Neuropathy (LHON), 10/17/14–10/17/16
Gensight Biologics: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single, Intravitreal Injection of GS010 (RAAV2/2-ND4) A, 1/11/16–1/11/18
Gensight Biologics: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single, Intravitreal Injection of GS010 (RAAV2/2-ND4) B, 1/12/16–1/12/18
Stealth Biotherapeutics Inc.: A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of MTP-131 TOPI, 2/12/16–2/12/18

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Pasadena

Board-certified and award-winning Doheny Eye Center UCLA ophthalmologists are members of the UCLA Department of Ophthalmology.
James C. Tan, MD, PhD
Associate Professor

RESEARCH SUMMARY
Glaucoma

Dr. Tan is a dual fellowship-trained glaucoma specialist. He treats the full spectrum of cataract and glaucoma conditions, ranging from mild to complex. His treatments and surgeries focus on safe and effective outcomes using advanced techniques. Dr. Tan has authored over 100 scientific papers, abstracts, book chapters, and books. His glaucoma research addresses advanced imaging, molecular pathogenesis, drug development, and surgical techniques. He has received awards from the National Institutes of Health, Research to Prevent Blindness, and the American Glaucoma Society.

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Pasadena

Research Grants
National Eye Institute Role of Trabecular Meshwork Contractility in Modulating Outflow Resistance, 9/1/14–8/31/15

PRACTICE LOCATIONS
Doheny Eye Center UCLA–Arcadia
Doheny Eye Center UCLA–Pasadena

Deming Sun, MD
Professor

RESEARCH SUMMARY
Research Scientist

Dr. Sun is a researcher whose primary areas of investigation include uveitis, autoimmune diseases, optic neuritis, animal disease models, and T-cell biology.
James W. Bisley, PhD
Associate Professor of Neurobiology and Psychology
Member of the Stein Eye Institute
Member of the Brain Research Institute

RESEARCH SUMMARY
Cognitive Processing of Visual Information
Dr. Bisley’s research revolves around understanding the neural mechanisms underlying the cognitive processing of visual information. These cognitive processes include visual perception, visual memory, and visual attention. His recent work has focused on how the responses of neurons in the posterior parietal cortex are involved in the allocation of visual attention to neurons in visual cortices and how they guide eye movements in goal-directed visual search.

Patrick T. Dowling, MD, MPH
Chairman, UCLA Department of Family Medicine
Kaiser Benefit Fund Endowed Professor of Community Medicine
Member of the Stein Eye Institute

Health Care Policy and Access for Underserved Populations
Dr. Dowling is a member of the California Community Foundation’s Board of Directors and the Board of Trustees at the Charles R. Drew University of Medicine and Science in South Los Angeles. He has received numerous grants for international medical graduate training, residency training, and family medicine training. He has made unparalleled contributions to the community and to the training of physicians to support the community at a primary level. He is a Commissioner of Public Health for the Los Angeles County Department of Health. In that role, Dr. Dowling currently has funding for, and co-directs, an innovative program that assists bilingual-bicultural immigrant Hispanic physicians who are residing here legally to obtain residency training in Family Medicine and to be licensed to practice in California. Upon completion of their residency, the physicians must work in a health center in a designated health professional shortage area in the state. To date, 105 physicians have completed the program.

Dr. Dowling has worked closely with Dr. Anne Coleman on the Remote Area Medical Program, as well the Care Harbor program, which provides care to the homeless and indigent in the Los Angeles community. Dr. Dowling’s presence as a member of the Stein Eye Institute adds a new dimension that is being developed and pioneered by Dr. Coleman at the Institute’s Center for Eye Epidemiology.

Antoni Ribas, MD
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology
Member of the Stein Eye Institute

RESEARCH SUMMARY
The Immune System and Oncogene-Targeted Therapies in the Treatment of Cancer
Dr. Antoni Ribas conducts research focused on melanoma, an aggressive form of skin and eye cancer. His research aims at developing more effective and less toxic therapies for patients with advanced melanoma by studying how the immune system can be effectively used to fight cancer and also how targeted therapies can specifically block cancer genes. His projects include laboratory and clinical translational research in adoptive cell transfer therapy using T-cell receptor engineered lymphocytes designed to seek out melanoma cells, with the application of molecular imaging and advanced monitoring of the immune system to better study how it can fight cancer. Another way to engage an anti-cancer immune response is through the use of immune modulating antibodies, in particular by releasing the immune breaks CTLA4 and PD-1. He is also testing, both in the laboratory and the clinic, novel targeted therapies blocking cancer-causing events that result in melanoma, as well as the potential clinical applications of nanoparticle delivery of siRNA, which interferes with gene expression related to cancer. Dr. Ribas’ goal is to bring new concepts from the laboratory to the clinic to help patients with advanced melanoma.

Dario L. Ringach, PhD
Professor of Neurobiology and Psychology, Biomedical Engineering Program
Member of the Stein Eye Institute

RESEARCH SUMMARY
Visual Perception and Neurophysiology
Dr. Ringach’s research focuses on the relationship between eye movements and visual perception, as well as how motor planning and execution, such as reaching, grasping, navigating, and adjusting body posture, is influenced by visual information and impaired vision. In collaboration with a team of neurosurgeons at UCLA, Dr. Ringach’s laboratory is also recording the brain activity of patients with epilepsy who are undergoing clinical evaluation for surgical treatment. This unique opportunity is shedding new light into the processes involved in object recognition and perception.
Guido A. Zampighi, PhD
Professor of Neurobiology
Member of the Stein Eye Institute

RESEARCH SUMMARY

Intercellular Junctions and Communication

A fundamental property of cells organized in tissues is their ability to communicate with each other via highly specialized areas of plasma membrane contact, called junctions. Dr. Zampighi is studying the gap junction and the chemical synapse, two specialized junctions that mediate electrical and chemical transmission, respectively. The gap junction is composed of specialized channels containing small hydrophilic pores that span the two plasma membranes and the intervening extracellular space (the cell-to-cell channel). He is investigating the high-resolution structure of the channels as well as the mechanisms of assembly, insertion, and retrieval of the connexin proteins that form them. The chemical synapse is composed of a presynaptic neuron filled with small diameter vesicles that contain a high concentration of neurotransmitters and a postsynaptic neuron with receptors. He is studying the mechanisms by which the synaptic vesicles attach (“dock”) to the presynaptic membrane. He uses structural (electron microscopy), biochemical, and electrophysiological techniques in an attempt to identify, purify, and characterize the channels and transporters of both junctions in an effort to increase understanding of the mechanisms mediating cell communication.
The membrane protein rhodopsin is a critical first step in visual transduction, converting light energy into a chemical form in the photoreceptor cell of the eye. To understand this process on a detailed molecular level, Dr. Altenbach is using site-directed spin labeling and electron paramagnetic resonance spectroscopy to study the structure of rhodopsin in the absence of light, as well as the changes in structure caused by light.

Navid Amini, PhD
Assistant Research Ophthalmologist

**RESEARCH SUMMARY**

**Mobile Health**

Dr. Amini’s research interests lie in the area of mobile health. He develops signal processing and machine learning techniques in ophthalmic research, and utilizes such techniques in quantitative assessment of major ocular diseases, including glaucoma. In addition, Dr. Amini investigates the behavior of nonvisual sensory systems and the effects of low vision on activities of daily living.

Dr. Amini has served on the Technical Program Committee for several conferences in the field of medical informatics. He is a named inventor on three U.S. patents, two of which have been licensed and are moving towards commercialization. He is the recipient of the Edward K. Rice Outstanding Doctoral Student Award, UCLA Chancellor’s Award for Postdoctoral Research Honorable Mention, Alcon Young Investigator Award, and the Vodafone Wireless Innovation award. Dr. Amini has received unrestricted gifts from influential companies, such as Google and Symantec, for pursuing end-to-end collaborative research.

Barry L. Burgess, BS
Research Specialist

**RESEARCH SUMMARY**

**Degenerative Retinal Disease Research**

Mr. Burgess provides research support for the Photoreceptor/RPE Cell Biology Laboratory of Dr. David Williams. Research interests include production of differentiated RPE cells from human stem cell precursors and developing in vitro models of oxidative stress involved in degenerative retinal disease progression.

Jeremy D. Cook, PhD
Assistant Project Scientist

**RESEARCH SUMMARY**

**Regulation of the Visual Cycle**

Dr. Jeremy Cook is studying the role of peropsin, the non-visual opsin, in retinal pigment epithelial cells. This protein appears to regulate the metabolism of visual retinoids in a light-dependent fashion.

Rajendra Gangalum, PhD
Assistant Research Specialist

**RESEARCH SUMMARY**

**Function and Regulation of Small Heat Shock Protein αB-crystallin in Health and Disease**

Dr. Gangalum’s research seeks to gain understanding of the physiological function of αB-crystallin in the developing ocular lens and non-ocular tissues. αB-crystallin has been shown to associate with pathologies such as cataracts, cancer, age-related macular degeneration (AMD), and various neurodegenerative diseases. Dr. Gangalum has discovered that αB-crystallin is a Golgi-associated membrane protein, secreted into extracellular medium via exosomes from retinal pigment epithelial cells. These findings explain how αB-crystallin is detected in the protein-lipid deposits known as drusen in AMD. Dr. Gangalum is using a gene silencing approach and knockout mouse model to investigate the function of αB-crystallin. His recent findings have demonstrated that αB-crystallin silencing (αBshRNA) in retinal pigment epithelial cells inhibits secretion and enhances endo-lysosomal fusion. Dr. Gangalum has also generated the transgenic mice model of childhood lamellar cataract. Cataracts in infants are debilitating because opacities in the fiber cells are confined to the lens nucleus and hinder the transmission of light to the retina, which impairs the development of visual cortex in the brain. Dr. Gangalum is using next generation sequencing, cell and molecular biology approaches to understand the molecular basis of lamellar cataract pathology in single lens fiber cells. This model system is the only paradigm available for future investigations on early childhood cataracts.

Sonia Guha, PhD
Assistant Project Scientist

**RESEARCH SUMMARY**

**Unraveling New Therapeutic Targets for Ocular Albinism**

Dr. Guha’s research aims to study the genes that may be associated with the misrouting of retinal ganglion cell (RGC) axons at the brain’s optic chiasm in individuals affected with X-linked ocular albinism type 1 (OA1). This disease, caused by mutations in the OA1 gene that is mainly expressed in the retinal pigment epithelium (RPE), is also characterized by hypopigmentation and presence of macromelanosomes in the RPE. How the reduced pigmentation of OA1 RPE exerts its effects on the RGCs to influence the misrouting of their axons at the optic chiasm remains unsolved. Thus, Dr. Guha’s research finds the potential to unravel new therapeutic targets for OA1.
Joanna J. Kaylor, PhD  
Assistant Research Ophthalmologist

**RESEARCH SUMMARY**  
**Visual Chromophore Regeneration in the Retina of the Eye**

Recent biochemical and physiological studies support the regeneration of visual chromophore in the retina of the eye. Dr. Kaylor is using biochemistry and molecular biology to identify the enzymes and chemicals involved. Her work has led to the identification and characterization of two new vitamin A processing enzymes in the retina, including the retinyl-ester synthase multifunctional O-acyltransferase (MFAT) and the first vitamin A retinol isomerase, dihydroceramide desaturase-1 (DES1). Dr. Kaylor is now focused on the role that retinal G-protein coupled receptor (RGR) plays in visual chromophore processing in the retina.

Jacky M. K. Kwong, PhD  
Associate Research Ophthalmologist

**RESEARCH SUMMARY**  
**Degeneration of Retinal Ganglion Cells and Neuroprotection**

Dr. Kwong’s research goal is to identify novel neuro-protective therapies for glaucoma. To understand the loss of retinal ganglion cells in glaucoma, his research focuses on the response and the cell death pathway of retinal ganglion cells in animal models related to optic nerve injury and glaucoma. Dr. Kwong and his colleagues recently found retinal ganglion cell-specific proteins. He is utilizing these proteins to visualize retinal ganglion cells and to investigate their function in retinal ganglion cells during degeneration. He is also applying pharmacologic techniques to evaluate therapies that enhance endogenous neuroprotective responses against glaucomatous, excitotoxic, and axonal damage to nerve cells, and is utilizing multidisciplinary methods to understand the protective mechanisms.

Anna Matynia, PhD  
Associate Research Ophthalmologist

**RESEARCH SUMMARY**  
**Neural and Molecular Basis of Photoallodynia**

Dr. Matynia is investigating the mechanisms of photoallodynia, a condition in which normal levels of light produce or enhance ocular or headache pain. Using a combination of behavioral, molecular, and cellular approaches in genetic mouse models, the goal is to identify mechanisms of light-pain association for different causes of photoallodynia, including corneal, retinal, and central causes such as dry eye injury, achromatopsia, and migraine, respectively. The research findings will form the basis of treatment strategies for this condition.

Johan Pahlberg, PhD  
Assistant Project Scientist

**RESEARCH SUMMARY**  
**Optimal Processing of Sensory Signals in the Retina**

Dr. Pahlberg is interested in how noise in the mammalian retina is mitigated to allow for highly sensitive night vision. The research is focused on how rod photoresponses are processed and parsed into the retinal circuitry, the correlations between retinal physiology and behavior for low light level vision, and thus, how sensory systems increase their signal-to-noise ratio and the information encoded in the neural pathway.

Roxana A. Radu, MD  
Research Ophthalmologist

**RESEARCH SUMMARY**  
**Retinoids Metabolism in the Eye and Underlying Mechanisms of Macular Degeneration**

Dr. Radu’s research focuses on the visual cycle and underlying biochemical and molecular mechanisms of macular degeneration. She studies the in vivo association of the complement negative regulator genes and age-related macular degeneration (AMD) development. The mechanism by which dysfunction of complement factor H (CFH, one of the complement regulatory genes) causes AMD is not known. To investigate the relationship between abnormal build-up of vitamin A-based toxic compounds such as A2E and the complement system, Dr. Radu will generate a mouse lacking both genes ABCA4 and CFH. This complex mouse genetic model will advance understanding of the relationship between lipofuscin accumulation, complement activation, and photoreceptor degeneration in AMD, and it will be a valuable tool for developing new treatments for this disease.

Charles “Dutch” Ratliff, PhD  
Assistant Project Scientist

**RESEARCH SUMMARY**  
**Information Processing and Metabolism in the Retina**

Dr. Ratliff investigates the mechanisms by which the retina creates a metabolically efficient representation of visual information. This work combines techniques from patch-clamp electrophysiology, mathematical modeling, and molecular simulations.
Alberto C. Ruiz-Morales  
Research Specialist  

RESEARCH SUMMARY  
Visual Cycle  
Mr. Ruiz is a molecular biologist who has been directly involved in the cloning and characterization of important enzymes critical for the proper functioning of the visual cycle, such as the lecithin retinol acyltransferase (LRAT) enzyme. Another area of investigation is the generation and evaluation of knock-out mouse models for LRAT and a second visual cycle enzyme, the retinol binding protein receptor STRA6. Currently, Mr. Ruiz is analyzing genes, such as ARMS2 and HTRA1, which are thought to be involved in age-related macular degeneration.

Alejandra Young, PhD  
Assistant Project Scientist  

RESEARCH SUMMARY  
Ocular Albinism  
Dr. Young’s research is focused on the study of the molecular mechanisms that cause ocular albinism type 1 (OA1), a disease caused by mutations in the OA1 gene and characterized by hypopigmentation of the retinal pigment epithelium and abnormal crossing of the optic axons at the optic chiasm. She is investigating the potential therapeutic use of engineered human embryonic stem cell-derived microvesicles enriched in OA1 mRNA/protein for the treatment of ocular albinism.
Gavin G. Bahadur, MD  
Associate Physician Diplomate  
Clinical Instructor of Ophthalmology  
**Comprehensive Ophthalmology, Including Cataract, Pterygium, and Glaucoma Surgery**  
Dr. Bahadur teaches medical students during their ophthalmology surgical subspecialties clinical rotation. He is a full-time comprehensive ophthalmologist at the Stein Eye Center in Santa Monica.

Laura Bonelli, MD  
Associate Physician Diplomate  
**Neuro-Ophthalmology and Comprehensive Ophthalmology**  
Dr. Bonelli provides clinical supervision to resident physicians at the University Ophthalmology Associates and teaches medical students during their ophthalmology surgical subspecialties clinical rotation. She is collaborating on a study to learn and better understand giant cell arteritis (GCA), an inflammation of the lining of the arteries. GCA frequently causes blurred or double vision, and if left untreated, may result in loss of vision. She is also a co-investigator for the National Eye Institute-sponsored study of idiopathic intracranial hypertension.

Melissa W. Chun, OD  
Associate Clinical Professor of Ophthalmology  
Director of the UCLA Vision Rehabilitation Center  
**Vision Rehabilitation**  
Dr. Chun’s clinical research interests are in the areas of vision rehabilitation outcomes and training techniques that maximize visual function. She is a member of the Low Vision Research Network, a nationwide collaboration of low vision specialists for multicenter clinical studies. She is also involved in visual outcome measures for various clinical studies on macular degeneration.

Rachel Feit-Leichman, MD  
Associate Physician Diplomate  
**Cataract Surgery**  
Dr. Feit-Leichman divides her time between supervising residents and providing patient care at the Stein Eye Institute’s Urgent Care Clinic, University Ophthalmology Associates; and teaching cataract surgery and overseeing residents at the ophthalmology clinic of the Harbor-UCLA Medical Center. Dr. Feit-Leichman is also active in striving to improve patient access to eye care in the greater Los Angeles County Healthcare System.

Hamid Hosseini, MD  
Clinical Instructor of Ophthalmology  
**Retinal and Macular Eye Disease**  
Dr. Hosseini is a clinician and vitreoretinal surgeon with special interest in retinal and macular conditions, such as macular degeneration, diabetic retinopathy, and retinal detachment. He participates in all activities of the Retina Division, including research, education, and clinical care.

Catherine J. Hwang, MD, MPH  
Associate Physician Diplomate  
Assistant Clinical Professor of Ophthalmology  
**Thyroid Eye Disease, Ocular Surface Disease, and Eyelid Disorders**  
Dr. Hwang’s research includes studies involving thyroid eye disease (Graves disease), ocular surface disease, and eyelid disorders such as blepharospasm. Dr. Hwang has a dedicated thyroid eye disease clinic to investigate the clinical course of the disease and treatments, as well as to provide education and patient support. The clinic is the first in the country to provide an orbital specialist, Dr. Hwang, and a rheumatologist, Dr. Ben-Artzi, who work together to evaluate and treat patients affected with thyroid eye disease. Dr. Hwang will be starting a blepharospasm clinic in order to better educate patients, form support groups, and aid in clinical studies. In addition, Dr. Hwang collaborates with researchers from other departments, such as interventional radiology and head and neck surgery, on various projects.

Karen Hendler, MD  
Clinical Instructor of Ophthalmology  
**UCLA Mobile Eye Clinic**  
Dr. Hendler works with the UCLA mobile eye clinic providing services to the underserved children of Los Angeles County as part of the Center for Community Outreach and Policy at UCLA. The goal is to determine the need for prescriptive lenses in preschool children and to detect the presence of amblyopia or other eye conditions or diseases. Dr. Hendler is also participating in epidemiologic studies on the outcome of screening of preschool children.
Batool Jafri, MD
Associate Physician Diplomate
Assistant Clinical Professor of Ophthalmology

Cornea/External Disease/Refractive Surgery
Dr. Jafri provides patient care as well as supervision to resident physicians and cornea fellows at the Stein Eye Institute. Her focus is medical and surgical treatment of diseases of the cornea, external disease, and refractive conditions like near and far sightedness. She also provides general ophthalmic care and offers cataract surgery with premium intraocular lens implants.

Monica R. Khitri, MD
Associate Physician Diplomate

Pediatric Ophthalmic Diseases and Strabismus
Dr. Khitri specializes in the evaluation and treatment of pediatric ophthalmic diseases as well as childhood and adult strabismus. She teaches residents and fellows at both the Stein Eye Institute and Harbor-UCLA Medical Center, where she heads the pediatric ophthalmology service. Dr. Khitri is also actively involved with the UCLA Mobile Eye Clinic, bringing high quality eye care to children with otherwise poor access to ophthalmic providers.

Tania Onclinx, MD
Clinical Instructor of Ophthalmology
Associate Physician Diplomate

Urgent Care and Clinical Supervision
Dr. Onclinx attends at the Urgent Care Walk-In service at the Stein Eye Institute. She teaches resident physicians and medical students at the University Ophthalmology Associates during their subspecialty clinical rotation. She also provides clinical supervision to resident physicians at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica.

Susan S. Ransome, MD
Associate Physician Diplomate
Clinical Instructor of Ophthalmology

Cytomegalovirus Retinitis
Dr. Ransome is participating in a clinical research study involving HIV-infected patients who have diabetes to see whether there is increased risk of development or progression of diabetic retinopathy when subjects are treated for abdominal lipodystrophy with Egrifta (tesamorelin).

Meryl L. Shapiro-Tuchin, MD
Associate Physician Diplomate
Assistant Clinical Professor of Ophthalmology
Co-Director of the Ophthalmology Inpatient Consultation Service

Comprehensive Ophthalmology
Dr. Shapiro-Tuchin provides clinical supervision to resident physicians. She functions as Co-Director of the Ophthalmology Inpatient Consultation Service, assisting resident physicians in their evaluation of inpatients admitted to the Ronald Reagan UCLA Medical Center and the UCLA Medical Center, Santa Monica.

LECTURER

Kathleen L. Boldy, VMD
Lecturer in Ophthalmology
Dean Bok, PhD
Dolly Green Chair of Ophthalmology
Professor of Ophthalmology Emeritus
(Active Recall)
Distinguished Research Professor of Neurobiology
Member of the Brain Research Institute
Member of the Stein Eye Institute

Michael O. Hall, PhD
Professor of Ophthalmology Emeritus
Founding Member of the Stein Eye Institute

Robert S. Hepler, MD
Professor of Ophthalmology Emeritus
(Active Recall)
Founding Chief of the Neuro-Ophthalmology Division
Member of the Stein Eye Institute

Allan E. Kreiger, MD
Professor of Ophthalmology Emeritus
(Active Recall)
Founding Chief of the Retina Division

Bradley R. Straatsma, MD, JD
Professor of Ophthalmology Emeritus
(Active Recall)
Founding Chairman of the Department of Ophthalmology
Founding Director of the Stein Eye Institute

Barry A. Weissman, OD, PhD
Professor of Ophthalmology Emeritus
(Active Recall)

Marc O. Yoshizumi, MD
Professor of Ophthalmology Emeritus
Member of the Stein Eye Institute

Richard W. Young, PhD
Professor of Neurobiology Emeritus
Member of the Stein Eye Institute
Programs
The Institute’s program of care for patients encompasses the full range of eye diseases. Nationally and internationally renowned faculty, along with highly skilled clinical fellows and physician residents, provide integrated consultation and treatment, including new diagnostic and therapeutic procedures that have been made available through recent scientific advances. Skilled optometricists, orthoptists, technicians, and nurses support institute ophthalmologists in their efforts. Care is delivered in distinctive subspecialty treatment centers, service areas, and clinical laboratories, as well as in specially equipped ophthalmic surgical suites. In addition, the Stein Eye Center–Santa Monica and the Doheny Eye Center UCLA offer premier eye care services in convenient neighborhood locations.

**Faculty Consultation Service**
Institute faculty members provide direct consultation and treatment, including emerging therapies, to patients through the Ophthalmology Faculty Consultation Service. Faculty members have extensive, advanced training in ophthalmic subspecialties, providing referring physicians and patients with a valuable resource for special eye problems.

**Inpatient Consultation Service**

**Stein Eye Institute–Westwood**
The Ophthalmology Inpatient Consultation Service, operating 24 hours a day through the Ronald Reagan UCLA Medical Center, provides consultation and treatment to pediatric and adult patients admitted to the hospital’s medical, surgical, and psychiatric inpatient services. Led by Dr. Meryl L. Shapiro-Tuchin, the consultation team consists of physician-residents. Subspecialty coverage from faculty is provided as needed.

---

From the westside to the eastside and south to Orange County, access to the UCLA Department of Ophthalmology physicians you know and trust has never been easier.

**UCLA Ophthalmology**
LA and Beyond
Stein Eye Center–Santa Monica

The Ophthalmology Inpatient Consultation Service, operating through the Stein Eye Center–Santa Monica, provides consultation and treatment to pediatric and adult patients admitted to the hospital’s medical, surgical, and psychiatric inpatient services. Led by Dr. Laura Bonelli, the consultation team consists of physician-residents. Subspecialty coverage from faculty is provided as needed.

Surgical Services

Ophthalmic surgery of every kind, from cataract extraction to removal of ocular and orbital tumors, is performed in the Institute’s dedicated operating rooms. Additionally, laser vision-correction surgeries, such as laser-assisted in situ keratomileusis (LASIK) and certain aesthetic and retinal laser surgeries and injection procedures, are performed in designated outpatient procedure rooms. Faculty members perform surgical procedures according to their specific ophthalmic specialty. They are joined by other medical specialists, including anesthesiologists, nurses, and technicians to ensure the highest quality preoperative and postoperative care.

The award-winning Edie & Lew Wasserman Building houses the Institute’s expanded surgery center, which enables the Stein Eye Institute to provide a greater number of surgical services to patients in need.

Six operating suites, a sterile processing area, procedure treatment units, and postoperative areas serve all ophthalmic specialties, including retina, glaucoma, cataract, strabismus, cornea, and oculoplastics. In addition, there are three procedure rooms for physicians to perform minor laser treatments and ophthalmologic surgical procedures.

University Ophthalmology Associates

Comprehensive and subspecialty eye care in all medical and surgical areas of ophthalmology is offered through University Ophthalmology Associates. Dr. John D. Bartlett is medical director, and ophthalmologists who are members of the UCLA Medical Group staff the practice.

Stein Eye Institute, Westwood
100 Stein Plaza, UCLA
Los Angeles, CA 90095
Referral Service: (310) 825-5000
Emergency Service: (310) 825-3090
After-Hours Emergency Service: (310) 825-2111

Stein Eye Center–Santa Monica

The Stein Eye Center–Santa Monica, under the direction of Dr. Colin A. Mc-Cannel, offers the world-renowned comprehensive and subspecialty eye care of the Stein Eye Institute at a convenient location in Santa Monica. Established in 2011, the Stein Eye Center–Santa Monica features well-equipped exam rooms, an optical shop, on-site parking for easy access, and testing facilities offering a wide range of examinations, including visual field, corneal mapping (corneal topography), intraocular lens measurement, fluorescein angiography, spectral domain optical coherence tomography, and other diagnostic retinal imaging techniques.

Nearly all the evaluation, diagnosis, testing, and treatment services available at the Stein Eye Institute in Westwood are offered at the Stein Eye Center–Santa Monica by experts in retinal disorders, corneal disorders, glaucoma, neuro-ophthalmology, and laser refractive surgery. For surgeries and seldom-needed tests requiring specialized laboratories, patients can be referred to the Institute’s main facility in Westwood.

Stein Eye Center–Santa Monica
1807 Wilshire Boulevard, Suite 203
Santa Monica, CA 90403
Telephone: (310) 829-0160
Fax: (310) 829-0170

Doheny Eye Center UCLA

The UCLA Department of Ophthalmology and the Doheny Eye Institute formed a historic affiliation in 2014, and patient access to eye care was immediately broadened across Los Angeles and into Orange County, with the opening of three Doheny Eye Center UCLA locations: Arcadia, Orange County, and Pasadena. The Doheny and Stein Eye Institutes share a long tradition of excellence, and through this partnership, the respective strengths that gained each Institute an international reputation have been combined. The board-certified Doheny ophthalmologists that patients and referring physicians know and trust are now members of the UCLA Department of Ophthalmology. The Doheny Eye Center UCLA is under the supervision of Vice Chairman Dr. Alfredo A. Sadun and Medical Director Dr. John A. Irvine. Dr. SriniVas R. Sadda is the president and chief scientific officer of the Doheny Eye Institute.

Doheny Eye Center UCLA–Arcadia

As Medical Director of the Doheny Eye Center UCLA–Arcadia, Dr. Kenneth L. Lu oversees a renovated office that includes 12 exam rooms, dedicated diagnostic equipment, and attractive patient areas. The Center provides comprehensive ophthalmology, and nearly all subspecialty services, including glaucoma, retina, and cornea.

The Doheny Eye Center UCLA–Arcadia, which opened April 1, 2014, serves patients in the broader Arcadia region and San Gabriel area, expanding the UCLA Department of Ophthalmology’s reach in Los Angeles County. The Arcadia Center is easily accessible from two freeways and provides on-site, free parking.

Doheny Eye Center UCLA–Arcadia
622 W. Duarte Road, Suite 101
Arcadia, CA 91007
Telephone: (626) 254-9010
Fax: (626) 254-9019

Patient Care Services | Stein Eye Institute 103
**Doheny Eye Center UCLA–Orange County**

The Doheny Eye Center UCLA–Orange County opened on May 15, 2014, in the Orange Coast Memorial Medical Center, broadening the reach of the UCLA Department of Ophthalmology south to Orange County. Newly renovated, the Orange County location, overseen by Medical Director **Dr. Brian A. Francis**, offers comprehensive ophthalmology, as well as glaucoma, retina, and cornea subspecialty services. The Doheny Eye Center UCLA–Orange County includes 12 exam rooms, dedicated diagnostic equipment, and inviting patient areas.

**Doheny Eye Center UCLA–Orange County**
Orange Coast Memorial Medical Center
18111 Brookhurst St., Suite 6400
Fountain Valley, CA 92708
Telephone: (714) 963-1444
Fax: (714) 963-1234

**Doheny Eye Center UCLA–Pasadena**

The Doheny Eye Center UCLA–Pasadena, which opened on July 1, 2014, serves as the primary hub of the Doheny Eye Center UCLA. Located on the second floor of the Huntington Pavilion, the Doheny Eye Center UCLA–Pasadena provides expanded vision care services and clinics devoted to retina and cornea; comprehensive ophthalmology and oculoplastics; neuro-ophthalmology; and glaucoma. Each subspecialty clinic has dedicated, state-of-the-art diagnostic laser suites, as well as in-office procedure rooms. More complex procedures are performed at the Huntington Pavilion Surgical Suites, which are located on the building’s third floor.

The Huntington Pavilion is home to a wide variety of medical practitioners, which provides physicians with ease of referral for patients requiring specialized eye care and provides patients with the added convenience of seeing their doctors and having any necessary services all in one location. The Medical Director of the Doheny Eye Center UCLA–Pasadena is **Dr. Vikas Chopra**.

**Doheny Eye Center UCLA–Pasadena**
Huntington Pavilion
625 S. Fair Oaks Blvd., 2nd Floor
Pasadena, CA 91105
Telephone: (626) 817-4747
Fax: (626) 817-4748

### Summary of Patient Care Statistics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Faculty Consultation Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient visits</td>
<td>133,207</td>
<td>136,419</td>
</tr>
<tr>
<td><strong>University Ophthalmology Associates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient visits</td>
<td>20,502</td>
<td>19,772</td>
</tr>
<tr>
<td><strong>Inpatient Consultation Service</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient evaluations</td>
<td>671</td>
<td>947</td>
</tr>
<tr>
<td><strong>Clinical Laboratories</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures</td>
<td>60,960</td>
<td>71,661</td>
</tr>
<tr>
<td><strong>Surgery Services</strong></td>
<td>27,014*</td>
<td>30,184</td>
</tr>
<tr>
<td>Number of procedures</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mobile Eye Clinic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients seen</td>
<td>21,422</td>
<td>24,442</td>
</tr>
<tr>
<td>Ocular abnormalities</td>
<td>16%</td>
<td>20%</td>
</tr>
<tr>
<td>Number of trips</td>
<td>945</td>
<td>1,059</td>
</tr>
</tbody>
</table>

1Includes lasers and injections

*Updated
The Research and Treatment Centers provide subspecialty care from faculty physicians who are actively involved in related research, enabling emerging and experimental treatment options to be developed for a gamut of eye disorders. In addition to comprehensive treatment, the centers provide both patients and physicians with expert diagnostic and consultation services for diseases that are difficult to identify and treat. Ophthalmology faculty work closely with other specialists, both within the Stein Eye Institute and in other UCLA clinical departments, to create a multidisciplinary team customized for each patient’s unique medical needs.

Aesthetic Center

The Aesthetic Center, under the direction of Dr. Robert Alan Goldberg, provides services to patients who are interested in enhancing their appearance through aesthetic surgery. Dr. Daniel B. Rootman also sees patients. Established in 1998, the Center has earned a reputation for high quality, individualized care delivered by surgeons trained in both ophthalmic and plastic surgery.

Surgical services include upper and lower eyelid blepharoplasty, endoscopic forehead lifting, endoscopic midface surgery, lifting of the neck and face, liposuction, fat transfer, and skin treatment, as well as dermal filler and other cosmetic injections to smooth facial lines. Minimally invasive approaches are utilized to provide the optimal aesthetic result. A major goal of the Center is to conduct research focused on improving understanding of facial aging, surgical healing, and on developing new techniques for aesthetic surgery. Center physicians have pioneered minimal incision surgical techniques to enhance the normal function and appearance of the eyes and face, and often receive referrals for complex and re-operative plastic surgery cases.

UCLA Mobile Eye Clinic

For more than 40 years, the UCLA Mobile Eye Clinic has supported patient care and screening programs in neighborhoods where poverty and vision disabilities intersect. The dedication and hard work of UCLA Mobile Eye Clinic ophthalmologists, technicians, and volunteers have touched the lives of hundreds of thousands of individuals.

The UCLA Mobile Eye Clinic, a 39-foot-long bus specially outfitted with eye examination equipment, is supported by charitable contributions to the Stein Eye Institute. The UCLA Mobile Eye Clinic’s staff of trained ophthalmic personnel provides general eye care to over 20,000 underserved adults and children annually throughout Southern California. Services include vision screening, ophthalmic examination and refraction, diagnosis of potential or existing eye disorders, treatment of some ocular diseases, and appropriate referral of patients who need additional care.

Center to Prevent Childhood Blindness

The Center to Prevent Childhood Blindness, under the direction of Dr. Sherwin J. Isenberg, is committed to reducing pediatric blindness. UCLA physicians and basic scientists, including Drs. Gary N. Holland, Steven Nusinowitz, and Irwin Weiss, collaborate on research, education, and patient care programs designed to increase awareness and help treat pediatric blindness. Significant emphasis is on the development and evaluation of ophthalmic medical and surgical options for children.

Center members are developing a new noninvasive method of measuring blood gases from the surface of the eye, which may be critical in preventing retinopathy of prematurity, a leading cause of blindness in premature newborns. In another avenue
of research, the Center developed an extremely inexpensive antiseptic solution to treat pediatric corneal infections in developing areas of the world and completed a study showing its effectiveness in treating corneal ulcers that now blind more than 400,000 children worldwide. A second study, which evaluated the solution’s effectiveness in treating fungal corneal infections, a major cause of pediatric blindness in tropical countries, has shown promise in treating the milder fungal infections.

Center for Regenerative Medicine in Ophthalmology

Representing a milestone in the therapeutic use of stem cells, in 2011, Stein Eye Institute clinician-scientists successfully transplanted the first human embryonic stem-cell-derived retinal pigment epithelial cells into the eyes of legally blind patients with Stargardt disease and dry macular degeneration.

The Center for Regenerative Medicine in Ophthalmology (CRMO), under the co-direction of Drs. Sophie X. Deng and Gabriel H. Travis, is building upon these efforts, using stem cells for the treatment of corneal disorders and retinal degenerative diseases. The CRMO fosters collaboration between basic scientists and clinicians, including Drs. Debora Farber, Jean-Pierre Hubschman, Steven D. Schwartz, and Xian-Jie Yang, to translate advances in basic science research into new and improved clinical therapies.

Many of the blinding eye diseases, including glaucoma, macular degeneration, and corneal diseases, are due to the loss of functional tissue. The development of effective and safe individualized stem-cell-based therapies relies on robust basic science, as well as translational and clinical research. The CRMO supports current stem cell studies and pursues new research programs to diagnose, treat, and ultimately cure and prevent blinding eye diseases.

Clinical Research Center

The UCLA Department of Ophthalmology Clinical Research Center (CRC) was established in 1998 to provide core support to faculty members who are conducting patient-based research studies. This support involves vital, behind-the-scenes activities that facilitate the clinical research process. Dr. Gary N. Holland serves as Director of the CRC working with full-time administrator, Ms. Ellen Pascual, and a Board of Directors composed of Department of Ophthalmology faculty members. The CRC has an in-house statistician, Fei Yu, PhD. CRC staff members interact with granting agencies and government regulatory bodies, assist with the preparation of grant applications, participate in the design and management of clinical studies, and perform data collection and analysis functions for investigators at both the UCLA Stein Eye Institute and the Doheny Eye Institute.

Institute faculty members are currently conducting almost 80 clinical research studies (listed in the Appendices). Patients can volunteer to participate in studies that contribute to a better understanding of ocular disorders or that evaluate new, potentially better treatments for various diseases of the eye.

Contact Lens Center

The Contact Lens Center, under the supervision of Dr. Vivian Phan Shibayama, serves patients with all ophthalmic diagnoses that can be treated with contact lenses. The Center’s primary focus is on customized specialty lenses that visually rehabilitate conditions, such as keratoconus, corneal transplants, corneal scarring, postrefractive surgery ectasia, ocular surface disease, and aphakia. Dr. Shibayama also prescribes contact lenses to address farsightedness, nearsightedness, and presbyopia.

The specialty lenses that are available through the Contact Lens Center include rigid gas permeable contact lenses, multifocal contact lenses, hybrid lenses, scleral lenses, custom soft lenses, soft lenses for irregular corneas, prosthetic soft lenses, pediatric aphakic lenses, and adult aphakic lenses.

Dr. Shibayama’s clinical research is focused on keratoconus and scleral lenses for the treatment of ocular surface disease. A large majority of her patients require custom contact lenses and are referred by corneal specialists.

Diabetic Eye Disease and Retinal Vascular Center

Under the direction of Dr. Steven D. Schwartz, the Diabetic Eye Disease and Retinal Vascular Center provides diabetic patients with comprehensive ophthalmic care. Established more than a decade ago, the Center has contributed significantly to the understanding, treatment, and prevention of diabetic eye disease. Current focus is on innovation in technologies and techniques that expand the standard of treatment, such as drugs and pharmacotherapeutic strategies, new lasers and laser strategies, refinement of microsurgical techniques specific to diabetic eye diseases, and nontraditional treatment approaches.

The Center’s treatment philosophy is based upon the systemic nature of diabetes. Patient care is coordinated with other UCLA departments to address the special needs of diabetics that lie outside the field of ophthalmology. Center treatment interventions include pharmacotherapy, laser and ophthalmic surgery. Recognizing the special care needed for diabetics in any surgical situation, Center physicians perform all eye surgeries for diabetics, including those specific to the disease, as well as vitrectomy, cataract surgery, and retinal reattachment.
Eye Trauma and Emergency Center
The Eye Trauma and Emergency Center, under the direction of Dr. Robert Alan Goldberg, provides immediate response to ophthalmic emergencies through an eye trauma team available 24 hours a day for consultative, medical, and surgical care involving both primary and secondary ocular repairs. Ophthalmic emergency care has been provided by the UCLA Department of Ophthalmology since its inception. In 1980, the Eye Trauma and Emergency Center was formally established to encompass all levels of ocular trauma within the UCLA hospital system, including support to affiliated institutions.

Patients are commonly referred to the Center for such ocular traumas as ruptured globe, intraocular foreign bodies, acute orbital hypertension, retinal detachment, chemical burns of the cornea and conjunctiva, and acute vitreous hemorrhage. The Center offers complete evaluation and treatment of the traumatically injured eye, including vitreoretinal and/or orbital and ophthalmic plastic surgery, anterior segment surgery, and medical follow up. Expertise is provided for both urgent primary repair and scheduled secondary repair.

Gerald Oppenheimer Family Foundation Center for the Prevention of Eye Disease
Established with a generous pledge from Gail and Gerald H. Oppenheimer, the Gerald Oppenheimer Family Foundation Center for the Prevention of Eye Disease is committed to the discovery of agents and methods to prevent ophthalmic diseases. Areas of study supported by the Foundation include genetic and environmental factors that may cause eye disease, and pharmacologic and natural agents to prevent eye disease. The Center complements an expanding array of research in many other fields at UCLA, where rigorous scientific methods are being applied to study novel approaches to health care.

Glaucanoma Center for Excellence in Care and Research
In the United States, glaucoma is the second cause of irreversible legal blindness. If glaucoma is detected early, however, vision loss can be slowed or even prevented. Under the direction of Dr. Joseph Caprioli, the Glaucoma Center for Excellence in Care and Research is committed to giving each patient a chance for a brighter future and a life filled with sight.

Stein Eye Institute researchers, Drs. Anne L. Coleman, JoAnn A. Giaconi, Jacky M. K. Kwong, Simon K. Law, Kouros Nouri-Mahdavi, and Natik Piri, are working with researchers and statisticians from the UCLA School of Public Health to identify individuals at greatest risk for vision loss, to develop and assess therapeutic strategies, and to implement new treatments to preserve vision.

UCLA Laser Refractive Center
The UCLA Laser Refractive Center is under the direction of Dr. David Rex Hamilton. Founded in 1991, the Center specializes in refractive surgery of both the cornea and lens of the eye, including clinical and research applications of new laser technology. The Center is one of a few in the United States to pioneer investigations into laser eye surgery.

The UCLA Laser Refractive Center offers all cornea refractive procedures, including LASIK and LASEK/PRK, astigmatic kerototomy, conductive keratoplasty, and intracorneal ring implantation. Advanced intraocular lens (IOL) procedures are also available, including presbyopia-correcting IOLs (multifocal and accommodating), toric IOLs, and phakic IOLs. Patients referred to the Center undergo a complete ocular examination that includes corneal topographic mapping, wavefront analysis, and corneal biomechanical measurements to identify conditions that may interfere with surgical correction of refractive errors. Candidates for laser or intraocular lens surgery receive intensive education to understand the benefits, risks, and alternatives to surgery. Participation in clinical trials for new refractive devices and techniques to treat nearsightedness, farsightedness, and presbyopia may be an option for qualified patients. For more information about the UCLA Laser Refractive Center, go to: www.uclaser.com and lasik.ucla.edu.

Macular Disease Center
The Macular Disease Center, under the direction of Dr. Steven D. Schwartz, was created in 1994 in response to the growing national incidence of macular degeneration. The Center’s mission is threefold: provide high-quality patient care, utilizing standard and developing treatments; offer associated rehabilitation services, such as low-vision aids and counseling, in order to enhance quality of life for patients; and promote collaborative translational research between clinicians and basic science researchers into the cause of macular disease.

Patients with the atrophic or dry form of macular disease are evaluated and often considered for clinical trials, such as the stem cell programs, and their cases are followed at the Macular Disease Center in conjunction with services offered by the Vision Rehabilitation Center. Patients with the exudative or wet form of macular disease are diagnosed and treated with cutting-edge therapies. Treatment options for wet macular disease include therapy and participation in clinical studies that are matched to the patient’s disease status. A patient coordinator is available to answer questions and provide information on an ongoing basis.
Ocular Inflammatory Disease Center
The Ocular Inflammatory Disease Center, under the direction of Dr. Gary N. Holland, was established in 1985 to coordinate research, educational activities, and patient-care services related to a broad spectrum of inflammatory eye disorders, including uveitis, infectious corneal ulcers, endophthalmitis, autoimmune diseases of the cornea and ocular surface, and the ophthalmic manifestations of HIV disease. The Center has a long history of participating in clinical studies and drug-therapy trials that have furthered the understanding and treatment of these diseases.

Center faculty members were the first to describe cytomegalovirus retinitis as an ophthalmic manifestation of AIDS; today the Center is a nationally recognized site of expertise for AIDS-related ophthalmic disease. Other special clinical and research programs have been developed in the following areas: ocular toxoplasmosis, uveitis in children, birdshot chorioretinopathy, immunogenetics of inflammatory eye diseases, unusual corneal infections, and mediators of intraocular inflammation.

Ophthalmic Oncology Center
The Ophthalmic Oncology Center, under the direction of Dr. Tara A. McCannel, is renowned for its expertise in teaching, research, and clinical management of adult posterior segment tumors. Established in the early 1980s by the Institute’s Founding Director, Dr. Bradley R. Straatsma, the Center is internationally recognized for the diagnosis and management of ocular melanoma. The Center serves as a hub for national, long-term studies investigating ocular melanoma, and played an important role in the Collaborative Ocular Melanoma Study sponsored by the National Eye Institute.

The Center’s clinical goal is successful treatment of the primary eye tumor. Patients diagnosed with ocular melanoma may be offered highly sophisticated treatment plans coordinated with UCLA radiation physicists and radiation oncologists. Patients may also qualify to participate in clinical research studies in partnership with the UCLA Jonsson Comprehensive Cancer Center. The Center’s primary research goal is to gain a fundamental understanding of the molecular biology of metastatic ocular melanoma. In addition to providing genetic prognostic information to patients on their risk of tumor metastasis, the Center has identified key genes associated with metastatic tumors.

Optic Neuropathy Center
Under the direction of Dr. Anthony C. Arnold, the Optic Neuropathy Center provides multidisciplinary consultation, diagnosis, and treatment for patients with complex diseases involving the optic nerve. Established in 1991, the Center incorporates specialized facilities and equipment for diagnostic testing and offers consultation from neuro-ophthalmologists, orbital surgeons, neurologists, neuro-radiologists, and neurosurgeons.

Patients referred to the Optic Neuropathy Center receive advanced diagnostic testing of the orbit and optic nerve to assist in evaluation. Extensive analysis of diagnostic data, together with information from the patient’s medical history and comprehensive physical examination, enables Center physicians to determine the nature of the disease and devise a treatment plan. Treatment may be medical or surgical depending on the nature of the referral and the patient’s disease status. As part of the Center’s clinical research effort, physicians are refining disease classifications along with diagnostic and treatment approaches to further the field of optic neuropathy and improve options for patients with these complex disorders.

Orbital Disease Center
The Orbital Disease Center, under the direction of Drs. Daniel B. Rootman and Robert Alan Goldberg, was founded in 1991. The Center brings multidisciplinary expertise to the treatment and study of orbital diseases arising from trauma, cancer, inflammation, and infection. Care is organized around a team of experts in ophthalmology, interventional neuroradiology, neurosurgery, head and neck surgery, radiation oncology, and craniofacial surgery, bringing to the treatment of orbital diseases a depth of knowledge and experience not available elsewhere in Southern California.

The Center provides both medical and surgical management of orbital diseases. The team performs procedures that are not usually available in the community, including orbital decompression, microsurgery for orbital apical tumors, optic canal decompression, combined interventional neuroradiology procedures for vascular tumors, and bony reconstruction to address traumatic or congenital defects. The Center has an active program in thyroid eye disease, where new surgical techniques are evaluated, and basic science research is carried out to advance understanding about the disease. A fellowship program trains future leaders, and teaching courses draw international audiences of highly trained orbital specialists to learn the latest advances in the field.
Vision Genetics Center

Initially established in 1978 as the UCLA Retinitis Pigmentosa Registry, the Vision Genetics Center, under the direction of Dr. Michael B. Gorin, is an integrated clinical and research program that addresses the full spectrum of hereditary eye disorders. Center members, representing multiple disciplines, combine their efforts to understand the underlying molecular basis of a broad range of ocular conditions, including those involving the development of the eye, cornea, lens, extracocular muscles, retina, vitreous, and optic nerve. Areas of interest include both simple inherited conditions caused by alterations in single genes, as well as conditions in which multiple genetic variations and other risk factors play a role.

The Center offers patients and their family members state-of-the-art diagnosis and care of the hereditary eye or vision condition. Services include genetic counseling, and when appropriate, DNA testing either as a clinical diagnostic service, a research program, or in combination. The Center’s faculty members collaborate with a number of genetic research groups around the world to ensure that patients can participate in the most advanced research for their particular condition.

During the past year, the Center has initiated involvement in a natural history study and clinical trial for gene therapy for choroideremia and a therapeutic clinical trial for Stargardt Disease.

Vision Proteomics Center

Genes encode the sequences of proteins, and knowledge of the structure and function of these proteins is required to unlock the secrets of the cell. That task is now set before current and future generations of scientists, and a new field of study, Proteomics, has been born. It is only through an understanding of protein function at the molecular level that researchers can learn the fundamental origins of disease and develop rational therapeutic designs to correct defects in the molecular machinery.

The Vision Proteomics Center at the Stein Eye Institute, under the direction of Dr. Wayne L. Hubbell, with researchers Drs. Ben J. Glasgow, Dean Bok, Joseph Horwitz, and Gabriel H. Travis, has pioneered the development of site-directed spin labeling—the only one of its kind in the world, ushering in a new era of exploration of structure/function relationships in proteins. Research groups at the Stein Eye Institute, departments at UCLA, and other major institutions throughout the United States and abroad, are taking advantage of the singular opportunities provided by the Vision Proteomics Center.

Vision Rehabilitation Center

The Vision Rehabilitation Center, under the direction of Dr. Melissa W. Chun with Dr. Steven D. Schwartz as medical advisor, was established to provide rehabilitation to maximize visual function and quality of life of patients with low vision, defined as best corrected vision of 20/70 or worse in the better eye. These outcomes are accomplished with a rehabilitation plan tailored to each patient’s specific needs and goals.

The Center provides assistance in the form of patient consultation and training, including reading and computer training, as well as evaluation with the latest low vision devices that can help patients adapt to their visual restrictions. The Center utilizes a wide array of technologically advanced devices, such as magnifiers, telescopes, and digital and computer technology. Customized for each patient’s individual needs, services may range from simple solutions to specialized approaches. One unique feature of the Center is a special “lending library” of select low-vision devices that enables patients to try devices at home or in the office prior to purchase. When appropriate, referrals are provided to assist independent living through occupational therapy and orientation and mobility training.
The Ophthalmology Clinical Laboratories provide precise measurements, photographs, and quantitative studies of the eye and the visual system. Quantitative information of this type enhances patient care by increasing the accuracy of diagnosis and enlarging the parameters employed to assess the clinical course and effectiveness of treatment. Additionally, the clinical laboratories expand the scope of treatment alternatives, promote clinical research, and generally augment the effectiveness of ophthalmic disease management. The laboratories are available to all ophthalmologists in the community.

**Corneal Diagnostic Laboratory**

The Corneal Diagnostic Laboratory, under the direction of Dr. Anthony J. Aldave, offers a comprehensive array of corneal imaging modalities. Services include imaging of the anterior and posterior corneal surfaces with the Marco OPD-Scan III and Optovue RTVue, and imaging of the corneal endothelial cell morphology and density using the KONAN CellChek XL specular microscope. Full-thickness confocal microscopic imaging of the cornea, a useful tool in the diagnosis of suspected fungal, acanthamoebic, and other parasitic infections of the cornea, is performed with the Heidelberg HRT3 confocal microscope. This instrument and the Optovue RTVue can also perform optical pachymetry to noninvasively measure LASIK residual bed thicknesses and flap thicknesses as well as evaluate the LASIK interface for possible infections, diffuse lamellar keratitis, and ingrowth.

**Glaucoma Photography Laboratory**

The Glaucoma Photography Laboratory, under the direction of Dr. Joseph Caprioli, provides specialized photographs for new and follow-up patients to assist the ophthalmologist in the management of patients with glaucoma. The GDX Nerve Fiber Analyzer utilizes polarized light in place of dilation to measure the thickness of the nerve fiber layer. This test is particularly useful in diagnosing new glaucoma. Heidelberg retinal tomography, using confocal laser light, measures additional parameters of the optic nerve and provides more information on the nerve fiber layer. Optical coherence tomography utilizes reflected light to measure the nerve fiber layer as well as to measure macular holes as a staging procedure for surgical repair. An ophthalmic fundus camera photographs the optic nerve in stereo. The Laboratory is conducting clinical studies to evaluate the effectiveness of each photographic modality in terms of predictive accuracy and early detection of glaucoma.

**Live Imaging and Functional Evaluation (LIFE) Core Laboratory**

The Live Imaging and Functional Evaluation (LIFE) Core Laboratory is jointly supervised by Drs. Steven Nusinowitz and Alapakkam Sampath. The LIFE Module directors are committed to the provision of state-of-the-art noninvasive in vivo imaging and functional analysis of animal models of ocular disease and treatments. Testing provided by the module includes full-field and multi-focal electroretinography (ERG), pattern electroretinography (pERG), and flash and pattern visually-evoked cortical potentials (fVECP and pVECP, respectively). For all of these tests, the ERG component of interest is extracted from the waveform targeting a specific cell type of interest. Structural analysis is provided by direct fundus imaging, auto-fluorescence imaging, angiography, and optical coherence tomography (OCT).
**Ocular Motility Clinical and Basic Science Laboratory**

The Ocular Motility Clinical and Basic Science Laboratory, under the direction of Dr. Joseph L. Demer, records and quantitatively analyzes eye movement abnormalities resulting from ocular and neurological disorders, such as ocular myasthenia gravis. Several types of tests are performed. The Hess test utilizes specialized eye charts and lenses to assist in the diagnosis of a number of problems, including double vision. Magnetic scleral search coil techniques are utilized in clinical research studies to detect fine movements not evident through normal visual examination. Another test involves the visual recording of eye movement using a video camera. The Laboratory also engages in basic science research to further understanding of eye movement, as well as diseases of the eye, brain, and muscles, and related tissues of the inner ear.

**Ophthalmic Photography Clinical Laboratory**

The Ophthalmic Photography Clinical Laboratory, under the direction of Dr. Tara A. McCannel, provides a wide array of photographic techniques important in patient care, research, and teaching. The primary purpose of ophthalmic photography in patient care is to record the present state of the eye, and in cases of abnormality, to establish a baseline and monitor the patient’s condition over time. Patient care services include photographic documentation of anterior segment diseases involving corneal problems like growths, infection, and trauma; photographs of ocular motility to record abnormalities in eye movement; fundus photography, which captures pictures of the retina; and diagnostic testing using fluorescein and indocyanine green angiography, which records the dynamics of blood flow in the eye. The Laboratory also supports the research and teaching activities of the Stein Eye Institute by preparing and duplicating graphic materials for presentation and publication.

**Ophthalmic Ultrasonography Clinical Laboratory**

The Ophthalmic Ultrasonography Clinical Laboratory, directed by Dr. Steven D. Schwartz, performs clinical examinations that are useful in diagnosing both ocular and orbital eye diseases. Diagnostic examinations include standardized A-scan, B-scan, and ultrasound biomicroscopy. Standardized A-scan is useful in tissue differentiation and is commonly employed to diagnose ocular and orbital tumors, including choroidal melanoma. B-scan provides location and contour information and is particularly useful in differentiating vitreous membranes from retinal detachment. Ultrasound biomicroscopy provides exquisitely detailed, high-resolution views of the anterior segment of the eye and is a critical tool for the evaluation of ocular pathology, especially in opaque corneas.

Biometry and intraocular lens calculations are also performed in the Laboratory, under the direction of Dr. Ralph Levinson. Biometry measures the axial eye length, anterior chamber depth, and lens thickness; intraocular lens calculations are performed to determine the power of the lens implant for cataract patients.

**Perimetry Laboratory**

The Perimetry Laboratory, under the direction of Dr. Joseph Caprioli, performs visual field examinations that determine the sensitivity of central and peripheral vision. Examinations are conducted with advanced Humphrey automated perimetry equipment. Testing detects visual field deficits associated with certain kinds of eye diseases such as glaucoma, retinal disorders, and neuro-ophthalmic conditions. Utilizing pinpoints of light around a perimetry bowl, the test evaluates different areas of the field of vision. Test results are computerized and compared to a range of normal values by age group. Patterns of diminished fields of vision are related to specific eye diseases. Perimetry testing is employed for diagnostic purposes and to monitor visual field sensitivity over time, especially for glaucoma patients. Both standard and shortwave automated techniques are available, in addition to frequency-doubling perimetry and motion-detection perimetry.

**Visual Physiology Clinical Laboratory**

The Visual Physiology Clinical Laboratory, under the direction of Drs. Michael B. Gorin and Steven Nusinowitz, quantitatively evaluates the function of the retina and visual pathways. Patients are referred for functional testing to confirm a specific diagnosis, or in cases where the etiology is unknown, to rule out alternative diagnostic possibilities. Electrophysiological tests, including both the full-field and multifocal electroretinograms (ERG and mfERG), the electro-oculogram (EOG), and visually evoked cortical potentials (VECP), record electrical signals from different layers of the visual system to identify the site responsible for visual symptoms. Psychophysical tests require the participation of the patient in specific tasks to evaluate visual functions like color blindness, contrast sensitivity, and visual acuity. In many cases, both electrophysiological and psychophysical tests are performed together to obtain the optimum amount of information for diagnosis.
he Stein Eye Institute and the UCLA Department of Ophthalmology jointly provide comprehensive training in ophthalmology and vision science to medical students, residents, and clinical and research fellows. The programs encompass the gamut of ophthalmic and vision science education, representing every level of training and incorporating a full range of subjects in the study of the eye. The residency program is rated one of the top in the country. A large patient population with diverse vision problems offers innumerable training opportunities for both residents and clinical fellows. The availability of more than 15 research laboratories ensures a wide choice of vision science projects for all trainees. Predoctoral and postdoctoral research fellows particularly benefit from the wealth of new and unfolding research generated by vision scientists at the Institute.

**UCLA Medical Student Program**

Each academic year, the UCLA Department of Ophthalmology and the Institute extend instruction to UCLA medical students in their second, third, and fourth years of instruction. Through lectures, small group discussions, and clinical experience, all students have numerous training sessions from which to gain knowledge about eye diseases and develop eye examination skills that should be known by all physicians, regardless of their specialties. Those students who are interested in ophthalmology as a career have additional learning opportunities in elective courses.

In their second year of instruction, all medical students attend a series of lectures distributed throughout their year-long Human Biology and Disease course, covering various topics related to eye diseases. Students also attend several afternoon workshops during which they learn eye examination skills and treatments for eye problems that can be managed by non-ophthalmologists. During their third year of instruction, medical students interested in additional training and experience can elect to spend two weeks of their surgical clerkship on the Ophthalmology Service, examining patients in clinic and observing eye surgeries. During the fourth year of instruction, a series of advanced clinical electives are available to medical students who plan eventually to practice ophthalmology as their specialty.

**UCLA Medical Student Research Program**

At the Stein Eye Institute, medical students have taken short-term laboratory and clinical research electives for decades. In addition, there is now a Medical Student Research Program that provides select medical students with a year-long opportunity to participate in laboratory or clinical research in the field of ophthalmology. Each year, a committee selects one or two medical student researchers to receive salary and research support for 12 months in the laboratory or clinical research area of the student’s chosen mentor. The goal of the program is to encourage medical students to pursue careers in academic ophthalmology.

**UCLA Ophthalmology Residency Program**

The Department of Ophthalmology conducts an accredited three-year residency program for 24 residents; eight new residents begin training each July. The full breadth of ophthalmology training is offered, including experience in general ophthalmology and ophthalmic subspecialties. Training incorporates the resources of the UCLA Stein Eye Institute, Harbor-UCLA Medical Center, Olive View-UCLA Medical Center, and the Veterans Affairs Greater Los Angeles Healthcare System at West Los Angeles and Sepulveda. Every resident has exposure to each medical center during the course of training, thereby ensuring clinical experience with a wide range of problems and patient populations. Certification by the American Board of Ophthalmology is a natural objective of the program.

**Clinical Rotations**

Clinical rotations at the Stein Eye Institute include both general ophthalmology and subspecialties. In general, ophthalmology residents work as a team, handling clinics, emergencies, and walk-in patients. They also serve as an ophthalmology consult service for inpatients in the UCLA Medical Center. Residents assigned to subspecialty service rotations are provided with intensive exposure to the various divisions within the Department, working closely with faculty members in a private practice environment. At the UCLA-affiliated medical centers, residents work in teams that provide both general and subspecialty patient care.

**Didactic Education**

Residents receive didactic education in the classroom on an ongoing basis. Once each week, all residents attend a mandatory half-day program that includes faculty lectures that, over the course of the three-year program, cover each of the required subjects in the American Academy of Ophthalmology Basic and Clinical Sciences Course. These lectures are followed by Grand Rounds, which consist of presentation and discussion of specific patient cases, and faculty lectures on clinical topics related to ophthalmic subspecialties. Throughout the week, clinical conferences in ophthalmic subspecialties are held where problems are presented and discussed.
Surgery Training

Residents begin to perform surgery in their first year of training and continue to operate throughout their residency. Surgical cases are assigned commensurate with level of training and experience. First-year residents begin in the Institute’s Microsurgery Laboratory, an organized surgical course that includes computerized surgical simulators. This facility is available to residents throughout their training. Residents first assist on selected surgical cases, and by the end of their residency, they are performing procedures independently.

Research

An understanding of and an appreciation for research are major prerequisites for assimilating future developments in ophthalmology. Accordingly, ophthalmic research is an integral component of residency training. Residents are expected to undertake independent investigation or to participate in ongoing clinical or basic science research projects in ophthalmology. Residents present the results of their work at the Stein Eye Institute Clinical and Research Seminar during their second and third years of residency. They are also encouraged to report their studies at regional and national meetings and publish their results in scientific journals. Residents with special clinical or research interests have an opportunity to use elective time to increase their exposure to a particular area of ophthalmology. This time can be spent with full-time or volunteer faculty at UCLA or at other institutions.

EyeSTAR Program

For physicians who are interested in academic careers and professional leadership as clinician-scientists, the Stein Eye Institute offers an Ophthalmology Specialty Training and Advanced Research Program, referred to as EyeSTAR, which offers vision science training combined with an ophthalmology residency. Appointees complete a residency program leading to certification in ophthalmology, as well as laboratory research experience leading to a doctorate, or postdoctoral training in the event that the trainee already has a doctorate. EyeSTAR trainees work under the guidance of a faculty advisory panel representing the trainee’s clinical and research interests.

The unique program began in 1995 and is geared to physicians committed to academic careers in ophthalmology, combining basic science with clinical practice in a five-year or six-year curriculum. EyeSTAR graduates are trained to compete not just with clinical scientists but also with top basic scientists from all institutions. Trainees select their faculty mentors from the Vision Research Division of the Stein Eye Institute or from the David Geffen School of Medicine at UCLA, College of Letters and Sciences, School of Public Health, Clinical Scholars Program, and RAND Graduate School.

EyeSTAR is recognized by the National Eye Institute and the Association of University Professors of Ophthalmology as a model training program for clinician-scientists in ophthalmology.

UCLA Clinical Ophthalmology and Vision Science Fellowship Programs

The Stein Eye Institute offers particularly well-qualified persons the opportunity to receive fellowship training in specific areas of clinical ophthalmology or vision science research.

Following successful completion of a residency program, a clinical fellowship combines outpatient, inpatient, and surgical experience in an ophthalmic subspecialty. The clinical fellow assumes increasing responsibility for patient care under the supervision of faculty members responsible for the program. In addition to receiving training from faculty, the fellow instructs medical students and residents. Research is considered an important aspect of specialty training and a major prerequisite for assimilating future developments in ophthalmology. Clinical fellows are expected to undertake independent investigation or to participate in one of the ongoing research projects in a field related to their specialty.

Vision-science fellowship training is laboratory based and offers both predoctoral and postdoctoral opportunities to trainees in specific areas of vision science that encompass a wide range of topics. Trainees work under the supervision of Institute faculty members who are engaged in basic science research and have active laboratories. The scope and nature of the training program for each predoctoral or postdoctoral fellow is developed by the trainee and his/her faculty mentor.

Fellowship in Cornea–External Ocular Diseases and Refractive Surgery

Under the direction of Drs. Anthony J. Aldave, Sophie X. Deng, David Rex Hamilton, and Kevin M. Miller, one-year fellowships are offered in the study of diseases of the cornea, external eye, anterior segment, and refractive surgery. Clinical experience consists of participation in the cornea faculty practices, including surgery, and in the care of emergency cornea cases at the Stein Eye Institute. Fellows work in the microsurgical laboratory and assist in teaching microsurgical skills to ophthalmology residents. Under the direction of faculty, fellows also perform primary surgical procedures in the UCLA Laser Refractive Center. In addition to in-depth training at the Institute, fellows provide medical and surgical care to patients at the Veterans Affairs Greater Los Angeles Healthcare System at West Los Angeles and at Harbor-UCLA Medical Center. Fellows typically complete an original clinical or laboratory research project, and frequently co-author a book chapter or review during their training.

Fellowship in Glaucoma

Under the direction of Drs. Joseph Caprioli, Anne L. Coleman, JoAnn A. Giaconi, Simon K. Law, and Kouros Nouri-Mahdavi, the one-year or two-year glaucoma fellowship provides clinical and laboratory experience in glaucoma diagnosis and
Fellows gain clinical experience by examining patients in the consultation suite and participating in the clinical and surgical management of patients. Fellows work in the Glaucoma Microsurgery Laboratory, participate in microsurgery courses, assist in the Glaucoma Clinic, and develop expertise in the various diagnostic techniques used in glaucoma treatment through preceptor-type relationships with faculty. Fellows participate in glaucoma teaching at the Stein Eye Institute and affiliated institutions, present cases at teaching rounds, and prepare presentations for regularly scheduled glaucoma conferences. Fellows also undertake at least one research project, which may be a clinical study or an applied research project in the laboratory, in cooperation with the faculty advisor.

Fellowship in Medical Retina

This combined Stein Eye Institute and Doheny Eye Institute one-year fellowship, under the co-directorship of Drs. Michael B. Gorin and Srinivas R. Sadda, provides clinical knowledge pertaining to the diagnosis and management of a broad array of retinal disorders, including age-related macular degeneration, diabetic retinopathy, retinal vascular disease, inflammatory retinopathies, drug-related toxic retinopathies, and retinal and macular degenerations and dystrophies. Fellows are instructed in the proper use and interpretation of noninvasive diagnostic tools, and training includes genetic counseling and the proper use of molecular genetic diagnostics. Fellows gain experience with a diverse set of interventional skills, including a wide spectrum of retinal laser procedures and pericocular and intravitreal injection of various classes of drugs.

Fellows divide their time among the clinical practices of Drs. Gorin, David Sarraf, and Colin A. McCannel within the Division of Retinal Disorders and Ophthalmic Genetics, the Retina Division of the Doheny Eye Institute, as well as in the Retinal Diagnostics Unit and the Visual Physiology Laboratory directed by Dr. Steven Nussinowitz at UCLA. Dr. McCannel’s clinic provides exposure to surgical retinal decision-making and management issues. The fellows also provide care and teach residents in retina subspecialty clinics at two UCLA-affiliated hospitals. Fellows are strongly encouraged to engage in translational clinical research and/or clinical trials and descriptive retrospective studies and develop an in-depth working knowledge of the current scientific literature of medical and genetic retina. They are expected to participate in genetic and imaging conferences as well as other relevant meetings.

Fellowship in Neuro-Ophthalmology

The one-year fellowship in neuro-ophthalmology, under the direction of Dr. Anthony C. Arnold, involves a close preceptor-preceptee relationship, participation in teaching rounds, and work in the private consultation suite. The David Geffen School of Medicine at UCLA maintains major clinical and research programs in neurology, neurosurgery, and neuro-radiology. Fellows attend the weekly Neurology and Neurosurgery Grand Rounds, take an active part in seeing relevant inpatient consultations throughout the Medical Center, and assist in selected surgical procedures of interest to neuro-ophthalmologists. Attendance at the weekly neuro-radiology teaching conferences is encouraged. Time is allotted for scientific reading and for research activities. Participation in clinical research, such as studies of eye movement disorders and disturbances of visual pathways, is expected.

Fellowship in Ophthalmic Pathology

Under the direction of Dr. Ben J. Glasgow, this fellowship provides preparation for an academic career in ophthalmic pathology. One-year, two-year, and three-year training programs are available depending on the background of the applicant. Training encompasses many aspects of ophthalmic pathology. Fellows may choose between a research-based or clinical-based curriculum. Clinical fellows gain expertise in surgical pathology; autopsy pathology; cytology, including fine-needle aspiration; electron microscopy; immunohistochemistry; DNA in situ hybridization; Southern blot analysis; and polymerase chain reaction techniques for diagnostic work. The fellowship programs are individualized according to the credentials and capabilities of each fellow.

Fellowship in Orbital and Ophthalmic Plastic Surgery

Fellowships in orbital and ophthalmic plastic surgery, under the overall supervision of Drs. Robert Alan Goldberg and Jonathan Hoenig, provide training for ophthalmologists who are interested in specializing in orbital and adnexal disorders, and in aesthetic and reconstructive orbitofacial surgery. Fellows participate in orbital and ophthalmic plastic surgery outpatient consultation, inpatient care, and surgical procedures at the Stein Eye Institute and affiliated hospitals. They also participate extensively in the teaching and research activities of the Orbital and Ophthalmic Plastic Surgery Division. In addition to publishing results of original research in peer-reviewed scientific journals, fellows complete a formal thesis that partially satisfies the membership requirements of the American Society of Ophthalmic Plastic and Reconstructive Surgery. International research fellows also participate in the program annually. The two-year fellowship program is approved by the American Society of Ophthalmic Plastic and Reconstructive Surgery.

Fellowship in Pediatric Ophthalmology and Strabismus

The division of Pediatric Ophthalmology and Strabismus offers one-year fellowships, under the directorship of Drs. Sherwin J. Isenberg and Joseph L. Demer. Clinical experience consists of supervised participation in the ophthalmic care of pediatric patients seen at the Stein Eye Institute, Harbor-UCLA Medical Center, and Olive View-UCLA Medical Center. Specific activities include participation in University Ophthalmology
Dr. Gary N. Holland prepare a book chapter or review on original research articles, frequently complete and publish one or two at other institutions. Fellows typically interact closely with members of other specialties according to their training needs.

**Fellowship in Ocular Inflammatory Disease Center**

The Ocular Inflammatory Disease Center offers a subject of interest, and present their research results at national academic meetings. Support is provided for fellows to participate in the activities of related subspecialty organizations, such as the annual meetings of the American Uveitis Society.

**Fellowship in Vitreoretinal Diseases and Surgery**

Under the co-directorship of Drs. Allan E. Kreiger and Steven D. Schwartz, the Vitreoretinal Diseases and Surgery Fellowship in the Department of Ophthalmology at the Stein Eye Institute is a two-year program designed to provide medical and surgical training and clinical and vision science research opportunities related to vitreoretinal disease. Major components of the fellowship relate to diabetic retinopathy, diseases of the macula and retina, hereditary retinal degenerations, ocular trauma, ophthalmic oncology, rhegmatogenous retinal disease, vitreoretinal surgery, pediatric retinal disease, and diagnostic imaging. Clinical training includes the prevention, diagnosis, and treatment of retinal, choroidal, vitreous, and related ocular diseases. Fellows participate in retinal clinics and surgical procedures at the Stein Eye Institute and affiliated institutions and case presentations at teaching sessions. The program also includes the participation of several international fellows.

**Fellowship in Vision Science**

Predoctoral and postdoctoral fellowships in vision science are offered to individuals who have an interest in specific research areas being pursued by Institute faculty in highly specialized laboratory environments. These fellowships are supported either by individual funds available to Institute professors or as part of a special program offered under the auspices of a National Eye Institute Vision Science Training Grant directed by Dr. Gabriel H. Travis.

Predoctoral fellows take a defined program of core courses and carry out eye-related research, obtaining doctorates in about six years. Fellows are required to present their research at informal and formal seminars, and are encouraged to participate in national and international meetings and publish scientific papers. They gain a broad background in the vision sciences by interacting with members of adjacent laboratories and collaborating with faculty members other than their own preceptors. Postdoctoral research fellowships are offered for one to three years. Each one is unique with research programs established according to mutual agreement between trainees and mentors. Research areas for postdoctoral fellows include molecular biology, genetics, biophysics, biomechanics, cell biology, eye development, and biochemistry. Upon completion of their fellowships, trainees usually pursue careers in academia or industry.

**International Fellowship and Exchange Program**

To promote and encourage research and education interaction with ophthalmology institutions throughout the world, the Stein Eye Institute offers an International Ophthalmology Fellowship and Exchange Program consisting of one-year to two-year fellowships under the supervision of specific Institute faculty. Candidates for these fellowships are nominated by prestigious institutions outside the United States and often hold academic positions within their own countries. Fellows participate in the clinical and research activities of ophthalmic subspecialties according to their training needs.
Appendices
Volunteer and consulting faculty—many of whom have contributed to the Department’s educational mission for more than 25 years—teach courses, participate in conferences, and bring hands-on practical experience and common-sense guidance that is invaluable to young ophthalmologists in training.

Volunteer Faculty

Clinical Professors of Ophthalmology

J. Bronwyn Bateman, MD
Henry I. Baylis, MD
Founding Chief of the Orbital and Ophthalmic Plastic Surgery Division
Bruce B. Becker, MD
Michael S. Berlin, MD
Norma Byer, MD (Senior Status)
William P. Chen, MD
Paul Deiter, MD (Senior Status)
Donald Dickerson, MD (Senior Status)
Donald S. Fong, MD, MPH
Leland M. Garrison, MD
Thomas A. Hanscom, MD
John D. Hofbauer, MD
Kenneth J. Hoffer, MD
C. Richard Hulquist, MD
Barry M. Kerman, MD
Roger A. Kohn, MD
Howard R. Krauss, MD
Benjamin C. Kwan, MD
Jeremy Levenson, MD (Senior Status)
Ezra Maguen, MD
Robert K. Maloney, MD
Samuel Masket, MD
Albert T. Milauskas, MD
Anthony B. Nesburn, MD
Leon G. Partamian, MD
George Primbs, MD (Senior Status)
Yaron S. Rabinowitz, MD
Teresa O. Rosales, MD
Robert J. Schechter, MD (Senior Status)
Stephen Seiff, MD (Senior Status)
Alan L. Shabo, MD
Norman Shorr, MD
Roger W. Sorenson, MD (Senior Status)

Associate Clinical Professors of Ophthalmology

Gerrald Barron, MD (Senior Status)
Arnold Barton, MD (Senior Status)
Kevin J. Belville, MD
Louis Bernstein, MD (Senior Status)
W. Benton Boone, MD
Harvey Brown, MD
Andrew E. Choy, MD
Melissa W. Chun, OD
Peter J. Cornell, MD
Bernard Davidord, MD (Senior Status)
Uday Devgan, MD
Chief of Ophthalmology
Olive View-UCLA Medical Center
Paul B. Donzis, MD
David R. Fett, MD (Senior Status)
Donald I. Goldstein, MD
Michael J. Groth, MD
Andrew Henrick, MD
Edwin P. Hill, MD
David F. Kamin, MD
Stanley Kopelow, MD (Senior Status)
Joseph Lambert, MD (Senior Status)
Brian L. Lee, MD
Steven Leibowitz, MD
Jonathan I. Macy, MD
Gene Matzkin, MD (Senior Status)
Joan E. McFarland, MD
James McKinzie, MD (Senior Status)
Alan Norton, MD (Senior Status)
John F. Paschal, MD (Senior Status)
Sidney Penn, MD (Senior Status)
Firas Rahhal, MD
George M. Rajacich, MD
Michael Reynard, MD
David S. Robbin, MD
David E. Savar, MD
Timothy V. Scott, MD
Albert Sheffer, MD
James D. Shuler, MD
Yossi Sidkario, MD, PhD
Matthew Sloan, MD
Ronald J. Smith, MD
Alfred Solish, MD, MS
Kenneth D. Steinsapir, MD
Sadiqa Stelzner, MD
William C. Stivelman, MD
Hector L. Sulit, MD
Kamal A. Zakka, MD

Assistant Clinical Professors of Ophthalmology

David H. Aizuss, MD
Malvin B. Anders, MD
Richard K. Apt, MD
Reginald G. Ariyasu, MD, PhD
Arthur A.Astorino, MD
Mark A. Baskin, MD
Arthur Benjamin, MD
Katherine L. Bergwerk, MD
Betsy E. Bleichman, MD
Cynthia A. Boxrud, MD
Amarpreet S. Brar, MD
Almirah W. Cann, MD, PhD
Annette Carraby, MD
Vicki K. Chan, MD
Andrew M. Chang, MD
Candice Chen, MD
Thomas B-H. Choi, MD
Milton W. Chu, MD
Robert A. Clark, MD
Charles A. Cooper, MD
Yadavinder P. Dang, MD
Jonathan M. Davidorf, MD
John L. Davidson, MD
Sanford S. Davidson, MD
Louise Cooley Davis, MD
Farid Eghbali, OD
Troy R. Elander, MD
Naomi L. Ellenhorn, MD
Calvin T. Eng, MD
Robert E. Engstrom, MD
Doreen T. Fazio, MD
Sanford G. Feldman, MD
Laura E. Fox, MD
Ronald P. Gallemore, MD
George H. Garcia, MD
Kathryn M. Gardner, MD
Leslie C. Garland, MD (Senior Status)
W. James Gealy, Jr., MD
Damien Goldberg, MD
Lawrence "Tim" Goodwin, MD
Lawrence H. Green, MD (Senior Status)
Richard Havunjian, MD
Man M. Singh Hayreh, MD
Matthew L. Hecht, MD
Jonathan A. Hoening, MD
Jeffrey Hong, MD
Catherine J. Hwang, MD, MPH
Morton P. Israel, MD
Steven J. Jacobson, MD
Batool Jafri, MD
Véronique H. Jotterand, MD
J. David Karlin, MD
David S. Katzir, MD

UCLA Department of Ophthalmology
Volunteer and Consulting Faculty
Assistant Clinical Professors of Ophthalmology continued

James F. Kleckner, MD (Senior Status)
Jerome R. Klein, MD
Craig H. Kliger, MD
Howard E. Lazerson, MD (Senior Status)
Robert T. Lin, MD
Joanne C. Low, MD
Bryant J. Lum, MD
Michael C. Lynch, MD
M. Polly McKinstry, MD
Kenneth J. Miller, MD (Senior Status)
David R. Milstein, MD
Ronald L. Morton, MD
Roger L. Novack, MD, PhD
Alpa A.S. Patel, MD
James H. Peace, MD
Gilbert Perlman, MD (Senior Status)
Cheryl J. Powell, MD
John R. Privett, MD (Senior Status)
Laurence N. Roer, MD
Aaron Savar, MD
Gerald Sanders, MD (Senior Status)
Barry S. Seibel, MD
Meryl Shapiro-Tuchin, MD
David M. Shultz, MD
Eliot B. Siegel, MD
Lance M. Siegel, MD
John D. Sianey, MD
Robert J. Smyth, MD
Kenneth O. Sparks, MD
Mehryar “Ray” Taban, MD, FACS
Robert C. Tarter, MD
Debra G. Tennen, MD
Teddy Y. Tong, MD
Sterling M. Trenberth, MD (Senior Status)
Robert C. Tudor, MD (Senior Status)
Henry E. Ullman, MD
Tay J. Weinman, MD (Senior Status)
Irwin S. Weiss, MD (Senior Status)
Sidney J. Weiss, MD
Scott Whitcup, MD
David L. Williams, MD (Senior Status)
Jeffrey V. Winston, MD
David M. Winters, MD (Senior Status)
David L. Wirta, MD
Barry J. Wolstan, MD
Wilson C. Wu, MD, PhD
Michael C. Yang, MD
Patrick C. Yeh, MD
Richard H. Yook, MD (Senior Status)
Peter D. Zeegen, MD (Senior Status)

Clinical Instructors in Ophthalmology

Gavin G. Bahadur, MD
Eduardo Besser, MD
Maria Braun, MD
Neil D. Brouman, MD
Stephen S. Bylsma, MD
Andrew Caster, MD
Joseph H. Chang, MD
Hajir Dadgostar, MD
Paul J. Daghothy, MD
Sean Darnars, MD
Daniel Ebroon, MD
Brad S. Elkins, MD
Satvinder Gujral, MD
Lawrence M. Hopp, MD, MS
Aarchan Joshi, MD
Anisha J. Judge, MD
Jason Jun, MD
Rajesh Khanna, MD
Julie A. King, MD
Mark H. Kramar, MD
Daniel Krivoy, MD
Laurie C. McCall, MD
David Paikal, MD
Jayantkumar Patel, MD
Susan S. Rauchman, MD
Richard H. Roe, MD
Aaron Savar, MD
Kayar Shah, MD
Mark Silverberg, MD
Abraham Soroudi, MD
Sharon N. Spooner-Dailey, MD
Homayoun Tabandeh, MD
Dana F. Tannenbaum, MD
William L. Trotter, MD
Rosalind Vo, MD
Mark Volpicelli, MD
Mathew Wang, MD
Peter H. Win, MD
Andrew Young, MD

Consulting Members of the Stein Eye Institute

Robert W. Baloh, MD
Professor of Neurology and Surgery (Head and Neck)
Ferdinand V. Coroniti, PhD
Professor, Department of Physics and Astronomy
David Eisenberg, DPhil
Investigator, Howard Hughes Medical Institute Director, UCLA-DOE Institute for Genomics and Proteomics Professor, Departments of Chemistry and Biochemistry, and Biological Chemistry Molecular Biology Institute
Alan M. Fogelman, MD
Castera Professor and Executive Chair Department of Medicine
Alan D. Grinnell, PhD
Professor of Physiology and Physiological Science Director, Jerry Lewis Neuromuscular Research Center Director, Ahmanson Laboratory of Neurobiology
Sherman M. Mellinkoff, MD
Professor Emeritus of Medicine Former Dean, UCLA School of Medicine
C. Kumar Patel, PhD
Professor, Department of Physics and Astronomy
Leonard H. Rome, PhD
Senior Associate Dean for Research Professor of Biological Chemistry
Peter C. Whybrow, MD
Judson Braun Professor and Executive Chair Department of Psychiatry and Biobehavioral Sciences Director and Physician in Chief Neuropsychiatric Institute
Residents and Fellows

Residents

Third-Year Residents 2013–2016
Jenny Chen, MD
Xuejing Chen, MD
Diana Katsman, MD, PhD (EyeSTAR)
Wonchon Liu, MD
Grant Moore, MD
Mitra Nejad, MD
Christian Sanfilippo, MD
Mauricio E. Vargas, MD, PhD (EyeSTAR)

Second-Year Residents 2014–2017
Joseph Christenbury, MD
Melinda Fry, MD
Janet Lee, MD
Theodor Sauer, MD
Daniel Su, MD
Andrew Tye, MD
Rany Woo, MD
Chengjie Zheng, MD

First-Year Residents 2015–2018
Todd H. Driver, MD
Juliet O. Essilfie, MD
Sean F. Garrity, MD
Wei “Wayne” Gui, MD
Shawn Lin, MD
Erika T. Tanaka Friesen, MD
Ye Elaine Wang, MD
David Xu, MD

EyeSTAR Trainees
Diana Katsman, MD, PhD
Tamara L. Lenis, MD
Anh H. Pham, MD, PhD
David Stark, MD, PhD
Victoria Tseng, MD
Mauricio E. Vargas, MD, PhD
Qing Wang, MD, PhD

Clinical Fellows

Corneal and External Ocular Diseases and Refractive Surgery
Andrew Salem, MD
Anushree Sharma, MD
Laura Vickers, MD
(Doheny Eye Center UCLA)

Glaucoma
Salwa Abdel-Aziz, MD
Daniel Choi, MD
Lilit Minasyan, MD
(Doheny Eye Center UCLA)

Medical Retina and Ophthalmic Genetics
Negin Agange, MD
Sohrab Tofigh, MD

Orbital and Ophthalmic Plastic Surgery
Hans Dieter Hertzog, MD
(Doheny Eye Center UCLA)
Erin Lesinner, MD
Wenjing Liu, MD

Pediatric Ophthalmology and Strabismus
Melinda Chang, MD
Tina Damarjian, MD

Uveitis and Inflammatory Eye Disease
Meghan Berkenstock, MD

Vitreoretinal Diseases and Surgery
Michael Klufas, MD
Robert Lalane, MD
Aaron Nagiel, MD, PhD
Elizabeth Richter, MD

International Fellows

Cornea Research
Maria Carolina Aravena Perez, MD
Chile
Pichaya Chuephanich, MD
Thailand
Chantaka Supiyaphun, MD
Thailand
Tahir Kansu Bozkurt, MD
Turkey

Comprehensive Ophthalmology/Cataract
None

Glaucoma
Reza Alizadeh, MD
Iran
Pradtna Hirunpatravong, MD
Thailand
Pablo Romero, MD
Chile

Medical Retina and Ophthalmic Genetics
Handan Akił, MD
(Doheny Eye Center UCLA)
Turkey
Mayss Al-Sheikh, MD
(Doheny Eye Center UCLA)
Germany
Khail Ghasemi Falavrajani, MD
(Doheny Eye Center UCLA)
Iran
Nopasak Phasukkijiwatana, MD
Thailand
Mansour Rahimi, MD
Iran

Neuro-Ophthalmology
Supanut Apinyawasisu, MD
Thailand

Orbital and Ophthalmic Plastic Surgery
Tomoyuki Kashima, MD, PhD
Japan

Pediatric Ophthalmology
Rui Hao, MD
China
Hiba Khraisat, MD
Jordan
Ghada Rajab, MD
Egypt
Fatma Yulek, MD
Turkey
Rui Zhang, MD
China

Pathology (Eye)
None

Uveitis
None

Visual Physiology
None

Vitreoretinal Diseases and Surgery
Nizar Abdelfattah, MD
(Doheny Eye Center UCLA)
Egypt
Wenying Fan, MD, PhD
(Doheny Eye Center UCLA)
China
Andrea Govetto, MD
Italy
Amirhossein Hariri, MD
Iran
Jianqin Lei, MD, MS
(Doheny Eye Center UCLA)
China
Eva Platner, MD
Israel
Sowmya Srinivas, MD
(Doheny Eye Center UCLA)
India
Hiroto Terasaki, MD
(Doheny Eye Center UCLA)
Japan
Akihito Uji, MD, PhD
(Doheny Eye Center UCLA)
Japan
Kang Wang, PhD
(Doheny Eye Center UCLA)
Japan
Ronglang Zhao, PhD
(Doheny Eye Center UCLA)
China

Histology
None

Neuro-Ophthalmology
Supanut Apinyawasisu, MD
Thailand

Orbital and Ophthalmic Plastic Surgery
Tomoyuki Kashima, MD, PhD
Japan

Pediatric Ophthalmology
Rui Hao, MD
China
Hiba Khraisat, MD
Jordan
Ghada Rajab, MD
Egypt
Fatma Yulek, MD
Turkey
Rui Zhang, MD
China

Pathology (Eye)
None

Uveitis
None

Visual Physiology
None

Vitreoretinal Diseases and Surgery
Nizar Abdelfattah, MD
(Doheny Eye Center UCLA)
Egypt
Wenying Fan, MD, PhD
(Doheny Eye Center UCLA)
China
Andrea Govetto, MD
Italy
Amirhossein Hariri, MD
Iran
Jianqin Lei, MD, MS
(Doheny Eye Center UCLA)
China
Eva Platner, MD
Israel
Sowmya Srinivas, MD
(Doheny Eye Center UCLA)
India
Hiroto Terasaki, MD
(Doheny Eye Center UCLA)
Japan
Akihito Uji, MD, PhD
(Doheny Eye Center UCLA)
Japan
Kang Wang, PhD
(Doheny Eye Center UCLA)
Japan
Ronglang Zhao, PhD
(Doheny Eye Center UCLA)
China

Histology
None

Neuro-Ophthalmology
Supanut Apinyawasisu, MD
Thailand

Orbital and Ophthalmic Plastic Surgery
Tomoyuki Kashima, MD, PhD
Japan

Pediatric Ophthalmology
Rui Hao, MD
China
Hiba Khraisat, MD
Jordan
Ghada Rajab, MD
Egypt
Fatma Yulek, MD
Turkey
Rui Zhang, MD
China

Pathology (Eye)
None

Uveitis
None

Visual Physiology
None

Vitreoretinal Diseases and Surgery
Nizar Abdelfattah, MD
(Doheny Eye Center UCLA)
Egypt
Wenying Fan, MD, PhD
(Doheny Eye Center UCLA)
China
Andrea Govetto, MD
Italy
Amirhossein Hariri, MD
Iran
Jianqin Lei, MD, MS
(Doheny Eye Center UCLA)
China
Eva Platner, MD
Israel
Sowmya Srinivas, MD
(Doheny Eye Center UCLA)
India
Hiroto Terasaki, MD
(Doheny Eye Center UCLA)
Japan
Akihito Uji, MD, PhD
(Doheny Eye Center UCLA)
Japan
Kang Wang, PhD
(Doheny Eye Center UCLA)
Japan
Ronglang Zhao, PhD
(Doheny Eye Center UCLA)
China

Histology
None

Neuro-Ophthalmology
Supanut Apinyawasisu, MD
Thailand

Orbital and Ophthalmic Plastic Surgery
Tomoyuki Kashima, MD, PhD
Japan

Pediatric Ophthalmology
Rui Hao, MD
China
Hiba Khraisat, MD
Jordan
Ghada Rajab, MD
Egypt
Fatma Yulek, MD
Turkey
Rui Zhang, MD
China

Pathology (Eye)
None

Uveitis
None

Visual Physiology
None

Vitreoretinal Diseases and Surgery
Nizar Abdelfattah, MD
(Doheny Eye Center UCLA)
Egypt
Wenying Fan, MD, PhD
(Doheny Eye Center UCLA)
China
Andrea Govetto, MD
Italy
Amirhossein Hariri, MD
Iran
Jianqin Lei, MD, MS
(Doheny Eye Center UCLA)
China
Eva Platner, MD
Israel
Sowmya Srinivas, MD
(Doheny Eye Center UCLA)
India
Hiroto Terasaki, MD
(Doheny Eye Center UCLA)
Japan
Akihito Uji, MD, PhD
(Doheny Eye Center UCLA)
Japan
Kang Wang, PhD
(Doheny Eye Center UCLA)
Japan
Ronglang Zhao, PhD
(Doheny Eye Center UCLA)
China

Histology
None

Neuro-Ophthalmology
Supanut Apinyawasisu, MD
Thailand

Orbital and Ophthalmic Plastic Surgery
Tomoyuki Kashima, MD, PhD
Japan

Pediatric Ophthalmology
Rui Hao, MD
China
Hiba Khraisat, MD
Jordan
Ghada Rajab, MD
Egypt
Fatma Yulek, MD
Turkey
Rui Zhang, MD
China

Pathology (Eye)
None

Uveitis
None

Visual Physiology
None

Vitreoretinal Diseases and Surgery
Nizar Abdelfattah, MD
(Doheny Eye Center UCLA)
Egypt
Wenying Fan, MD, PhD
(Doheny Eye Center UCLA)
China
Andrea Govetto, MD
Italy
Amirhossein Hariri, MD
Iran
Jianqin Lei, MD, MS
(Doheny Eye Center UCLA)
China
Eva Platner, MD
Israel
Sowmya Srinivas, MD
(Doheny Eye Center UCLA)
India
Hiroto Terasaki, MD
(Doheny Eye Center UCLA)
Japan
Akihito Uji, MD, PhD
(Doheny Eye Center UCLA)
Japan
Kang Wang, PhD
(Doheny Eye Center UCLA)
Japan
Ronglang Zhao, PhD
(Doheny Eye Center UCLA)
China

Histology
None
**Predoctoral Research Fellows**

Kevin Eden  
Katherine Fehlhaber  
Roni Hazim  
Norianne Ingram  
Yifeng Ke  
Margaux Kreitman  
Alan Le  
Joseph Park  
Asael Papour  
Yingqian Peng  
Gabriel Pollock  
Helen Voung  
Tongzhou Xu

**Postdoctoral Research Fellows**

Negin Ashki Ghouravan, MD, PhD  
Edouard Baulier, PhD  
Abhishek Chadha, PhD  
Doug Chung, PhD  
Sarah Dale, PhD  
Matthias Elgeti, PhD  
Sheyla Gonzalez-Garrido, PhD  
Lei Gu, PhD  
Michael Lerch, PhD  
Hua Mei, PhD  
Yu “Christie” Qin, PhD  
Charles Avery Sader, PhD  
Kwang Sup “Andrew” Shin, PhD  
Kaushali Thakore-Shah, PhD  
Ankita Umapathy, PhD  
Stefanie Volland, PhD  
Yanjie Wang, PhD  
Chi Zhang, PhD
To inform participants of the latest advances in the field, the UCLA Department of Ophthalmology is committed to the education and training of residents, fellows, and basic scientists, as well as the ongoing training of practicing ophthalmologists. The 2015–2016 academic year presented a wealth of Institute educational events.

Ophthalmology and Vision Science Training Programs

Ophthalmology Basic and Clinical Science Course
Course Chairman: Bartly J. Mondino, MD

This course is a major segment of the educational program for ophthalmology residents, as well as a review course for ophthalmologists. Sections are presented each year in a rotation designed to provide complete review of all sections in a two-year period. First-year residents participate in a more intensive curriculum in order to obtain a comprehensive foundation of ophthalmologic knowledge. In 2015–2016, the following course components were offered:

- **Fundamentals and Principles of Ophthalmology**
  Daniel B. Rootman, MD, MS
  August 26, 2015–September 16, 2016

- **Pathology**
  Ben J. Glasgow, MD
  September 23, 2015–October 14, 2015

- **Orbit, Eyelids, and Lacrimal System**
  Robert Alan Goldberg, MD
  October 21, 2015–December 30, 2015

- **External Disease and Cornea**
  Anthony J. Aldave, MD
  January 6, 2016–February 17, 2016

- **Refractive Surgery**
  David Rex Hamilton, MD, FACS
  February 24, 2016–March 9, 2016

**Lens and Cataract**
Kevin M. Miller, MD
March 16, 2016–April 13, 2016

**Glaucoma**
Joseph Caprioli, MD
April 20, 2016–June 1, 2016

**Southern California Basic Cataract Surgery Course; Southern California Advanced Cataract Surgery Course**
October 24, 2015; April 23, 2016

**Course Director:**
Kevin M. Miller, MD

The basic and advanced cataract surgery courses are key components of the residency-training program, as well as a resource for practicing ophthalmologists. Both classroom and laboratory instruction are offered, covering in detail the procedural and anatomical components of modern cataract surgery.

**21st Annual Vision Science Conference**
October 9–11, 2015

At this annual event, sponsored jointly by the Stein Eye Institute and the National Eye Institute Vision Science Training Grant, pre- and postdoctoral fellows and faculty discussed a wide range of topics in vision science research.

**Ophthalmology Clinical Conferences**
Coordinators: Anthony C. Arnold, MD Gary N. Holland, MD

The Clinical Conferences are offered in conjunction with the regular weekly Ophthalmology Basic and Clinical Science Course. These conferences review patient care activities of the UCLA Department of Ophthalmology, present general topics in ophthalmic science, and promote discussion of relevant aspects of ophthalmic pathology and pharmacy.

**Study Groups**

Focusing on specific topics in clinical ophthalmology, study groups meet regularly under the leadership of faculty members who are acknowledged specialists in their respective fields. The study groups are an integral part of the residency and clinical fellowship training programs and serve as an informal resource for practicing ophthalmologists in the community.

**Cornea Conference**
This conference meets bimonthly and includes full-time and volunteer clinical faculty and visitors from the community who discuss cornea cases presented by fellows and residents. The conferences are coordinated by Anthony J. Aldave, MD.

**Glaucoma Conference**
This weekly conference is designed to teach residents and fellows a basic understanding of the pathophysiology and clinical care of glaucoma. Faculty, fellows, and residents all participate in case and subject presentations and discussions. The conferences are coordinated by Joseph Caprioli, MD.

**Neuro-Ophthalmology Conference**

This conference meets bimonthly and includes full-time and volunteer clinical faculty and visitors from the community who discuss neuro-ophthalmology cases presented by fellows and residents. The coordinator for the year was Anthony C. Arnold, MD.

**Oculoplastics Conference**

This conference meets bimonthly and includes full-time and volunteer clinical faculty and visitors from the community who discuss oculoplastics and orbital cases presented by fellows and residents. The coordinator for the year was Robert Alan Goldberg, MD.

**Ophthalmic Pathology Conference**

Faculty and residents meet daily to review pathological findings from current ophthalmology cases. The coordinator for the year was Ben J. Glasgow, MD.
Pediatric Ophthalmology and Strabismus Conference
At monthly meetings rotating among Harbor-UCLA Medical Center, Olive View-UCLA Medical Center, and the Stein Eye Institute, difficult pediatric ophthalmology and strabismus cases are presented and discussed. These conferences were coordinated for the year by Sherwin J. Isenberg, MD, at Harbor-UCLA Medical Center, Federico Velez, MD, at Olive View-UCLA Medical Center, and Joseph L. Demer, MD, PhD, at the Stein Eye Institute.

Pediatric Rheumatology and Uveitis Conference
Members of the Uveitis Service meet each week with members of the Rheumatology Service from the Department of Pediatrics to discuss patient-care issues and research topics of mutual interest. The conference is attended by faculty, clinical fellows from the Departments of Ophthalmology and Pediatrics, and research staff. The conference is coordinated by Gary N. Holland, MD.

Retinal Imaging Conference
Arranged by the clinical fellows in vitreoretinal studies, this conference convenes periodically to review current angiograms representing disease entities, unusual abnormalities, and controversial interpretations of angiographic findings. Steven D. Schwartz, MD, and other members of the Retina Division supervise the conference.

Vision Science Seminar Series
Coordinators:
Sophie X. Deng, MD, PhD
David S. Williams, PhD

This seminar series, conducted throughout the academic year, allows faculty within the Stein Eye Institute to present their research to other members of the Institute, thereby fostering the exchange of knowledge and cooperation. The series frequently includes presentations by eminent visitors to the UCLA campus.

Continuing Education Programs

Aesthetic Eyelid and Facial Rejuvenation Course
July 31–August 1, 2014

Coordinators:
Henry I. Baylis, MD
Robert Alan Goldberg, MD
Jonathan A. Hoenig, MD
Catherine J. Hwang, MD
Norman Shorr, MD

The Orbital and Oculoplastic Surgery Division held its annual Aesthetic Eyelid and Facial Rejuvenation course at the Stein Eye Institute. The event attracted ophthalmologists, dermatologists, and cosmetic surgeons from around the world. The two-day event combined surgical demonstrations, a cadaver dissection, and didactic lectures that informed participants of the latest advances in the field of aesthetic and reconstructive surgery for the eyelids and face.

Comprehensive Ophthalmology Review Course
February 18–21, 2016

Course Directors:
Sherwin J. Isenberg, MD
John A. Irvine, MD

The Stein Eye Institute and the Doheny Eye Institute sponsored the 11th annual Comprehensive Ophthalmology Review Course. Developed to serve ophthalmology-training programs in Southern California, the program concentrated on the epidemiology, clinical presentation, diagnosis, and management of ophthalmological disease.

Stein Eye Institute Clinical and Research Seminar
June 10, 2016

Coordinators:
Anthony C. Arnold, MD
Robert Alan Goldberg, MD
Bartly J. Mondino, MD
Xian-Jie Yang, PhD

Geared to physicians and basic scientists, this seminar is an intensive course in which UCLA and guest faculty present current concepts and recent advances in ophthalmology. The Jules Stein Lecture, the Bradley R. Straatsma Lecture, and the Thomas H. Pettit Lecture, which commemorate each doctor’s contributions to ophthalmic science at UCLA and throughout the United States, are held in conjunction with this seminar and are among the academic highlights of the year.

47th Jules Stein Lecturer
SriniVas R. Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute
Stephen J. Ryan–Arnold and Mabel Beckman Endowed Chair
Professor of Ophthalmology
David Geffen School of Medicine at UCLA
Los Angeles, CA

14th Bradley R. Straatsma Lecturer
Alfredo A. Sadun, MD, PhD
Flora Thornton Chair of Vision Research
Vice-Chairman
Doheny Eye Center UCLA
Professor of Ophthalmology
David Geffen School of Medicine at UCLA
Los Angeles, CA

14th Thomas H. Pettit Lecturer
John A. Irvine, MD
Medical Director
Doheny Eye Center UCLA
Health Sciences Clinical Professor of Ophthalmology
David Geffen School of Medicine at UCLA
Los Angeles, CA
## Active Funding
### July 1, 2015–June 30, 2016

### Vision Science Grants

<table>
<thead>
<tr>
<th>Name</th>
<th>Project Description</th>
<th>Institute</th>
<th>Duration</th>
<th>Total Award</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthony J. Aldave, MD</strong></td>
<td>Identification and Characterization of the Genetic Basis of PPCD</td>
<td>National Eye Institute</td>
<td>12/1/12–11/30/17</td>
<td>$250,000</td>
</tr>
<tr>
<td></td>
<td>Genetic Factors in Keratoconus</td>
<td>National Eye Institute</td>
<td>12/1/14–2/28/17</td>
<td>$5,400</td>
</tr>
<tr>
<td><strong>Suraj P. Bhat, PhD</strong></td>
<td>Childhood Cataractogenesis: Heterogeneity of Gene Expression</td>
<td>National Eye Institute</td>
<td>1/1/15–12/31/18</td>
<td>$250,000</td>
</tr>
<tr>
<td><strong>Dean Bok, PhD</strong></td>
<td>Identification and Cellular Localization of Gene Products that Affect Photoreceptor Survival in Inherited Retinal Degeneration</td>
<td>Macula Vision Research Foundation</td>
<td>4/1/08–3/31/16</td>
<td>$50,000</td>
</tr>
<tr>
<td></td>
<td>Analysis of ARMS2 and HTRA 1 Gene Expression in Retinal Pigment Epithelium</td>
<td>Helen Keller Foundation for Research and Education Inc.</td>
<td>6/1/16–5/31/17</td>
<td>$37,500</td>
</tr>
<tr>
<td><strong>Anne L. Coleman, MD, PhD</strong></td>
<td>UCLA Mobile Eye Clinic Child Vision Program</td>
<td>LA County Children and Families First (First 5 LA)</td>
<td>7/1/13–9/30/17</td>
<td>$942,920</td>
</tr>
<tr>
<td></td>
<td>Ocular Hypertension Treatment Study 20-Year Follow-Up:</td>
<td>National Eye Institute</td>
<td>7/1/15–6/30/16</td>
<td>$39,525</td>
</tr>
<tr>
<td><strong>Joseph L. Demer, MD, PhD</strong></td>
<td>Training Mentors in Developing Countries</td>
<td>Pediatric Ophthalmology Fellowship (Ghada Sein El-Abedin Rajab, MD, Fellow)</td>
<td>9/1/15–8/31/16</td>
<td>$60,000</td>
</tr>
<tr>
<td></td>
<td>Biomechanical Analysis in Strabismus Surgery</td>
<td>National Eye Institute</td>
<td>5/1/16–4/30/20</td>
<td>$380,104</td>
</tr>
<tr>
<td><strong>Sophie X. Deng, MD, PhD</strong></td>
<td>Ex VIVO Expansion of Human Limbal Stem Cells for Transplantation</td>
<td>National Eye Institute</td>
<td>9/1/12–8/31/17</td>
<td>$245,000</td>
</tr>
</tbody>
</table>
Debora B. Farber, PhD, DPhhc
Edouard Baulier, PhD
Patient-derived iPSCs, CRISPR/Cas and RPE-derived Exosomes for the Treatment of Ocular Albinism
Vision of Children
Duration: 6/1/16–5/31/19 $151,427

Lynn K. Gordon, MD, PhD
Pd-Ligand, a Paradoxical Role in Experimental Uveitis
Pathogenesis and Therapy
National Eye Institute
Duration: 4/1/15–3/31/17 $125,000

Michael B. Gorin, MD, PhD
Natural History of the Progression of Choroideremia Study (Night)
Nightstarx
Duration: 6/18/15–5/31/17 $65,428

Gary N. Holland, MD
Multicenter Uveitis Steroid Treatment (MUST) Trial
National Eye Institute
Sub-award from Johns Hopkins University
Duration: 6/1/12–4/30/17 $8,354
Macular Edema Treatment Trials Associated with MUST (META-MUST)
National Eye Institute
Sub-award from Johns Hopkins University
Duration: 9/30/14–1/31/17 $10,545

Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (SITE)
University of Pittsburgh
Duration: 3/2/16–3/2/21 Non-monetary Contract

Systemic Immunosuppressive Therapy for Eye Disease
(Cancer Surveillance and Research Branch/CCR)
University of Pittsburgh
Duration: 3/2/16–3/2/21 Non-monetary Contract

Joseph Horwitz, PhD
Analysis of Lens Crystallins and Cataractous Mutants at High Hydrostatic Pressure
National Eye Institute
Duration: 4/1/14–3/31/19 $150,000

Alex A. Huang, MD, PhD
Discovery and Characterization of Anterior Sclera Pathology in Glaucoma
National Eye Institute
Duration: 9/30/14–9/29/19 $203,981
Research to Prevent Blindness Career Development Award
Research to Prevent Blindness, Inc.
Duration: 1/1/16–12/31/19 $75,000

Validation of a Cephalad Fluid Shift Countermeasure
National Space Biomedical Research Institute
Sub-award from Baylor College of Medicine
Duration: 6/1/15–5/31/17 $15,225

Wayne L. Hubbell, PhD
Molecular Basis of Membrane Excitation
National Eye Institute
Duration: 5/1/15–4/30/20 $323,795
Jean-Pierre Hubschman, MD
Intraocular Robotic Interventional Surgical System for Cataract Surgery Project
National Eye Institute
Duration: 9/30/14–9/29/16 $240,051

Michael Ip, MD
Studies of Comparative Treatments in Retinal Vein Occlusion 2 (SCORE 2)
National Eye Institute
Sub-award from Penn State University College of Medicine
Duration: 6/16/16–3/31/19 $39,540

Bartly J. Mondino, MD
RPB Unrestricted Grant
Research to Prevent Blindness, Inc.
Duration: 1/1/12–12/31/16 $115,000

Kouros Nouri-Mahdavi, MD
Detection of Glaucoma Progression with Macular OCT Imaging
National Eye Institute
Duration: 7/1/12–6/30/17 $212,166

Steven Nusinowitz, PhD
Michael B. Gorin, MD, PhD (Co-Principal Investigator)
Scotopic Critical Flicker Fusion in Preclinical AMD
BrightFocus Foundation
Duration: 7/1/15–6/30/17 $80,000

Stacy L. Pineles, MD
Binocular Summation in Strabismus
NIH/National Eye Institute
Duration: 9/1/11–2/28/17 $200,237

Integrating Perceptual Learning Approaches into Effective Therapies for Low Vision
National Eye Institute
Sub-award from University of California Riverside
Duration: 9/1/13–7/31/16 $27,333

Pediatric Eye Disease Investigator Group (PEDIG)
JAEB Center for Health Research
Duration: 2/28/11–12/31/18 $10,998

Daniel B. Rootman, MD, MS
Hyaluronic Acid Gels for Upper Lid Retraction in Thyroid Eye Disease
Galderma Laboratories L.P.
Duration: 6/8/16–10/8/17 $5,500

Alappakam P. Sampath, PhD
Functional Characteristics of Rod Pathways in the Retina
National Eye Institute
Duration: 2/1/14–7/31/17 $245,000

Experimental and Clinical Investigations of Retinal Stimulation
National Eye Institute
Sub-award from University of Southern California
Duration: 10/1/13–2/28/17 $95,488
Gabriel H. Travis, MD
The Role of Müller Cells in Visual Pigment Regeneration
National Eye Institute
Duration: 7/1/13–6/30/18 $319,853

Vision Science Training Grant to Researchers at the Stein Eye Institute
National Eye Institute
Duration: 9/30/11–9/29/16 $230,089

Instrumentation Grant for Stein Eye Investigators
Bruce Ford and Anne Smith Bundy Foundation
Duration: 8/16/11–8/15/16 $100,829

Functional Characterization of RGR-OPSIN in Retinal Müller Cells
National Eye Institute
Distribution: 9/1/15–8/31/18 $250,000

Frederico G. Velez, MD
An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Population Diagnosed with Early Onset Idiopathic Bilateral Cataract
Retrophin, Inc.
Duration: 1/6/16–1/5/18 $10,750

David S. Williams, PhD
The Photoreceptor Cilium
National Eye Institute
Duration: 5/1/13–4/30/18 $245,000

Photoreceptor Disk Membrane Morphogenesis
National Eye Institute
Sub-award from University of California, Santa Barbara
Duration: 4/1/15–3/31/17 $125,000

Stein Eye Institute Core Grant for Vision Research
National Eye Institute
Duration: 9/1/15–6/30/20 $383,453

Xian-Jie Yang, PhD
Neuroprotection Mechanism for Photoreceptors
National Eye Institute
Duration: 5/1/16–4/30/21 $250,000

Professional Research Series

Roxana Radu, PhD
The Role of Complement in Recessive Stargardt Disease
National Eye Institute
Distribution: 8/1/15–7/31/20 $250,000

Gene Therapy to Prevent Visual Loss in Macular Degenerations by Increasing Expression of Complement Negative-Regulatory Proteins in the RPE
Macula Vision Research Foundation
Duration: 10/1/13–9/30/16 $100,000

Alejandra Young, PhD
Stem Cell Derived, OA1-Enriched, Microvesicles: Do They Rescue Ocular Albinism?
The Vision of Children
Duration: 11/1/13–10/31/16 $185,361
Residents and Fellows

Sheyla Gonzalez Garrido, PhD (Vision-Science Fellow)
Comparative Study on Different Xenobiotic-Free Culture Media for Human Limbal Epithelial Stem Cells
Eye Bank Association of America
Duration: 7/1/16–6/30/17 $4,719

David Stark, MD (EyeSTAR Resident)
Endocannabinoids in Retinal Ganglion Cell Regeneration
Foundation for Glaucoma Research
Duration: 3/1/16–2/28/17 $40,000

Kaushali Thakore-Shah, PhD (Vision-Science Fellow)
Testing Matrices for Corneal Endothelial Cell Culture
Eye Bank Association of America
Duration: 7/1/15–6/30/16 $4,760

Clinical Trials

Joseph Caprioli, MD
A Randomized Study Comparing the Safety and Efficacy of the Innfocus Microshunt® Glaucoma Drainage System to Standard Trabeculectomy in Subjects with Primary Open Angle Glaucoma
Protocol INN-005
Infocus Inc.
Duration: 2/4/16–2/4/18 $435,556

Sophie X. Deng, MD, PhD
An 8-week Phase II, Multicenter, Randomized, Double-Masked,
Vehicle Controlled Parallel Group Study with a 24 or 32 Week Follow-Up Period to Evaluate the Efficacy of a Formulation Containing Antioxidant of Recombinant Human Nerve Growth Factor
Dompe Pharmaceutical
Duration: 3/17/15–3/16/17 $29,400

Brian A. Francis, MD, MS
Study for Benchmarking the Management of Ophthalmic Diseases Using the Diopsys Visual Evoked Potential/Pattern ERG/ERG Protocol
Diopsys Inc.
Duration: 2/21/16–1/31/18 $65,840

Michael B. Gorin, MD, PhD
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Protocol ALK-001
Alkeus Pharmaceuticals Inc.
Duration: 5/23/16–5/23/18 $46,070

Colin A. McCannel, MD
A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (GX28228)
Genentech, Inc.
Duration: 9/22/15–1/31/17 $381,650
Alfredo A. Sadun, MD, PhD
A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single, Intravitreal Injection of GS010 (RAAV2/2-ND4) A
Gensight Biologics
Duration: 1/11/16–1/11/18  $44,064

A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single, Intravitreal Injection of GS010 (RAAV2/2-ND4) B
Gensight Biologics
Duration: 1/12/16–1/12/18  $44,063

A Prospective, Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of MTP-131 TOPI
Stealth Biotherapeutics Inc.
Distribution: 2/12/16–2/12/18  $217,681

David Sarraf, MD
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neurovascular Age-Related Macular Degeneration
Sequoia Study
Allergan Pharmaceutical
Duration: 4/14/16–5/31/20  $465,359

Steven D. Schwartz, MD
A Phase III, Multicenter, Randomized Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to ARMD
Genentech, Inc./Hoffman-La Roche Inc.
Duration: 11/18/14–9/27/18  $262,529

A Phase 2, Double-Masked, Randomized, Parallel Group, Sham Surgery Placebo Controlled Multicenter Study to Evaluate Systemic Immunosuppression Regimens as Graft Rejection Prophylaxis Following Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to ARMD (#MA09-hRPE AMD 02)
Ocata Therapeutics
Duration: 10/7/15–10/7/17  $386,873

Frederico G. Velez, MD
A Randomized, Double-Masked, Parallel-Group, Phenylephrine Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction with or Without Lens Replacement
Omeros Inc.
Duration: 8/6/15–8/6/17  $65,300

A Randomized, Multicenter, Double Masked, Parallel-Group Study Assessing the Safety and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5% Versus Prednisolone Acetate Ophthalmic Suspension, 1% for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract
Bausch and Lomb
Duration: 9/17/15–9/17/17  $100,250
Research Contracts and Grants
Active Funding
Administered by Doheny Eye Center UCLA

Vision Science Grants

Alex A. Huang, MD, PhD
Structure and Function of Aqueous Humor Outflow
American Glaucoma Society and Allergan
Young Clinician Scientist Award
Duration: 3/17/15–3/16/16 $20,000

SriniVas R. Sadda, MD
Multimodal Image Analysis in Age-Related Macular Degeneration
Macula Vision Research Foundation
Duration: 1/1/15–12/31/18 $100,000/year

Advanced Image Analysis Tools for Diabetic Retinopathy
Teledicine Applications
Eyenuk, Inc.
Sub-award on NIBI EB013585
Duration: 7/15/14–6/30/17 $48,581

Automated Image-Based Biomarker Computation Tools
for Diabetic Retinopathy
Eyenuk, Inc.
Sub-award on NCATS Grant TR000377
Duration: 9/26/14–6/30/17 $101,147

Advanced Retinal Image Analysis for AMD Screening
Eyenuk, Inc
Sub-award on NEI Grant EY025984
Duration: 8/1/15–7/31/16 $28,662

High Resolution Retinal Imaging by Fourier Ptychography
CalTech
Sub-award on NEI Grant EY026228
Duration: 4/1/16–3/31/18 $25,000

Deming Sun, MD
Regulation by Gamma/Delta T Cells of Autoimmune Uveitis
National Eye Institute
Duration: 5/1/12–4/30/16 $147,000

Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
National Eye Institute
Duration: 9/1/09–7/31/19 $274,912

James C. Tan, MD, PhD
Karl Kirchgessner Foundation Vision Research Grant
The Karl Kirchgessner Foundation
Duration: 10/17/09–Open $50,000

Clinical Trials

SriniVas R. Sadda, MD
Genetic Epidemiology of Age-Related Macular Degeneration
in the Older Order Amish
University of Pennsylvania
Sub-award on NEI Grant EY023164
Duration: 2/1/13–1/31/18 $60,784
Research Contracts and Grants
Totals Reported in Previous Years

Vision Science Grants

Anthony J. Aldave, MD
Effect of Corneal Preservation Time on Long-Term Graft Success (CPTS)
JAEB Center for Health Research
Duration: 3/6/12–8/31/17

Joseph Caprioli, MD
Clinical Research Program in Glaucoma
Simms-Mann Family Foundation
Duration: 7/1/14–6/30/18

Anne L. Coleman, MD, PhD
UCLA Mobile Clinic Project and UCLA Mobile Eye Clinic
Andrea Bocelli Foundation
Duration: 2/6/14–12/31/16

Center for Community Outreach
Jules Stein Eye Institute at UCLA 2014–2015
The Nicholas Endowment
Duration: 1/1/14–12/31/15

Michael B. Gorin, MD, PhD
Genetics-Based Testing of Functional and Structural Endophenotypes
for Pre- and Early-Age-Related Macular Degeneration (AMD)
Arnold and Mabel Beckman Foundation
Duration: 7/1/14–6/30/17

Alex A. Huang, MD, PhD
Real-Time Imaging of Aqueous Humor Outflow
American Glaucoma Society
Duration: 1/1/15–12/31/15

Kouros Nouri-Mahdavi, MD
Intra-Session Variability of Regional Macular Thickness Measurements
American Glaucoma Society
Duration: 3/1/15–3/31/16

Stacy L. Pineles, MD
RPB Walt and Lily Disney Award for Amblyopia Research
Research to Prevent Blindness, Inc.
Duration: 7/1/14–6/30/19

David Williams, PhD
Degradative Processes in RPE-Photoreceptor Renewal
National Eye Institute
Sub-award from University of Pennsylvania
Duration: 2/1/14–1/31/16

Jie Zheng, PhD
Structural Investigation of Focal Adhesion Formation and Disassembly
National Institute of General Medical Sciences
Duration: 4/1/15–3/31/17
**Professional Research Series**

*Sonia Guha, PhD*
Role of Doublecortin in Axonal Misrouting in Oal -/-Mice
Vision of Children
Duration: 7/1/14–6/30/16

**Clinical Trials**

*Joseph Caprioli, MD*
The Efficacy and Safety of Bimatoprost Sr in Patients with Open-Angle Glaucoma or Ocular Hypertension
Allergan Pharmaceutical Corp.
Duration: 4/22/15–1/31/19

*Sophie X. Deng, MD, PhD*
Regeneration of Functional Human Corneal Epithelial Progenitor Cells
California Institute for Regenerative Medicine (CIRM)
Duration: 3/1/11–4/30/15

*Brian A. Francis, MD, MS*
Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered By a Single Intravitreal Injection to Subjects with Acute Primary Angle-Closure Glaucoma
Quark Pharmaceuticals, Inc.
Duration: 9/25/14–4/30/16

*Robert Alan Goldberg, MD*
A Multicenter Double-Masked Placebo-Controlled Efficacy and Safety Study of RV001, an Insulin-Like Growth Factor-1 Receptor Antagonist Antibody (Fully Human), Administered Every 3 Weeks by Intravenous Infusion in Patients Suffering from Active Thyroid Eye Disease
Premier Research International, LLC
Duration: 4/16/13–12/15/16

*Gary N. Holland, MD*
ARO Agreement for a Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with SMD
Ocata Therapeutics (formerly Advanced Cell Technology)
Duration: 4/25/11–12/12/16

ARO Agreement for a Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Sub-Retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (Ma90-hRPE) Cells in Patients with Advanced Dry AMD
Ocata Therapeutics (formerly Advanced Cell Technology)
Duration: 5/31/11–12/12/16

Monitoring of a Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to MMD
Ocata Therapeutics (formerly Advanced Cell Technology)
Duration: 3/31/14–3/31/16
**Jean-Pierre Hubschman, MD**

A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti-PDGF-B Pegylated Aptamer) for ARMD

Ophthotech Corporation

Duration: 12/4/13–12/3/16

Ocriplasmin Research to Better Inform Treatment (ORBIT-Protocol# TG-MV-018)

Thrombogenics, Inc. (Belgium)

Duration: 7/16/14–7/15/16

A Ph 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (Mac Tel)

Lowy Medical Research Institute

Duration: 9/6/14–6/30/18

**Jean-Pierre Hubschman, MD**

*Steven D. Schwartz, MD (Previous Principal Investigator)*

A Natural History of Macular (Parfoveal) Telangiectasia

Lowy Medical Research Institute

Duration: 9/1/05–12/31/18

**Olivia L. Lee, MD**

A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Noninfectious Intermediate Posterior or Pan-Uveitis Currently Controlled with Systemic Treatment

Xoma (US) LLC

Duration: 1/8/13–3/31/16

A Randomized Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Noninfectious Intermediate, Posterior, or Pan-Uveitis

Xoma (US) LLC

Duration: 1/8/13–3/31/16

**Kevin M. Miller, MD**

Safety and Effectiveness of the Customflex Artificial Iris Prosthesis for the Treatment of Iris Defects

Clinical Research Consultants, Inc.

Duration: 6/12/14–4/26/17

A Prospective Randomized Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens in Subjects with Pre-Existing Corneal Astigmatism

Calhoun Vision, Inc.

Duration: 7/26/12–7/28/16

Post Approval Study of the Acrysof IQ Toric High Cylinder Power Intraocular Lens

Alcon Laboratories, Inc.

Duration: 4/17/12–11/18/16

**SriniVas R. Sadda, MD**

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration

CEDAR Study

Allergan Pharmaceutical Corp

Duration: 3/8/16–5/31/20
Alfredo A. Sadun, MD, PhD
Emergency Administration of EPI-743 to a Single Patient with Leber’s Hereditary Optic Neuropathy (LHON)
Edison Pharmaceuticals, Inc.
Duration: 10/17/14–10/17/16

David Sarraf, MD
Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment (EVEN Study)
Southern California Desert Retina Consultants
Duration: 2/7/13–7/21/16
A Phase III, Multicenter, Randomized Double-Masked Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to ARMD
Genentech, Inc.
Duration: 11/21/14–9/27/18

Steven D. Schwartz, MD
A Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells in Patients with Stargardt Macular Dystrophy
Ocata Therapeutics (formerly Advanced Cell Technology)
Duration: 3/23/11–1/12/17
A Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells in Patients with Advanced Dry AMD
Ocata Therapeutics (formerly Advanced Cell Technology)
Duration: 4/5/11–1/28/17
A Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Subretinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to Myopic Macular Degeneration
Ocata Therapeutics (formerly Advanced Cell Technology)
Duration: 4/10/14–9/1/16
A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasis Type 2
Neurotech Pharmaceuticals, Inc.
Duration: 7/19/11–7/18/17
Clinical Research Studies

In the 2015–2016 academic year, UCLA Department of Ophthalmology faculty conducted innovative research in the preservation and restoration of vision, including almost 80 clinical research studies to better understand the eye and its ocular disorders, as well as to evaluate new and potentially sight-saving treatments.

Cornea and External Eye

A Clinical Trial to Evaluate the Efficacy of an Investigational Drug for the Treatment of State 2 and 3 Neurotrophic Keratitis

The purpose of this study is to find out the effectiveness of a formulation containing anti-oxidant of recombinant human nerve growth factor (rhNGF) eye drops solution in healing the corneal epithelium or corneal ulcers in patients with neurotrophic keratitis. Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD, PhD

Analysis of the Corneal and Limbal Epithelial Changes in Limbal Stem Cell Deficiency Using In Vivo Confocal Microscopy

Investigators are working to establish a system for diagnosing limbal stem cell deficiency at a cellular level by correlating the information from impression cytology tests, confocal microscopy pictures, and medical records. Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD, PhD

Effect of Corneal Preservation Time on Long-Term Graft Success

The purpose of this study is to evaluate the effect of preservation time on corneal transplants. It will compare the preservation time up to the FDA limit of 14 days and hopes to determine that longer preservation time does not adversely impact graft success and endothelial cell density. Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD, PhD

Genetic Basis of Posterior Polymorphous Corneal Dystrophy

Funded by the National Eye Institute, this study seeks to identify the gene(s) responsible for posterior polymorphous dystrophy, an inherited corneal endothelial disorder that may result in irreversible corneal swelling and loss of vision. Investigators: Anthony J. Aldave, MD, and Gary N. Holland, MD

Identifying Novel Genes for Fuchs Corneal Endothelial Dystrophy

In this multicenter study, investigators are working to identify the gene(s) responsible for Fuchs corneal endothelial dystrophy, an inherited disorder that may result in irreversible corneal swelling and loss of vision. Investigators: Anthony J. Aldave, MD, Gary N. Holland, MD, and Bartly J. Mondino, MD

Keratoprosthesis Implantation in Patients with Corneal Opacification

This study aims to determine the success rate of keratoprosthesis (artificial corneal) transplantation for visual rehabilitation in patients with corneal opacification. Investigators: Anthony J. Aldave, MD, and Gary N. Holland, MD

Eye Infections and Inflammations

Corneal Endothelial Cell Changes in Children with Uveitis

This is a prospective study to evaluate the cornea, specifically endothelial cells, in children with uveitis. Uveitis is a general term that means inflammation inside the eye. Inflammation can damage any part of the eye, such as the corneal endothelium, which is an important tissue layer at the back of the cornea (clear part in front of the eye) responsible for the maintenance of corneal clarity. Uveitis may lead to a change in the number of endothelial cells and their shape. Specular microscopy, which is a noninvasive corneal-imaging technique, helps to estimate changes in corneal endothelium long before clinical signs of corneal damage. Investigators: Joseph Caprioli, MD, JoAnn A. Giaconi, MD, Gary N. Holland, MD, Simon K. Law, MD, PharmD, and Ralph D. Levinson, MD

Factors Related to the Severity of Ocular Toxoplasmosis

Toxoplasmosis is a common parasitic disease that can cause a vision-threatening infection of the retina. Individuals with and without ocular toxoplasmosis are being evaluated with a blood test to determine whether (1) people can have a genetic predisposition to severe disease when infected with the parasite, or (2) there is a particular strain of parasite that causes more severe disease than others. Investigators: Gary N. Holland, MD, and Ralph D. Levinson, MD

Multicenter Uveitis Steroid Treatment (MUST)

Investigators are comparing two currently available treatments for uveitis. Systemic treatment utilizing medications taken orally, by injection, or by intravenous infusion is being compared to treatment with an intraocular implant containing corticosteroid. Investigators: Gary N. Holland, MD, Jean-Pierre Hubbschman, MD, and Ralph D. Levinson, MD

Natural Killer Cell Receptor Genes and AIDS-Related CMV Retinitis

Institute faculty members are studying why some people with AIDS develop CMV retinitis, an infection of the retina, while others do not. This study aims to determine whether KIR genes, which control natural killer cell activities and other immune functions, differ between HIV-infected individuals who develop CMV retinitis and those who do not, despite similar risk factors. Investigators: Gary N. Holland, MD, and Ralph D. Levinson, MD

Studies Evaluating a New Drug in the Treatment of Patients with Uveitis

Uveitis is caused by inflammation of the middle layer of the eye. The purpose of this study is to find out more about how the drug works, and if it is effective for treating uveitis by limiting one of the proteins that causes inflammation. Investigators: Gary N. Holland, MD, Olivia Lee, MD, and Ralph D. Levinson, MD
Corticosteroids for Uveitic Macular Edema

The purpose of this research study is to compare three treatments for macular edema in patients who have the eye condition known as uveitis (inflammation inside the eye). Macular edema is swelling of the retina at the back of the eye, and it can cause vision loss. The standard treatment is to inject corticosteroid drugs next to the eye or directly into the eye. Investigators: Gary N. Holland, MD, and Colin A. McCannel, MD

Glaucome

A Clinical Trial to Evaluate the Efficacy and Safety of an Investigational Eye Drop in Patients with Open-Angle Glaucome or Ocular Hypertension

The study objective is to evaluate the intraocular pressure-lowering efficacy and safety of two dose strengths of an investigational eye drop in patients with open-angle glaucoma or ocular hypertension after initial and repeated administrations. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Kouros Nouri-Mahdavi, MD

Ocular Biometric Measurements in Angle-Closure Glaucome

The purpose of this study is to determine the potential contributing factors in angle-closure patients of different ethnicities and to determine predictive factors for this type of glaucoma. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, Simon K. Law, MD, PharmD, and Kouros Nouri-Mahdavi, MD

Clinical Measurements of the Optic Nerve in Glaucome

The goal of this study is to develop novel structural measures of the optic nerve and nerve fiber layer, which are sensitive and specific for early and progressive glaucomatous optic nerve damage. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Kouros Nouri-Mahdavi, MD

Effect of Yoga on Glaucome

The purpose of this study is to examine the practice of yoga and its ability to improve a patient’s vision by relieving stress and reducing eye pressure. Investigator: Anne L. Coleman, MD, PhD

Eye Health Imaging Study

The purpose of this study is to expand the normative database for the Heidelberg Spectralis OCT by collecting ophthalmic data from healthy eyes of people of Hispanic/Latino, Asian, and African American descent. Investigators: Joseph Caprioli, MD, and Kouros Nouri-Mahdavi, MD

Glaucome Imaging Study

This study is evaluating different imaging techniques and their use in improving open-angle glaucoma detection. Investigators: Joseph Caprioli, MD, and Kouros Nouri-Mahdavi, MD

Ocular Hypertension Treatment Study

Since topical hypotensive medications are safe and effective in delaying or preventing primary open-angle glaucoma, this study is examining whether other forms of treatment can be deferred with little or no penalty. Investigator: Anne L. Coleman, MD, PhD

Optic Nerve Appearance in Age-Related Macular Degeneration

In order to evaluate the relationship between macular degeneration and optic nerve change, digital imaging technology and photography are being used to assess the structural appearance of the optic nerve in patients with age-related macular degeneration. Investigator: Simon K. Law, MD, PharmD

Role of Pattern Electroretinogram (PERG) in Glaucome

This study is researching an electrophysiological test called pattern electroretinogram (PERG). The goal is to determine the role of PERG in estimating the risk of future glaucoma progression and the reversibility of glaucomatous damage after treatment. The latter could help clinicians better determine to what extent eye pressure needs to be lowered to prevent disease progression. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Kouros Nouri-Mahdavi, MD

Vision-Related Quality of Life and Ocular Dominance

This study is designed to evaluate how quality of life is impacted by glaucoma in relation to eye dominance. It aims to determine whether quality of life is affected more by glaucoma if it primarily affects the dominant eye. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, and Simon K. Law, MD, PharmD

Clinical Trial to Evaluate a Microshunt for the Treatment of Glaucome

The objective of this study is to assess the safety and efficacy of a microshunt when used to lower intraocular pressure (IOP) in subjects with primary open-angle glaucoma whose IOP is not controlled when using maximum-tolerated glaucoma medications. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Brian A. Francis, MD, MS

Analysis of Visual Function in Glaucome

The purpose of this study is to establish electrophysiological benchmarks using the Visual Evoked Potential/Pattern Electroretinogram (VEP/PERG) protocols of populations with glaucoma before treatment and after treatment. Investigators: Brian A. Francis, MD, MS, Alex A. Huang, MD, PhD, Vikas Chopra, MD, Srinivas R. Sadda, MD, and Gad Heilweil, MD

Ocular Imaging in Simulated Microgravity

Special consideration needs to be given to how microgravity may influence the biology and well-being of astronauts. It has been well-documented that astronauts returning from space experience visual disturbance in addition to pathological changes to the eye. This study will noninvasively estimate intracranial pressure in study participants and obtain intraocular/vascular imaging in simulated microgravity environments. Investigator: Alex A. Huang, MD, PhD
Lens and Cataract

Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

This study is being conducted to evaluate the safety and effectiveness of an artificial iris prosthesis for the treatment of full or partial aniridia resulting from congenital aniridia, acquired iris defects (including traumatic iris defects and mydriasis), or conditions associated with full or partial aniridia, such as ocular or oculocutaneous albinism and iridocorneal endothelial (ICE) syndrome, and iris coloboma. Investigators: Anthony J. Aldave, MD, and Kevin M. Miller, MD

Macula, Retina, and Vitreous

Air, Perfluoropropane, and Sulfur Hexafluoride Gas Disappearance Variability after Vitrectomy

The purpose of this study is to evaluate different gases used in vitrectomy surgeries and to understand why there is variability in the time that the different gases remain in the eye after vitrectomy surgery. Investigators: Jean-Pierre Hubschman, MD, and Steven D. Schwartz, MD

A Phase 2 Clinical Trial to Assess the Efficacy and Safety of an Investigational Drug for Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Investigators are currently evaluating intravitreal injection for patients with geographic atrophy secondary to age-related macular degeneration. Investigators: Michael B. Gorin, MD, PhD, Jean-Pierre Hubschman, MD, Colin A. McCannel, MD, David Sarraf, MD, and Steven D. Schwartz, MD

A Safety and Tolerability Trial ofCNTF in Patients with MacTel Type 2

This study is assessing the safety of the NT-501 implant in patients with macular telangiectasia type 2. The device, an implant, is a small capsule of cells that is placed inside the eye. This allows a controlled, sustained release ofCNTF directly to the retina. Investigators: Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, and Steven D. Schwartz, MD

A Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered every four weeks or every six weeks by intravitreal injections for approximately a two-year (96-week) treatment period in patients with geographic atrophy of the retina resulting from age-related macular degeneration. Investigators: David Sarraf, MD, and Steven D. Schwartz, MD

A Study to Evaluate the Treatment of Subfoveal Pigment Epithelial Detachment Associated with Choroidal Neovascularization

The aim of this study is to see if the treatment of pigment epithelial detachment is safe and effective with the regular dose of intravitreal aflibercept injection. This study is being performed in collaboration with Southern California Desert Retina Consultants. Investigator: David Sarraf, MD

Clinical Characterization, Genetic Testing, and Visual Function in Patients with Stargardt Disease

Investigators are doing a comprehensive analysis of visual function in patients diagnosed with Stargardt disease, an early onset form of macular degeneration caused by a number of mutations in the ABCR gene. They are performing molecular genetic testing to confirm the Stargardt diagnosis and better understand the diversity of the condition. Investigators: Deboraa B. Farber, PhD, DPhtc, Michael B. Gorin, MD, PhD, and Steven Nusinowitz, PhD

Incidence of Late Macular Degeneration in Older Women

The goal of this research is to determine the incidence of late age-related macular degeneration (AMD), the rate of progression of AMD, and the association of specific risk factors such as diabetes mellitus and prior cataract surgery with late AMD and its progression in older women. Investigator: Anne L. Coleman, MD, PhD

Lucentis and Fovista Combination Therapy for Wet AMD Compared to Lucentis Only

The purpose of this study is to evaluate the safety and efficacy of Fovista™ intravitreal administration when administered in combination with Lucentis® compared to Lucentis monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Investigator: Jean-Pierre Hubschman, MD

Modified Retinal Fundus Camera

This study evaluates a modified retinal fundus camera to see if significant differences can be found in patients with choroidal melanoma, age-related macular degeneration, or diabetic retinopathy. Investigator: Irena Tsui, MD

Natural History Study of Macular Telangiectasia

Investigators are collecting data about macular telangiectasia with the goal of acquiring more knowledge of and developing a treatment for this rare retinal disease. Investigators: Michael B. Gorin, MD, PhD, Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, Tara A. McCannel, MD, PhD, David Sarraf, MD, and Steven D. Schwartz, MD

Natural History of the Progression of Choroideremia

This is a one-year natural history, observational study to characterize the visual function and retinal structural changes associated with X-linked choroideremia with the intention of determining the best means of measuring disease progression and the rate of natural progression for this condition. Investigators: Michael B. Gorin, MD, PhD, and Steven Nusinowitz, PhD

P200CAF Autofluorescence Ultra-Widefield Scanning Laser Ophthalmoscope in Subjects with Vitreoretinal Disease

This study utilizes an ultra-widefield scanning laser ophthalmoscope with autofluorescence (SLO-AF) to take pictures of the retina in a noninvasive way. Images acquired with the SLO-AF are compared with those from other currently available instruments to evaluate the potentially improved resolution for diagnosis of retinal eye diseases. Investigators: Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, Tara A. McCannel, MD, PhD, and Steven D. Schwartz, MD

Appendices | Stein Eye Institute 137
Pars Plana Vitrectomy with and Without ILM Peel
This study is evaluating and comparing possible differences in the vision, as well as the thickness and shape of the back of the eye, following pars plana vitrectomy surgery with and without internal limiting membrane peeling in patients with complications of diabetic retinopathy. Investigator: Jean-Pierre Hubschman, MD

Research with Retinal Cells Derived from Stem Cells for Dry Age-Related Macular Degeneration (AMD)
This study is evaluating the safety and efficacy of the implantation of MA09-hRPE cells, assessing the number of cells to be transplanted in future studies, and evaluating measures for determining the effectiveness of future stem cell therapy for AMD. Investigators: Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, and Steven D. Schwartz, MD

Research with Retinal Cells Derived from Stem Cells for Stargardt Macular Dystrophy
This study is evaluating the safety and efficacy of the implantation of MA09-hRPE cells, assessing the number of cells to be transplanted in future studies, and evaluating measures for determining the effectiveness of future stem cell therapy for Stargardt macular dystrophy. Investigators: Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, and Steven D. Schwartz, MD

Study of Macular Disease Using Spectral Domain Optical Coherence Tomography Angiography (SD-OCTA)
The RTVue XR 100 Avanti with SSADA will be used to screen patients with macular disease (eg, vitreomacular disorders, diabetic retinopathy, retinal vascular disease, retinal toxicity, age-related macular degeneration, or any other retinal or macular disorder) as detected with clinical examination or ancillary testing, such as with standard OCT or with color fundus photography or fluorescein angiography (FA) or fundus autofluorescence. Investigators: Michael B. Gorin, MD, PhD, Colin A. McCannel, MD, David Sarraf, MD, and Steven D. Schwartz, MD

Understanding the Genetics of Inherited Eye Disorders
The Institute is participating in a study to search for the gene(s) responsible for inherited disorders that are either specific to the eye or have eye findings as part of the medical condition. This study provides for the clinical characterization of affected individuals and at-risk family members, in conjunction with molecular genetic testing, to identify the causative genes and mutations. Investigators: Anthony J. Aldave, MD, and Michael B. Gorin, MD, PhD

Analysis for Visual Function in Age-Related Macular Degeneration
Establish electrophysiological benchmarks, using the Visual Evoked Potential/Pattern Electoretinogram (VEP/PERG) protocols of populations with glaucoma before treatment and after treatment. Investigators: Srinivas R. Sadda, MD, Gad Helvie, MD, Brian A. Francis, MD, MS, Alex A. Huang, MD, PhD, and Vikas Chopra, MD

Evaluating the Use of an Implant for Patients with Macular Degeneration
This clinical trial is to determine the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the implant using three ranibizumab formulation arms compared with the control arm in patients with subfoveal neovascular (wet) age-related macular degeneration (AMD). The study will also evaluate the safety of the ranibizumab port delivery system (RPDS) combination product. Screening and randomization visits will be followed by a treatment period. Investigators: Colin A. McCannel, MD, Tara A. McCannel, MD, PhD, Pradeep S. Prasad, MD, Michael B. Gorin, MD, PhD, and David Sarraf, MD

Evaluation of a New Drug for Stargardt Disease
The purpose of this research study is to find out whether a new drug for Stargardt disease is safe and effective. There are currently no proven treatments for Stargardt disease, a disease that leads to blindness in almost all cases. Investigators: Michael B. Gorin, MD, PhD, and Steven Nusinowitz, PhD

Neuro-Ophthalmology
Analysis of Samples from Patients with Rhegmatogenous Retinal Detachment (RRD) to Identify Potential Biochemical Markers of Retinal Stress
Vision loss from a retinal detachment is due in part to ischemia that occurs when the retina moves away from the choroidal vessels that supply oxygen and nutrition to the outer two-thirds of the retina. Studying the biochemical mechanisms of retinal stress and death can be useful in understanding the cellular mechanisms and timeline of vision loss, leading to new ways to improve vision. The aim of the study is to identify biomarkers for rhegmatogenous retinal detachment in aqueous (the fluid in the front of the eye), vitreous (the gel filling the center of the eye), and blood. Investigators: Brian A. Francis, MD, MS, and Alfredo A. Sadun, MD, PhD

Natural History Study of Leber Hereditary Optic Neuropathy
Leber hereditary optic neuropathy (LHON) is one of the diseases where the mitochondria of the retina cells are not functioning correctly, which can lead to loss of vision. Currently there are no FDA-approved treatments for LHON. The purpose of this study is to obtain electroretinography (ERG) data and optical coherence tomography (OCT) data from patients who carry the Leber hereditary optic neuropathy gene. Investigator: Alfredo A. Sadun, MD, PhD

A Protocol to Follow-up with Patients on Emergency Administration of EPI-743 with Leber Hereditary Optic Neuropathy
EPI-743 is a new experimental drug that may improve mitochondrial function. EPI-743 is a form of vitamin E that has been changed to a new compound in the laboratory. The experimental drug EPI-743 was selected because the mitochondrial disease manifestations appeared to improve when the drug was given to cells from a patient with Leber hereditary optic neuropathy (LHON), which were grown in the laboratory. Investigator: Alfredo A. Sadun, MD, PhD
Evaluation of a Drug for the Treatment of Leber Hereditary Optic Neuropathy

The objective of this study is to evaluate the safety, tolerability, and efficacy of a topical ophthalmic solution in the treatment of subjects with Leber Hereditary Optic Neuropathy (LHON). The study drug has been shown to enhance or benefit mitochondria function in studies done on cells grown in the laboratory. Investigator: Alfredo A. Sadun, MD, PhD

Evaluating the Efficacy of a Single Intravitreal Injection for Patients with Leber Hereditary Optic Neuropathy

The goal of this clinical trial is to assess the effectiveness of a gene therapy in improving the visual outcome in patients with Leber Hereditary Optic Neuropathy (LHON) due to a mitochondrial mutation. Investigator: Alfredo A. Sadun, MD, PhD

Ocular Melanoma

Molecular and Cytogenetic Studies of Ocular Melanoma

The goal of this research is to study ocular melanoma tumor tissue and to identify key molecular and genetic features that could help predict those patients who may be at high risk for metastasis. Investigators: Lynn K. Gordon, MD, PhD, Tara A. McCannel, MD, PhD, and Bradley R. Straatsma, MD, JD

Optical Coherence Tomography of Regional Abnormalities Associated with Choroidal Nevus, Choroidal Melanoma, and Choroidal Melanoma Treated with Iodine-125 Brachytherapy

In this study, optical coherence therapy (OCT) imaging is performed during regularly scheduled visits on patients with choroidal nevus, choroidal melanoma, and choroidal melanoma treated with iodine-125 brachytherapy. The purpose is threefold: to study the structure and function of the retina overlying the tumor and the macula, to evaluate the effects of radiation on the retina, and to compare OCT imaging to other imaging procedures. Investigators: Tara A. McCannel, MD, PhD, and Bradley R. Straatsma, MD, JD

PET/CT Imaging for Early Detection of Ocular Melanoma

This research involves the use of combined positron emission tomography (PET)/computed tomography (CT) scans in subjects with ocular melanoma. It may ultimately provide new knowledge that will be used to develop better ways of monitoring for tumor spread and allow for early treatment if metastasis is found. Investigators: Tara A. McCannel, MD, PhD, and Bradley R. Straatsma, MD, JD

Orbital and Ophthalmic Plastic Surgery

A Research Study Evaluating a New Drug for the Treatment of Thyroid Eye Disease

The purpose of this study is to obtain information on the safety and effectiveness of an investigational drug to treat thyroid eye disease (TED). People with TED experience eye problems often due to an overactive thyroid caused by Graves disease. Investigators: Robert Alan Goldberg, MD, Daniel B. Rootman, MD, MS, and Catherine J. Hwang, MD

Characteristics of the Brow–Eyelid Margin Relationship

The purpose of this study is to determine if changing the effect of gravity has an effect on eyelid position. Investigators: Robert Alan Goldberg, MD, and Daniel B. Rootman, MD, MS

Hyaluronic Acid Gels for Upper Lid Retraction in Active State Thyroid Eye Disease

This study is to determine if hyaluronic acid gel (HAG) can be used reliably and reproducibly to correct upper eyelid retraction, improve dry eye related symptoms, aesthetic appearance, and quality of life in active-stage thyroid eye disease (TED). The study also aims to determine the long-term outcome of TED and how long the effects of HAG can last. Investigator: Daniel B. Rootman, MD, MS

Pro-Inflammatory Cytokines, Dry Eye, and Thyroid Eye Disease

This study’s purpose is to determine whether there are specific inflammatory proteins in tears of patients with active-stage thyroid eye disease (TED). If these inflammatory proteins exist, the study aims to determine whether they can be used to predict dry eye symptomatology and if they can be used to predict TED activity. Investigators: Robert Alan Goldberg, MD, and Daniel B. Rootman, MD, MS

Studies on Tissue in Autoimmune Diseases

This study aims to determine the cause of eye problems in Graves disease and other autoimmune diseases. Examination is being done of material removed from orbits during surgical therapy for Graves disease or other problems requiring surgery on the tissue surrounding the eyes, of thyroid tissue removed during the course of surgical therapy, or of blood drawn for laboratory tests. Investigator: Robert Alan Goldberg, MD

Ptosis Surgery Outcomes Scale

Currently there are no standardized reporting criteria for research on ptosis outcomes, making the literature difficult to interpret. In order to assess the relative efficacy of surgical techniques and to understand the value of an individual intervention, standardization is vital. The purpose of this investigation is to define and validate a universal measure for ptosis outcomes that can be used in defining both value and efficacy in ptosis surgery. Investigator: Daniel B. Rootman, MD, MS

Effect of External Eyelid Weighting on Lid Position in Normal and Ptosis Patients

The purpose of this investigation is to compare the ability of normal and ptotic patients to maintain eyelid position by adapting to acute and dramatic changes in protracting forces by using eyelid weights. This project will help elucidate the physiology of the eyelid position maintenance system, and provide insight into its ability to respond to changes in disease. Investigator: Daniel B. Rootman, MD, MS
Temporal Fossa in Different Ethnicities
Previous studies have determined differences in anatomy between different ethnicities. For example, Asians have more prominent subcutaneous, sub-orbicularis, and pretarsal fat tissue in upper eyelid compared to Caucasians. Better knowledge of these differences is important for cosmetic procedures to achieve better results and fewer complications. The aim of this study is to investigate differences in anatomy of temporal fossa between different ethnicities using three-dimensional CT scan images. Investigators: Robert Alan Goldberg, MD, and Catherine J. Hwang, MD

Ocular Protrusion in Sitting and Supine Positions
There is still controversy in the literature as to the difference in the degree of ocular protrusion (proptosis) between the supine and upright positions in normal subjects and in patients with thyroid eye disease with and without extraocular muscle involvement. The aim of this study is to compare the degree of ocular protrusion in normal individuals and patients with thyroid eye disease between sitting and lying (supine) positions. Investigators: Robert Alan Goldberg, MD, and Daniel B. Rootman, MD, MS

Clinical Presentation and Management of Orbital Plasmacytoma
Orbital plasmacytoma is a rare monoclonal proliferation of plasma cells that can be associated with multiple myeloma. The purpose of this study is to contribute to the largest case series of orbital plasmacytomata to date and review its clinical characteristics. Investigator: Daniel B. Rootman, MD, MS

Neuroendocrine Tumors Metastases in the Eye and Orbit
The purpose of this study is to understand the diversity in presentation of carcinoid tumors of the orbit, as well as to identify, stage, and grade related factors that may affect prognosis and thus treatment decisions. In addition, we aim to answer the question if there are any features of carcinoid tumor presentations in the orbit that can predict outcome and thus guide therapeutic decision-making. Investigators: Daniel B. Rootman, MD, MS

Pediatrics and Strabismus

A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia
Although occlusion treatment, or patching of the eye, is a widely used treatment for intermittent exotropia (IXT), there have been no randomized clinical trials evaluating its effectiveness. This study is being conducted to assess the natural history of IXT and to establish the effectiveness of patching in its treatment. Investigators: Stacey L. Pineles, MD, and Federico G. Velez, MD

Pediatric Cataract Surgery Outcomes Registry
This study aims to collect core clinical data on children and teens undergoing surgery for cataracts in order to conduct analyses and generate hypotheses. The proposed research model is a patient registry. Clinical outcomes data will be collected from affected subjects after cataract surgery has been performed. Investigators: Stacey L. Pineles, MD, and Federico G. Velez, MD

A Prospective Observation Study of Adult Strabismus
The purpose of this study is to learn about treatments for strabismus in adults. There are several different treatment options for strabismus: sometimes these conditions are treated with special glasses that help to align the eyes (prism) or with exercises that help the eyes work together, and sometimes these conditions are treated with surgery or Botox injection to straighten the eyes. Investigators: Stacey L. Pineles, MD, and Federico G. Velez, MD

Clinical Trial to Evaluate Antibiotics Used During Surgery
This prospective, randomized trial will enroll children who are undergoing cataract surgery. The study will evaluate two antibiotics to treat inflammation after surgery—drugs that are currently FDA approved for adults. Investigators: Federico G. Velez, MD, Stacey L. Pineles, MD, and Joseph L. Demer, MD, PhD

An Observational Study in Patients Diagnosed with Idiopathic Bilateral Cataracts
The purpose of this study is to understand better how many people who have been diagnosed with early-onset idiopathic bilateral cataracts may have a rare but treatable disease called cerebrotendinous xanthomatosis (CTX). In people who have CTX, one of the first signs of the disease is often cataracts from an unknown cause at an early age. Investigators: Federico G. Velez, MD, Stacey L. Pineles, MD, and Joseph L. Demer, MD, PhD

Evaluation of a Drug During Pediatric Cataract Surgery
The purpose of this research study is to determine if adding a drug to the rinsing solution helps keep the pupil dilated (open) during cataract surgery and to see if the drug reduces eye pain after surgery. The study doctor is also doing this study to find out if receiving this drug is better in children than receiving the standard-of-care treatment, Phenylephrine HCl alone. Investigators: Federico G. Velez, MD, Stacey L. Pineles, MD, and Joseph L. Demer, MD, PhD

Biomechanical Analysis in Strabismus Surgery
This study aims to develop new diagnostic tests and computer models that will lead to improvements in strabismus surgery. Tests of binocular alignment and eye movements, as well as magnetic resonance imaging of the extraocular muscles, are being performed in the Institute’s Clinical and Basic Science Ocular Motility Laboratory before and after strabismus surgery. To date, this research has fundamentally contributed to the knowledge of the functional anatomy of the extraocular muscles and connective tissues, and allowed discovery of causes of common strabismus and development of new types of surgeries. Investigator: Joseph L. Demer, MD, PhD
Genetic and Anatomic Studies of Eye Movement Disorders
This collaborative National Eye Institute-funded study is conducting magnetic resonance imaging of the extraocular muscles. This procedure clarifies the phenotypes and mechanisms of congenital cranial dysinnervation syndromes whose hereditary properties have been characterized using modern molecular genetics. Patients with these syndromes have severe forms of strabismus. Investigator: Joseph L. Demer, MD, PhD

Optical Coherence Tomography in the Newborn Eye
The purpose of this study is to better characterize the retina and optic nerve in newborns using spectral-domain optical coherence tomography (SD-OCT). SD-OCT has been used for many years to help diagnose and treat adults with eye diseases, but it has never been studied in newborns, where it could potentially help in the diagnoses of glaucoma, optic nerve hypoplasia, foveal hypoplasia, and colobomata, among many other disorders. Investigator: Sherwin J. Isenberg, MD

Optic Nerve in Amblyopia
Amblyopia is a major cause of childhood visual loss. This study uses high resolution, surface-coil magnetic resonance imaging to study optic nerve size in amblyopia. It tests the theory that the optic nerve is smaller than normal in amblyopia and that optic nerve size may be a limiting factor in restoration of vision by amblyopia treatment. Investigator: Joseph L. Demer, MD, PhD

Prevention of Visual Impairment in School-Age Children
In this community-based participatory intervention to promote the use of eyeglasses in schools, first- and second-grade students with refractive errors receive two pairs of eyeglasses, with one pair staying at home and the other in the classroom. School nurses collaborate with teachers in monitoring the use of eyeglasses in the classroom, and parents receive eye care education. Investigator: Anne L. Coleman, MD, PhD

Prospective Study to Determine the Proportion of Patients with Isolated Third, Fourth, and Sixth Nerve Palsies of Microvascular Versus Nonmicrovascular Etiology
Currently, magnetic resonance imaging scanning is only recommended in atypical cases (ie, young age, no vascular risk factors). The purpose of this multicenter study is to determine whether central nervous system abnormalities are detected in patients who otherwise would not have neuroimaging. Investigator: Stacey L. Pineles, MD

Sensory Processing and Learning
This study evaluates amblyopic patients, who are traditionally thought to be beyond the critical period for treatment. Those subjects will be enrolled and randomized to one of the two amblyopia therapies using a perceptual learning technique. Investigator: Stacey L. Pineles, MD

Sweep Visual Evoked Potential for Use in Amblyopia and Pediatric Optic Nerve Disorders
Using a new technique, investigators are measuring vision in preverbal children to diagnose and follow optic nerve diseases. Currently, treatment decisions are based on clinical examinations that are insensitive and reveal vision loss well after permanent damage has taken place. This technique allows more accurate examinations, which leads to provision of treatments at the first signs of vision loss and thereby decreases the risk of permanent damage. Investigators: Joseph L. Demer, MD, PhD, Sherwin J. Isenberg, MD, Stacey L. Pineles, MD, and Federico G. Velez, MD
In the 2015–2016 academic year, UCLA Department of Ophthalmology full-time faculty published nearly 270 peer-reviewed articles and book chapters, further advancing vision-science research.

Publications are ordered chronologically: July 1, 2015–June 30, 2016

July 2015


August 2015


September 2015


October 2015


November 2015


October 2016


December 2015


January 2016


González S, Mei H, Nakatsu MN, Baclagon ER, Deng SX. A 3D culture system enhances the ability of bone marrow stromal cells to support the growth of limbal stem/progenitor cells. Stem Cell Res. 2016 Mar;16(2):358–64. Epub 2016 Feb 6.


March 2016


April 2016


May 2016


Ingram NT, Sampath AP, Fain GL. Why are rods more sensitive than cones? J Physiol. 2016 May 24.


June 2016


**Giving Opportunities**

UCLA Stein Eye Institute is dedicated to the preservation of sight and the prevention of blindness. Today, UCLA’s vision scientists are extending the boundaries of current knowledge and approaching the goal for a lifetime of good vision for everyone, due in large part to a strong tradition of philanthropy from private sources.

Contributions from individuals, foundations, and corporations, help underwrite exemplary patient-care programs, innovative scientific advances, key community engagement, and the highest-quality training and education. The Institute offers a variety of giving options to those who wish to contribute to this tradition of excellence.

### How to Support the UCLA Stein Eye Institute

**Direct Gifts**
Direct gifts—whether by cash, check, or credit card—are critically important to Stein Eye because the gifts can be put to work immediately, increasing their impact and extending their reach.

**Pledges**
A pledge is a formal statement of intention to make a gift to the Institute. Donors who seek to defer the bulk of their giving until a future date, or who want to give via installments over time, may use this giving strategy. A pledge may be followed by an immediate gift, or may simply confirm your intention to make a gift in the future. Pledges are typically made in concert with a preliminary first-installment gift and provide a source of consistent and dependable funding for the University. This method often allows donors to give more generously than they may have originally considered.

**Securities**
Gifts of appreciated securities are tax deductible at their full market value. In most cases, appreciation in the value of the security benefits the University and is not taxable to the donor.

**Matching Gifts**
Many corporations have demonstrated their support by matching or multiplying their employees’ gifts to the Institute up to a set amount. Before making a gift, you may want to ask whether your employer participates in a matching gift program. Certain restrictions apply to matching gifts. Please consult your company’s personnel office.

**Real Estate**
Real estate (your primary residence, vacation home, commercial property, or land) is an asset that you can leverage in a variety of ways to support UCLA Stein Eye Institute while reducing taxes and eliminating the burden of maintaining or selling your property. You can also use real estate to fund gifts that provide you with an income stream for life.

**Bequests**
Making a gift to the UCLA Stein Eye Institute through your will or living trust gives you the immediate satisfaction of creating a lasting and personal legacy that ensures Stein Eye’s future and costs nothing now.

**Charitable Gift Annuity**
In exchange for a gift of cash or appreciated securities, you can receive fixed income for life and an immediate charitable income tax deduction. In addition, a portion of the annuity payments is tax-free.

**Qualified Retirement Plans**
Naming The UCLA Foundation as a beneficiary of some or all of your qualified retirement plan may help you minimize taxes and maximize your philanthropic impact for the UCLA Stein Eye Institute, while leaving to your loved ones, assets that are less taxed.

**Tribute Gifts**
Contributions may be made in memory, honor, or celebration of a loved one, or to commemorate a special occasion. Donations can be used for unrestricted program support or be directed to any area of the Institute.

**Endowments**
A gift of an endowment demonstrates a long-term commitment to the Institute, since the fund is maintained in perpetuity. A portion of the annual investment income is used to support clinical, educational, and scientific initiatives and the remaining investment yield is returned to principal, thus, over the years, the fund can grow and provide continuous support.

An endowment serves as an enduring legacy as it can bear the donor’s name or honor a loved one. These funds can be made payable for up to five years. Giving opportunities exist for endowed chairs, endowed fellowships, and endowed funds for research, education, and patient care.

### Your Gift Can Make a Difference

However you choose to support the Institute, you will be embarking on a partnership with one of the world’s preeminent eye research centers. Such an investment will greatly expand our understanding of the causes of eye diseases, expose alternative treatment options, and ultimately prevent blindness.

For information on how to incorporate UCLA Stein Eye Institute into your estate and retirement planning, or to make a gift of any kind, please contact:

UCLA Stein Eye Institute
Development Office
100 Stein Plaza, Room 1-124
Los Angeles, California 90095-7000
Phone: (310) 206-6035
Fax: (310) 794-1665
giving@sei.ucla.edu